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Résumé 
L’accumulation de triglycérides (TG) dans les hépatocytes est caractéristique de la stéatose 
hépatique non-alcoolique (SHNA). Cette dernière se produit dans diverses conditions dont 
le facteur commun est le métabolisme anormal des lipides. Le processus conduisant à 
l'accumulation des lipides dans le foie n’a pas encore été totalement élucidé. Toutefois, des 
lipides s'accumulent dans le foie lorsque les mécanismes qui favorisent leur exportation 
(oxydation et sécrétion) sont insuffisants par rapport aux mécanismes qui favorisent leur 
importation ou leur biosynthèse. De nos jours il est admis que la carence en œstrogènes est 
associée au développement de la stéatose hépatique. Bien que les résultats des études 
récentes révèlent l'implication des hormones ovariennes dans l'accumulation de lipides dans 
le foie, les mécanismes qui sous-tendent ce phénomène doivent encore être étudiés.  En 
conséquence, les trois études présentées dans cette thèse ont été menées sur des rates 
ovariectomizées (Ovx), comme modèle animal de femmes post-ménopausées, pour étudier 
les effets du retrait des œstrogènes sur le métabolisme des lipides dans le foie, en 
considérant l'entraînement physique comme étant un élément positif pouvant contrecarrer 
ces effets. Il a été démontré que l'entraînement physique peut réduire l'accumulation de 
graisses dans le foie chez les rates Ovx. 
Dans la première étude, nous avons montré que chez les rates Ovx nourries à la diète riche 
en lipides (HF), les contenus de TG hépatiques étaient élevées (P < 0.01) comparativement 
aux rates Sham, 5 semaines après la chirurgie. Le changement de la diète HF par la diète 
standard (SD) chez les rates Sham a diminué l’accumulation de lipides dans le foie. 
Toutefois, chez les rates Ovx, 8 semaines après le changement de la HF par la SD le niveau 
de TG dans le foie était maintenu aussi élevé que chez les rates nourries continuellement 
avec la diète HF. Lorsque les TG hépatiques mesurés à la 13e semaine ont été comparés aux 
valeurs correspondant au retrait initial de la diète HF effectué à la 5e semaine, les niveaux 
de TG hépatiques chez les animaux Ovx ont été maintenus, indépendamment du 
changement du régime alimentaire; tandis que chez les rats Sham le passage à la SD a 
réduit (P < 0.05) les TG dans le foie. Les mêmes comparaisons avec la concentration des 
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TG plasmatiques ont révélé une relation inverse. Ces résultats suggèrent que la résorption 
des lipides au foie est contrée par l'absence des œstrogènes. Dans cette continuité, nous 
avons utilisé une approche physiologique dans notre seconde étude pour investiguer la 
façon dont la carence en œstrogènes entraîne l’accumulation de graisses dans le foie, en 
nous focalisant sur la voie de l'exportation des lipides du foie. Les résultats de cette étude 
ont révélé que le retrait des œstrogènes a entraîné une augmentation (P < 0.01) de 
l’accumulation de lipides dans le foie en concomitance avec la baisse (P < 0.01) de 
production de VLDL-TG et une réduction l'ARNm et de la teneur en protéines 
microsomales de transfert des triglycérides (MTP). Tous ces effets ont été corrigés par la 
supplémentation en œstrogènes chez les rates Ovx. En outre, l'entraînement physique chez 
les rates Ovx a entraîné une réduction (P < 0.01) de l’accumulation de lipides dans le foie 
ainsi qu’une diminution (P < 0.01) de production de VLDL-TG accompagnée de celle de 
l'expression des gènes MTP et DGAT-2 (diacylglycérol acyltransférase-2). Des études 
récentes suggèrent que le peptide natriurétique auriculaire (ANP) devrait être au centre des 
intérêts des recherches sur les métabolismes énergétiques et lipidiques. Le ANP est relâché 
dans le plasma par les cellules cardiaques lorsque stimulée par l’oxytocine et exerce ses 
fonctions en se liant à son récepteur, le guanylyl cyclase-A (GC-A). En conséquence, dans 
la troisième étude, nous avons étudié les effets du blocage du système ocytocine-peptide 
natriurétique auriculaire (OT-ANP) en utilisant un antagoniste de l’ocytocine (OTA), sur 
l'expression des gènes guanylyl cyclase-A et certains marqueurs de l’inflammation dans le 
foie de rates Ovx. Nous avons observé une diminution (P < 0.05) de l’ARNm de la GC-A 
chez les rates Ovx et Sham sédentaires traitées avec l’OTA, tandis qu’une augmentation (P 
< 0.05) de l'expression de l’ARNm de la protéine C-réactive (CRP) hépatique a été notée 
chez ces animaux. L’exercice physique n'a apporté aucun changement sur l'expression 
hépatique de ces gènes que ce soit chez les rates Ovx ou Sham traitées avec l’OTA.  
En résumé, pour expliquer l’observation selon laquelle l’accumulation et la 
résorption de lipides dans le foie dépendent des mécanismes associés à des niveaux 
d’œstrogènes, nos résultats suggèrent que la diminution de production de VLDL-TG 
induite par une déficience en œstrogènes, pourrait être un des mecanismes responsables de 
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l’accumulation de lipides dans le foie.  L’exercice physique quant à lui diminue 
l'infiltration de lipides dans le foie ainsi que la production de VLDL-TG indépendamment 
des niveaux d'œstrogènes. En outre, l'expression des récepteurs de l’ANP a diminué par 
l'OTA chez les rates Ovx et Sham suggérant une action indirecte de l’ocytocine (OT) au 
niveau du foie indépendamment de la présence ou non des estrogènes. L’axe ocytocine-
peptide natriurétique auriculaire, dans des conditions physiologiques normales, protègerait 
le foie contre l'inflammation à travers la modulation de l’expression de la GC-A.   
 
Mots-clés: Stéatose hépatique, ovariectomie, rat, hormones ovariennes, diète riche en 
lipides, protéine microsomale de transfert des triglycérides (MTP), diacylglycérol 
acyltransférase-1 et -2 (DGAT-1 et -2), entraînement en endurance, récepteur hépatique de 
GC-A, antagoniste de l’ocytocine (OTA). 
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Abstract 
Excessive accumulation of triglycerides (TGs) in hepatocytes is the characteristic of non-
alcoholic hepatic steatosis (NAHS). NAHS occurs in various conditions in which abnormal 
fat metabolism is a common factor. The primary processes leading to lipid accumulation in 
the liver are not well understood. However, lipid in the form of TG accumulates within 
liver cells when mechanisms that promote their removal (by oxidation or secretion) cannot 
keep pace with mechanisms that promote lipid import or biosynthesis. Today, it is well 
accepted that estrogen deficiency is associated with the development of a state of hepatic 
steatosis. Although recent findings indicated the implication of ovarian hormones in liver 
lipid accumulation, mechanisms underlying this phenomenon need to be further 
investigated. Therefore, the three studies presented in this thesis have been conducted in 
ovariectomized (Ovx) rats, as animal model of post-menopausal women, to investigate the 
effects of estrogen withdrawal on liver fat metabolism and considering the effects of 
exercise training as a positive counteractive factor. It has been shown that exercise training 
can reduce liver fat accumulation in Ovx rats. 
In the first study, we showed that in high fat (HF) fed animals, liver TG content was 
higher (P < 0.01) in Ovx compared to Sham rats as soon as 5-week after the surgery. 
Switching from the HF to a standard (SD) diet resulted in a decrease in liver fat 
accumulation in Sham animals. However, 8 weeks after the diet switch, liver fat 
accumulation was as high in Ovx rats as those maintained on the HF diet. When liver TG 
content measured at week 13 was compared to initial pre-switching values (week 5), liver 
TG levels in Ovx animals were maintained at the same level independently of the diet 
switch, while in Sham rats switching to a SD diet reduced liver TG accumulation (P < 
0.05). The same comparisons with plasma TG levels revealed an opposite relationship. 
These results may be taken as evidence that indeed liver fat resorption is hampered in the 
absence of estrogens. To go one step further, we used a physiological approach in our 
second study to investigate how estrogen deficiency affects liver fat accumulation putting 
  
 
v
an emphasis on the pathway of lipid exportation from the liver. Results of this study 
showed that estrogen withdrawal resulted in higher (P < 0.01) liver fat accumulation 
concomitantly with lower (P < 0.01) very low density lipoprotein-triglyceride (VLDL-TG) 
production and lower mRNA and protein content of hepatic microsomal triglyceride 
transfer protein (MTP). All of these effects in Ovx rats were corrected with estrogen 
supplementation. Moreover, exercise training in Ovx rats reduced (P < 0.01) liver fat 
accumulation and further reduced (P < 0.01) hepatic VLDL-TG production along with gene 
expression of MTP and diacylglycerol acyltransferase-2 (DGAT-2). A recent growing body 
of literature suggests that atrial natriuretic peptide (ANP) hormone should be the interest of 
new investigations in the field of energy and lipid metabolism. ANP is released from the 
heart into plasma by oxytocin (OT) stimulation and exerts its biological action by binding 
to its receptor, guanylyl cyclase-A (GC-A: ANP receptor). Therefore, in the third study, we 
investigated the effects of blocking the oxytocin-atrial natriuretic peptide (OT-ANP) 
system, using an OT antagonist (OTA), on the gene expression of hepatic guanylyl cyclase-
A and some inflammatory markers in the liver of Ovx rats. Hepatic GC-A mRNAs were 
decreased (P < 0.05) in Ovx and Sham OTA-treated rats in the sedentary state, contrary to 
hepatic C-reactive protein (CRP) mRNA expression that increased in these animals (P < 
0.05). Exercise training had no effect on hepatic expression of these genes in both Sham 
and Ovx rats receiving OTA. 
Overall, our results point to the interpretation that hepatic fat accumulation and 
resorption are dependent on mechanisms associated with a normal estrogenic status; 
indicating that a decrease in VLDL-TG production might be a contributing factor 
responsible for the hepatic fat accumulation induced by estrogen deficiency. Exercise 
training lowers liver fat accretion and VLDL-TG production independently of the estrogen 
levels. Moreover, hepatic expression of ANP receptors is decreased by OTA in both Sham 
and Ovx rats suggesting an indirect action of the OT system on the liver independently of 
the estrogenic status of the animal. Oxytocin-atrial natriuretic peptide axis may contribute 
to the protection of hepatic tissue under normal physiological conditions such as reducing 
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inflammatory markers within the hepatocytes by exerting its role through guanylyl cyclase-
A expression.  
 
Keywords: Hepatic steatosis, Ovariectomy, Rat, Ovarian hormones, High-fat diet, 
Microsomal triglyceride transfer protein (MTP), Diacylglycerol acyltransferase-1 and -2 
(DGAT-1 and -2), Endurance training, Hepatic GC-A receptor, Oxytocin antagonis (OTA). 
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Introduction 
Obesity is now recognized as a major public health problem that constitutes a risk 
factor for life-threatening diseases such as type 2 diabetes and cardiovascular disease.  
These disorders represent major causes of morbidity and mortality throughout the world. 
Excess caloric intake and/or dietary fat intake along with sedentarity play a central role in 
inducing obesity which translates not only on peripheral fat accumulation but additionally 
impacts on fat accumulation in the liver (Liu, Bengmark et al. 2010). In fact, the majority of 
non-alcoholic fatty liver disease (NAFLD) patients are obese (Marchesini, Brizi et al. 
2001). NAFLD represents a spectrum of liver diseases that range from simple non-
alcoholic hepatic steatosis (NAHS), to a more severe stage termed non-alcoholic 
steatohepatitis which may in turn progress to hepatic fibrosis, cirrhosis, and liver failure 
(Patrick-Melin, Kalinski et al. 2009). Although it is a very common disorder, NAFLD has 
only recently gained broader interest among physicians and scientists (Duvnjak, Lerotic et 
al. 2007). Excessive fat accumulation within hepatocytes has been reported to play an 
important role in the development of insulin resistance and is even considered as a hepatic 
component of the metabolic syndrome (Kadowaki, Hara et al. 2003; Samuel, Liu et al. 
2004; Marchesini, Marzocchi et al. 2005). The importance of the phenomenon is 
highlighted by recent data suggesting that ectopic fat in liver may be even more important 
than visceral fat in characterization of metabolically benign obesity in humans (Stefan, 
Kantartzis et al. 2008). 
There is accumulating evidence that estrogen deficiency increases the risk of hepatic 
steatosis in post-menopausal women (Park, Jeon et al. 2006; Suzuki and Abdelmalek 2009) 
as well as in different animal models (Deshaies, Dagnault et al. 1997; Picard, Deshaies et 
al. 2000). Hepatic steatosis is twice as common in post-menopausal women as in pre-
menopausal women (Hagymasi, Reismann et al. 2009). It thus seems that menopause plays 
a central role in the pathogenesis of NAHS in women. However, strong valuable evidence 
on the protective effects of estrogen on the liver is lacking (Volzke, Schwarz et al. 2007; 
Frith and Newton 2010). The increased risk of liver lipid infiltration in post-menopausal 
women is, therefore, a concern that needs to be well characterized, especially in relation to 
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the high dietary fat intake of Western societies. Over the last decade, the laboratory of Prof. 
Jean-Marc Lavoie has been using ovariectomized (Ovx) rat model as an experimental 
model of human post-menopausal obesity. The studies conducted in his laboratory 
convincingly indicated the importance of estrogen withdrawal on hepatic fat accumulation 
(Latour, Shinoda et al. 2001; Shinoda, Latour et al. 2002; Paquette, Shinoda et al. 2007). 
However, it was not until recently that our group started to investigate the underlying 
mechanisms of the relationship between estrogen deficiency and liver lipid infiltration. 
Therefore, the purpose of the studies presented in this thesis was to extend our 
understanding regarding the development of NAHS associated with estrogen deficiency 
state using an Ovx rat model.  
In the first study, we designed an experiment to test the hypothesis that the livers of 
Ovx rats are resistant to reversal of liver lipid infiltration. To verify our hypothesis, we 
stimulated fat accretion in livers of Ovx and Sham rats by submitting them to a high fat 
(HF) diet (containing 43% of its energy from lipids) and evaluated reversal of liver fat 
accumulation by switching the feeding to a standard (SD) diet (containing 12.5% of its 
energy from lipids). Results of this study supported our hypothesis. Also, the results 
suggest that liver fat infiltration in Ovx rats is not solely related to an increased hepatic 
lipid uptake, but also facilitated by an intra-hepatic mechanism related to the absence of 
estrogens. Results of this study led us to test a mechanism that might explain liver fat 
accumulation in Ovx rats. In line with this, we used a physiological approach in the second 
study to determine if hepatic very low density lipoprotein-triglyceride (VLDL-TG) 
production is altered following a 3-h infusion of lipids in Ovx rats. We also measured the 
hepatic gene expression and the protein content of microsomal triglyceride transfer protein 
(MTP), a molecule that exerts a central role in the synthesis and secretion of hepatic VLDL 
(Gibbons, Wiggins et al. 2004).  
The protective effects of exercise training on some of the mechanisms involved in 
hepatic lipid accumulation in this hormonal context, such as liver lipogenesis and lipid 
oxidation, have been recently investigated (Pighon, Gutkowska et al. 2010). To 
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complement these studies, we also examined the effects of exercise training on hepatic 
VLDL-TG production and gene expression of related makers in Ovx rats and compared 
these responses with the effects of 17β-estradiol supplementation. Finally, it has been 
suggested that cardiac oxytocin-atrial natriuretic peptide (OT-ANP) system is under 
estrogenic control and it is positively influenced by exercise training (Gutkowska, Paquette 
et al. 2007). In the last study, we investigated the OT-ANP system in Ovx rats with a 
hepatico-metabolic approach. Many studies have shown an organ-protective effect of ANP 
against serious liver damages such as ischemia/reperfusion (I/R) injury (Bilzer, Witthaut et 
al. 1994; Gerbes, Vollmar et al. 1998; Kiemer, Vollmar et al. 2000; Kiemer, Gerbes et al. 
2002; Carini, De Cesaris et al. 2003; Gerwig, Meissner et al. 2003; Kulhanek-Heinze, 
Gerbes et al. 2004). In addition, OT-ANP axis has been shown to have an effect on lipid 
metabolism via increased lipolysis (Moro, Crampes et al. 2004). This triggers our interest 
in investigating if this axis influence lipid metabolism in liver. Therefore, the aim of this 
study was to investigate the metabolic actions of OT antagonist (OTA) in liver of Ovx rats 
and if exercise training plays a role in these actions.  
This thesis consists of three chapters. Chapter 1 is devoted to the review of the 
literature which is divided into three sections: the objective of the first section is to provide 
the reader with an overview of NAHS, with an emphasis on major metabolic pathways 
associated with this phenomenon; in the second section, we review the role of estrogen in 
the development of hepatic steatosis with a special attention given to hepatic lipid 
elimination via the VLDL-TG production pathway; lastly, we review the OT-ANP system 
focusing on the ANP receptor; guanylyl cyclase-A (GC-A) and its physiological and 
metabolic functions. Chapter 2 introduces the original research articles of this thesis that are 
presented according to the format required by the journals to which they are published or 
submitted. Finally, chapter 3 provides a general discussion and conclusion on the findings 
of the thesis. 
 
  
Chapter 1: Review of literature  
1.1 Non-alcoholic hepatic steatosis (NAHS) 
As the worldwide obesity epidemic continues to increase, the prevalence of NAHS, 
will become increasingly prominent (Pillai and Rinella 2009). NAHS has been identified as 
an independent risk factor of insulin resistance, metabolic syndrome, and cardiovascular 
disease (Johnson, Sachinwalla et al. 2009). In recent years, high dietary fat intake has been 
considered as a main contributing factor for obesity (Satia-Abouta, Patterson et al. 2002) 
inducing several obesity related metabolic deteriorations including liver lipid infiltration 
(Marchesini, Marzocchi et al. 2005; Kotronen, Westerbacka et al. 2007). Both alcoholic 
and non-alcoholic fatty liver are characterized by lipid deposition in hepatocytes. NAFLD 
is defined as accumulation of fat in the liver which exceeds 5% to 10% of liver weight in 
individuals who do not use significant amounts of alcohol (Neuschwander-Tetri and 
Caldwell 2003). Almost one quarter of adults in many industrialized countries have 
excessive hepatic fat accumulation (Lazo and Clark 2008). There is currently no accepted 
treatment for NAHS. To date, the most effective treatments for this disease are lifestyle 
changes like diets inducing weight reduction and exercise (Postic and Girard 2008). 
Importantly, post-menopausal women are sub-group of the population that is particularly at 
an increased risk of hepatic fat accumulation. There are several evidences indicating that, 
indeed, menopause is associated with an increased risk of hepatic steatosis development 
(Clark 2006; Volzke, Schwarz et al. 2007). Increased risk of liver lipid infiltration in post-
menopausal women is, therefore, a concern that needs to be characterized especially in 
relation to the high dietary fat intake of Western societies. The origin of the fat (mainly TG) 
that accumulates in the liver is complex and only partially understood (Pessayre and 
Fromenty 2005; Postic and Girard 2008). On the other hand, it is a condition usually 
associated with obesity, diabetes, and insulin resistance. The overall mechanism of liver fat 
accumulation involves an imbalance between lipid availability (from circulating lipid 
uptake or de novo lipogenesis) and lipid disposal (through fat oxidation or triglyceride-rich 
lipoprotein secretion). In the following sections we will review the metabolic pathways 
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implicated in the metabolism of lipids in liver that may have an incidence on hepatic fat 
accumulation.  
1.1.1 Free fatty acid (FFA) influx into the liver 
The mammalian body greatly relies on fatty acids as suppliers of chemically stored 
energy, building blocks of cellular membranes and signal transducers (van der Vusse 2009). 
The main source of fatty acids is dietary lipid, digested in the gastro-intestinal tract by the 
catalytic action of pancreatic hydrolytic enzymes. Part of fatty acid production also 
originates from synthesis in the liver using carbohydrates as substrate. Large amounts of 
fatty acids are stored in fat cells in adipose tissue. Fatty acids are transported in the body 
via the lymphatic and vascular systems. Basically, two transport forms are used: fatty acids 
are transported as TG, the main lipid component of circulating lipoproteins such as 
chylomicrons (CM) and VLDL, or FFA (van der Vusse 2009). FFA whether obtained 
through dietary sources or produced via de novo lipogenesis, may generally undergo three 
fates: stored intracellularly in adipose tissue in the form of TG (Yu and Ginsberg 2005), 
exported from the liver into the plasma in the form of VLDL-TG, or used as an energy 
source via FFA oxidation. FFA may also be stored in non-adipocyte cells as TG which is 
usually a source of lipotoxicity (Manco, Calvani et al. 2004). Non-adipose TG storage 
usually happens in situations where available FFA exceeds the catabolic capacity of 
peripheral tissues, or when adipose tissue storage is impaired (Yu and Ginsberg 2005). It 
has been shown that mammalian liver is normally capable of storing considerable amounts 
of TG. The liver accommodates TG in storage droplets in the cytosol of hepatocytes 
(Gibbons, Islam et al. 2000).  
It is now proposed that the development of NAHS is closely linked to an excess 
flow of FFA toward the liver (Cusi 2009). Potential sources of FFA for liver fat consist of: 
(1) peripheral fats stored in adipose tissue that flow to the liver by the plasma FFA pool; (2) 
FFAs synthesized within the liver through de novo lipogenesis; (3) dietary fatty acids that 
are transported through CM from the intestine to the FFA pool and then to the liver; and (4) 
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uptake of CM remnants by the liver (Fig. 1) (Adiels, Olofsson et al. 2008; Postic and Girard 
2008). Using a multiple stable isotope approach in humans, Donnelly et al. (Donnelly, 
Smith et al. 2005) estimated that while 60% of the accumulated TG in the hepatic steatosis 
conditions originates from plasma FFA pool, approximately 10% comes from the diet and 
about 30% from de novo lipogenesis. 
Catecholamines (e.g. epinephrine and norepinephrine) and insulin are the major 
hormones that control lipolytic activity. On the adipocyte surface catecholamines bind to its 
receptor and stimulate lipolysis though β-adrenergic receptors (β-ARs) coupled to 
stimulatory GTP-binding protein (Gs). Activation of Gs proteins stimulates the adenylate 
cyclase (AC), the enzyme that catalyzes the formation of cyclic adenosine monophosphate 
(cAMP) (Duncan, Ahmadian et al. 2007). Increasing concentrations of cAMP in the cell 
activates protein kinase A (PKA) (Belfrage, Fredrikson et al. 1982), which catalyzes the 
phosphorylation and subsequent activation of hormone sensitive lipase (HSL) (Holm 2003; 
Duncan, Ahmadian et al. 2007; Granneman and Moore 2008). Activated HSL is able to 
break down TGs to fatty acids and glycerol (Arner and Langin 2007). The cAMP/PKA-
HSL pathway has long been considered to be the only regulator of adipocyte lipolytic 
cascade (Langin 2006). However, a novel lipolytic pathway in human adipocytes which 
does not involve cAMP has been observed, this pathway acts through natriuretic peptides 
(NPs) (Lafontan, Moro et al. 2005). NPs bind to their specific receptors (this action will be 
explained in details in the section of metabolic effects of NPs) on human fat cells and 
subsequently activate protein kinase G (PKG), which causes phosphorylation and activation 
of HSL. It seems that these NPs stimulate lipolysis to the same extent as catecholamines 
(Arner and Langin 2007). On the other hand, insulin acts as a potent inhibitor of lipolysis 
via binding to its receptor. Binding of insulin to its receptor stimulates the degradation of 
cAMP using the enzyme phosphodiesterase 3B (PDE 3B), leading to a decreased activity of 
PKA and inhibition of HSL activity (Arner and Langin 2007).  
It appears that insulin resistance in adipose tissue plays an important role in the 
pathogenesis of NAHS. In the insulin resistance state, the inhibitory action of insulin on  
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Figure 1. Sources of fatty acids for liver fat. Fatty acids (FA) may enter the liver via 4 different pathways:  
(1) FFA derived from adipose tissue, (2) hepatic de novo lipogenesis (DNL), (3) spillover of FA from 
lipolysis of chylomicron (CM)-triglycerides (TG) into the FFA pool, (4) and uptake of TG from CM 
remnants. Adapted from Adiels et al.  (Adiels, Olofsson et al. 2008). 
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adipocyte lipolysis is impaired, thus resulting in an increase in the rate of adipocyte 
lipolysis and an increased influx of FFA into the liver (Browning and Horton 2004; Zak 
and Slaby 2008). Additionally, fatty acid flux into the plasma FFA pool is more facilitated 
in insulin resistance by decreasing glucose uptake in adipocytes which reduces glycerol-3-
phosphate levels, thus reducing the reutilization of fatty acids for TG synthesis (Tamura 
and Shimomura 2005). Moreover, it has been shown that the severity of NAHS is 
positively related to the visceral fat accumulation independently of body mass index 
(Eguchi, Eguchi et al. 2006). In this regard, in vitro evidence indicates that lipolytic 
sensitivity to catecholamines is higher in fat cells from intra-abdominal adipose tissue than 
from subcutaneous fat of the gluteal/femoral region (Richelsen, Pedersen et al. 1991). 
Furthermore, this study shows that the antilipolytic effect of insulin is greater in fat cells 
from subcutaneous than from intra-abdominal adipose tissue suggesting the enhanced 
lipolytic activity in intra-abdominal adipose tissue. Higher fatty acid flux from this depot 
into the portal circulation is primarily taken up by the liver (Horowitz 2001) providing an 
important source of substrate for hepatocellular TG synthesis (Bradbury and Berk 2004). 
Nevertheless, it has been reported that the major source of FFA delivered to the liver might 
be derived from FFA released from subcutaneous adipose tissue during postabsorptive 
conditions through the systemic circulation (Fabbrini, Sullivan et al. 2010). As a whole, 
Adiels et al. suggest that the increased release of fatty acids to the liver from adipose tissue 
is the most important factor in liver fat accumulation (Adiels, Olofsson et al. 2008).  
On the other hand, dietary fatty acids after entering the circulation through CM from 
the intestine can be taken up by the liver as CM remnants. Alternatively, lipoprotein lipase 
(LPL) catalyzes the release of fatty acids from the CMs at a rate that exceeds tissue uptake, 
resulting in a spillover of these fatty acids into the plasma FFA pool (Barrows and Parks 
2006). The contribution of dietary fatty acids to liver TGs, therefore, depends on the fat 
content of the diet (Adiels, Olofsson et al. 2008). It has been shown that NAHS is linked to 
obesity for which caloric overconsumption is considered as a main factor (Festi, Colecchia 
et al. 2004). Since dietary fat is the most energy-dense macronutrient, with about 38 kJ/g 
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(in comparison, carbohydrate and protein only provide about 17 kJ/g), an increase in 
dietary fat intake can easily promote an increase in energy intake (Schrauwen and 
Westerterp 2000). It is well established that HF diets induce deleterious metabolic effects in 
both rodents and humans (Kraegen, Clark et al. 1991; Ghibaudi, Cook et al. 2002; Satia-
Abouta, Patterson et al. 2002). Animal studies clearly indicate that the ingestion of a HF 
diet in sedentary rats results in obesity which is accompanied by liver lipid infiltration 
(Collin, Chapados et al. 2006; Gauthier, Favier et al. 2006). There are also studies in human 
identifying high dietary fat intake as a main contributing factor to obesity (Satia-Abouta, 
Patterson et al. 2002) that induced several obesity related metabolic deteriorations including 
liver lipid infiltration (Marchesini, Marzocchi et al. 2005; Kotronen, Westerbacka et al. 
2007). Taken together, the main contributing factor for excess TG accumulation in NAHS 
seems to be the increased release of fatty acids from adipose tissue and dietary fatty acids, 
which flow to the liver via the FFA pool. 
1.1.2 Metabolic pathways contributing in the development of NAHS 
NAHS occurs when there is an imbalance between pathways of lipid accumulation 
and lipid elimination. TGs consisting of a glycerol and three long chain fatty acids (LCFA) 
are the main lipid component in the liver (Choi and Diehl 2008). The four pathways leading 
to hepatic TG accumulation include: (1) increased lipid uptake by liver (2) increased 
hepatic de novo lipogenesis (3) reduced hepatic oxidation of fatty acids and (4) diminished 
export of lipids from the liver (Fig. 2). Imbalance between these metabolic steps will 
increase TG accumulation within the cytoplasm of hepatocytes (Wei, Rector et al. 2008). In 
the next section we will explain the intra-hepatic-related metabolic pathways leading to 
NAHS.  
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Figure 2. Overview of the four main pathways involved in the development of NAHS and their 
regulatory factors. NAHS is characterized by (1) an increase in the uptake of lipids by the liver, (2) an 
increase in hepatic de novo lipogenesis (DNL), and an insufficient elimination of excess liver triacylglycerol 
(TAG) by means of (3) hepatic lipid oxidation and (4) very low density lipoprotein (VLDL) assembly and 
secretion. HSL, hormone sensitive lipase; LPL, lipoprotein lipase; FAT/CD36, fatty acid translocase/cluster 
of differentiation 36; SREBP-1c, sterol regulatory element-binding protein-1c; ChREBP, carbohydrate 
response element-binding protein; LXR, liver X receptors; PPAR, peroxisomal proliferator-activated 
receptors; AMPK, AMP-activated protein kinase; PGC-1α, peroxisome proliferator-activated receptor gamma 
coactivator-1 alpha; MTP, microsomal triglyceride transfer protein; DGAT, diacyglycerol acyltransferase; 
ARF-1, ADP-ribosylation factor 1; ApoB, apolipoprotein B. Taken from Lavoie et al.  (Lavoie and Gauthier 
2006). 
 
 
  
 
11
1.1.2.1 Fatty acid uptake pathway 
Circulating FFAs, either of dietary or endogenous origin (adipose tissue lipolysis), 
provide most of the hepatic lipid content in the development of NAHS (Musso, Gambino et 
al. 2009). It seems that the rate of hepatic FFA uptake depends on the delivery of FFA to 
the liver and the liver’s ability for FFA transport (Fabbrini, Sullivan et al. 2010). LCFA 
cross the mammalian cells either through the diffusion or the facilitated protein-mediated 
mechanism (Bradbury and Berk 2004). Over 90% of the LCFA uptake into tissues 
including hepatocytes is mediated by proteins through a facilitated mechanism (Stump, Fan 
et al. 2001). Several membrane proteins that are involved in the uptake of LCFA have been 
identified. The most important of these proteins are: fatty acid translocase (FAT, also 
known as cluster of differentiation 36 (CD36)), long chain fatty acyl-coenzyme A 
synthetases (LACS) and fatty acid transport protein (FATP). Stahl (Stahl 2004) suggested a 
model for LCFA uptake in which, LCFA are either transported directly by FATP 
complexes across the plasma membrane or alternatively, are first accumulated on the 
plasma membrane by binding to CD36, which subsequently gives the fatty acids to the 
FATP (Fig. 3). After uptake, LCFA is activated quickly by LACS to prevent efflux. In  
addition, binding of intracellular LCFA and acyl-CoA to fatty acid binding protein (FABP) 
and acyl-CoA binding proteins (ACBP) facilitate the unloading of transporters and act as an 
intracellular fatty acid buffer (Fig. 3) (Stahl 2004). FFA and fatty acyl-CoA bounded to 
FABP and ACBP transport them to intracellular compartments for metabolism or the 
nucleus to interact with transcription factors (Nguyen, Leray et al. 2008). 
Any condition that constantly raises plasma FFA concentrations (obesity, metabolic 
syndrome and type 2 diabetes) will lead to increased hepatic FFA uptake (Bradbury 2006). 
For instance, HF diet in rats resulted in significantly higher plasma FFA leading to hepatic 
steatosis (Gauthier, Couturier et al. 2003). In contrast, in mice lacking HSL, plasma FFA  
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Figure 3. A model for cellular fatty acid uptake. Extracellular long chain fatty acids (LCFA) might directly 
bind to fatty acid transport protein (FATP) complexes (blue) and be transported into cells. Alternatively, 
LCFA could bind first to cluster of differentiation 36 (CD36) (yellow), which hands on the LCFA to FATP 
dimmers. Intracellular LCFA are coupled to coenzyme A (CoA) by long chain fatty acyl-CoA synthetase 
(LACS, green), preventing their efflux, while fatty acid binding proteins (FABP) act as a cytoplasmic buffer 
for incorporated LCFA (ACBP acyl-CoA binding protein). Taken from Stahl et al.  (Stahl 2004). 
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concentration is low and as a consequence no steatosis is observed (Voshol, Haemmerle et 
al. 2003). In this regard, it has been shown that following a HF diet or fasting, the liver of 
LFABP (liver type FABP) knockout mice (LFABP-/-) were protected from steatosis while 
wild type mice developed fatty liver in both situations (Martin, Danneberg et al. 2003; 
Newberry, Xie et al. 2006). Newberry et al. (Newberry, Xie et al. 2003) also showed that in 
response to 48-h fasting, wild type mice demonstrated a 10-fold increase in hepatic TG 
content while LFABP-/- mice demonstrated only a 2-fold increase. In this last study the 
lower hepatic TG content observed in LFABP-/- mice was due to a reduction in fatty acids 
uptake by the liver in a situation of increased mobilization from adipocytes TG stores and 
FFA availability due to the fasted state, and not by increased hepatic TG secretion or fatty 
acid oxidation, since both of them were reduced in LFABP-/- mice. In another study it was 
reported that gene expression and/or protein content of FAT/CD36 were increased in liver 
of obese subjects with NAFLD compared with those who have normal intra-hepatic TG 
content (Greco, Kotronen et al. 2008; Fabbrini, Magkos et al. 2009).  
1.1.2.2 De novo lipogenesis pathway 
Fatty acid synthesis is expressed in two major tissues, liver and adipose tissues, but 
the relative contribution of these sites to de novo lipogenesis is variable among species. In 
human, it appears that the liver is the major site of de novo lipogenesis (Patel, Owen et al. 
1975), while in rodents, both liver and adipose tissue are important (Pullen, Liesman et al. 
1990). In adipose tissue, de novo synthesis of fatty acids contributes to fat deposition and 
long term energy reservoir while in the liver, synthesized fatty acids are exported via 
lipoprotein production, and thus provide an energy source for the body and structural 
component for membrane building (Nguyen, Leray et al. 2008). The de novo lipogenic 
pathway is highly dependent upon nutritional and hormonal conditions as it is now clearly 
established that insulin and glucose are required for lipogenic enzyme transcription 
(Foufelle and Ferre 2002). Conditions associated with high rates of lipogenesis, such as a 
low fat/high carbohydrate diet, hyperglycemia and hyperinsulinemia, are associated with a 
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shift in cellular metabolism from lipid oxidation to TG synthesis, thereby increasing the 
availability of liver TG (Postic and Girard 2008). The two key transcriptional regulators in 
hepatic de novo lipogenesis, sterol regulatory element-binding protein-1c (SREBP-1c) and 
carbohydrate responsive element-binding protein (ChREBP), are respectively activated in 
response to insulin and glucose, and control lipogenic gene expressions such as acetyl-CoA 
carboxylase (ACC) and fatty acid synthase (FAS) (Fig. 4)  (Dentin, Girard et al. 2005). It 
appears that abnormal transcription of one or two of these regulators can result in 
accumulation of TG in the liver. The role of SREBP-1c in the pathogenesis of fatty liver 
has been explored in different animal models. SREBP-1c levels are elevated in fatty livers 
of obese, insulin resistant and hyperinsulinaemic ob/ob mice (Shimomura, Bashmakov et 
al. 1999; Shimomura, Matsuda et al. 2000). Conversely, expression of lipogenic enzymes 
and liver fatty acid infiltration are dramatically reduced by SREBP-1c suppression (Sekiya, 
Yahagi et al. 2003; Teran-Garcia, Adamson et al. 2007). On the other hand, studies using 
ChREBP-/- rodents have indicated that hepatic ChREBP is required for the normal lipogenic 
response to a carbohydrate load (Iizuka, Bruick et al. 2004). Dentin et al. (Dentin, Pegorier 
et al. 2004) demonstrated that glycolytic and lipogeneic gene expression is synergistically 
regulated by SREBP-1c and glucose acting through ChREBP and showed that decreased 
hepatic ChREBP gene expression resulted in reducing lipogenic gene expressions of FAS 
and ACC. It seems like liver de novo lipogenesis is a highly regulated metabolic pathway in 
which transcription factors such as liver X receptor (LXR), SREBP-1c, and ChREBP play 
an important role over the enzymes involved in de novo synthesis of fatty acids including 
ACC, FAS, and stearoyl-coenzyme A desaturase-1(SCD-1) (Strable and Ntambi 2010). In 
humans, it has been reported by Schwarz et al. (Schwarz, Linfoot et al. 2003) that the 
contribution of FFA synthesized from hepatic de novo lipogenesis in liver TG formation 
was 4 times higher in hyperinsulinemic patients with NAFLD compared to healthy 
subjects. Hyperinsulinemia and hyperglycemia, often found in a context of NAFLD, and 
their effect on SREBP-1c and ChREBP respectively, (Girard, Perdereau et al. 1994) are 
therefore likely to induce an abnormal increase in lipogenic activity and  
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Figure 4. SREBP-1c and ChREBP act in synergy to regulate lipogenic gene expression. The 
phosphorylation of glucose in glucose 6-phosphate, by hepatic glucokinase, is an essential step for glucose 
metabolism as well as for the induction of glycolytic and lipogenic genes. The recent identification of 
ChREBP has shed light on the possible mechanism whereby glucose affects gene transcription. The activity 
of ChREBP requires a mechanism of phosphorylation/dephosphorylation which is determined by the relative 
activity of protein phosphatase 2A (PP2A), regulated by X5P concentrations. SREBP-1c, which is induced by 
insulin, also plays an important role in mediating insulin signaling on lipogenic gene expression. These two 
transcription factors work synergistically to induce transcription of the lipogenic genes in the presence of 
glucose and insulin. Adapted from Dentin et al.  (Dentin, Girard et al. 2005). 
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contribute to the development of NAFLD. After converting fatty acids into TG, TG can 
then be stored as lipid droplets within hepatocytes or secreted into the blood as VLDL, but 
they can also be hydrolyzed and the fatty acids channeled towards the β-oxidation pathway 
(Postic and Girard 2008).  
1.1.2.3 Hepatic lipid oxidation  
Lipid oxidation is one of the lipid elimination pathways in the liver. Fatty acid 
oxidation is the main source of energy for skeletal muscle and the heart, while the liver 
oxidizes fatty acids mostly under the conditions of prolonged fasting, during illness and 
increased physical activity (Wei, Rector et al. 2008). Fatty acid oxidation in the liver takes 
place in three sub-cellular organelles: the β-oxidation occurs in mitochondria and 
peroxisomes, whereas ω(omega)-oxidation occurs in the smooth endoplasmic reticulum 
(Tessari, Coracina et al. 2009). It seems that peroxisome proliferator–activated receptor α 
(PPARα) plays a key role in these oxidation systems by transcriptionally controlling their 
important enzymes. Although mitochondria and peroxisomes have similar function (β-
oxidation), there is a difference between these two pathways for fatty acid oxidation. 
Peroxisomal β-oxidation is responsible for the metabolism of very LCFA while 
mitochondrial β-oxidation is responsible for the oxidation of short, medium, and long chain 
fatty acids (Nguyen, Leray et al. 2008). Short and medium chain fatty acids (12 carbon or 
less) freely enter the mitochondria and via intra-mitochondrial oxidation results in the 
formation of acetyl-CoA (Wei, Rector et al. 2008). LCFA (14 carbon or more) entry into 
the mitochondria is regulated by the activity of the enzyme carnitine palmitoyl transferase-1 
(CPT-1) (Kerner and Hoppel 2000). Therefore this enzyme is considered as a rate limiting 
step in the oxidation of fatty acids (Horowitz 2001). Once inside the mitochondria, the fatty 
acids proceed through a sequence of metabolic processes to synthesize adenosine 
triphosphate (ATP) for energy. Destruction in any of these processes could reduce fat 
oxidation resulting in liver lipid accumulation (Horowitz 2001). For instance, it has been 
shown that the activity of mitochondrial respiratory chain complex is decreased in the liver 
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of patients and animal models with NAFLD (Perez-Carreras, Del Hoyo et al. 2003; Garcia-
Ruiz, Rodriguez-Juan et al. 2006). Moreover, many enzymes are implicated in 
mitochondrial β-oxidation and deficiency of these enzymes can lead to the development of 
hepatic steatosis. For instance, mice with disrupted medium chain and very long chain acyl-
CoA dehydrogenase genes manifest defects in fatty acid oxidation that likely lead to the 
observered micro and macrovascular hepatic steatosis found in these mice (Wei, Rector et 
al. 2008). As we mentioned earlier, peroxisomal β-oxidation metabolizes very LCFA (> 
C20) (Musso, Gambino et al. 2009). Deficiency in peroxisomal β-oxidation enzymes has 
been recognized as an important cause of microvesicular steatosis and steatohepatitis (Fan, 
Pan et al. 1998). Long chain and very long chain fatty acids are also metabolized by the 
cytochrome P450 CYP4A ω-oxidation system to dicarboxylic acids that provide as 
substrates for peroxisomal β-oxidation (Reddy and Hashimoto 2001). Dicarboxylic acids 
are toxic for mitochondria, since they inhibit fatty acid oxidation system (Macdonald and 
Prins 2004). An effective peroxisomal β-oxidation system is needed to minimize the 
deleterious effects of dicarboxylic and other toxic fatty acids to prevent hepatic steatosis 
(Musso, Gambino et al. 2009).  
1.1.3 Hepatic VLDL-TG production 
This section on VLDL-TG production will be presented as a separate one in regards 
to its importance for the work presented in this thesis. Lipoproteins are particles that 
contribute to overall metabolic homeostasis by transporting hydrophobic lipids including 
TG and cholesterol ester (CE) (Dixon 1970) in the circulation to and from different tissues 
in the body (Mason 1998). Transport of TG throughout the body is crucial for the 
maintenance of whole body energy balance. A particular lipoprotein class termed VLDL is 
the primary vehicle synthesized by the liver for the transport of endogenous TG (Mason 
1998). In the body, two types of lipoproteins mainly transport TG to peripheral tissues such 
as muscle and adipocytes: CM and hepatic VLDL. CMs produced by enterocytes transport 
  
 
18
the majority of TG from nutrition while VLDL synthesized and secreted by hepatocytes 
transport TG from the liver (Gibbons, Wiggins et al. 2004). 
For many years it has been thought that the major role of VLDL was the effective 
control of the plasma glucose concentration by transporting de novo fatty acids synthesized 
in liver toward adipose tissue for storage as TG  (Schwarz, Linfoot et al. 2003). This view 
has been challenged by the fact that, even under conditions in which hepatic de novo 
lipogenesis is high, the hepatic VLDL-TG is not derived from this source but from pre-
formed fatty acids entering the liver from adipose tissue (Gibbons 1990; Hellerstein, 
Schwarz et al. 1996). VLDL-TG is hydrolyzed by LPL to fatty acids which are stored in 
adipose tissue. Therefore, liver plays a very important protective role in efficiently 
modulating plasma FFA concentrations. Liver, as a valuable buffer, removes fatty acids 
from the circulation, temporarily stores them as a benign derivative (TG) and secretes them 
at a later time as VLDL when the period of maximum danger is passed (Gibbons, Wiggins 
et al. 2004). However, although fat may accumulate in liver substantially, the capacity of 
liver tissue for TG storage is limited (Berk and Stump 1999). It seems that higher liver lipid 
concentrations resulting from enhanced entrance of fatty acids, high rate of de novo 
lipogenesis, down-regulated fatty acid oxidation (or their combinatory effect) increases the 
secretion of VLDL-TG from the liver (McGarry, Mannaerts et al. 1977; Schwarz, Linfoot 
et al. 2003). The importance of hepatic TG for the assembly and secretion of VLDL is 
supported by in vivo observations that the secretion of VLDL increases with increasing 
hepatic concentrations of lipids (Adiels, Taskinen et al. 2006). 
1.1.3.1 Mechanism of hepatic VLDL-TG production 
The hepatic VLDL-TG production is a complex mechanism that involves several 
regulatory molecules and enzymes, which takes place in the membrane and lumen of 
endoplasmic reticulum (ER: the secretory apparatus) (Gibbons, Wiggins et al. 2004) (Fig. 
5). In the process of VLDL assembly, the newly formed cytosolic TG pool from 
extracellular fatty acids or de novo synthesized endogenous fatty acids, is not directly 
  
 
19
 
Figure 5. Role of the cytosolic and microsomal pools of liver TG in the assembly of VLDL in ER. For 
explanation refer to text and see list of abbreviations for meaning of acronyms. Taken from Lavoie et al. 
(Lavoie and Gauthier 2006). 
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incorporated into the VLDLs. Extracellular fatty acids from the plasma come into the 
hepatocyte and are esterified by diacylglycerol acyltransferase-1 enzyme (DGAT-1, also 
called overt DGAT) producing TG which is stored in the cytosol (cytosolic TG pool). Most 
of the TG utilized for the assembly of VLDL in the ER of the hepatocyte, is mobilized by 
lipolysis of the cytosolic TG pool (through the lipolytic action of arylacetamide deacyclase 
(AADA) and TG hydrolase (TGH)). The products of lipolysis are re-esterified by 
diacylglycerol acyltransferase-2 enzyme (DGAT-2, also called latent DGAT) producing the 
microsomal TG pool in ER membrane (Fig. 5). Some of these microsomal TGs are recycled 
to the cytosol and some are channeled into a TG-rich VLDL precursor. The formation of 
this precursor is positively regulated by MTP and negatively regulated by insulin (Gibbons, 
Wiggins et al. 2004).  
A useful working model of VLDL assembly originates from the data of Alexander 
et al. in 1976  (Alexander, Hamilton et al. 1976). This model proposes that TG becomes 
associated with apolipoprotein B (apoB) in at least two distinct stages of the assembly 
process (Shelness and Sellers 2001). In the first stage, a small quantity of TG is transferred 
to apoB in the ER forming small apoB-containing VLDL precursors which is dependent 
upon MTP (Rustaeus, Stillemark et al. 1998). The second stage of VLDL formation, 
referred as the maturation phase, is characterized by the fusion of the apoB-containing 
VLDL precursor with a larger droplet of TG resulting in a ready for secretion mature 
VLDL (Rava, Ojakian et al. 2006). The details of this process remain unclear, but it seems 
that the formation of TG-rich particle and fusion of this molecule with the VLDL precursor 
is dependent on the activity of the ADP-ribosylation factor-1 protein (ARF-1) that activates 
phospholipase D (PLD) to form phosphatidic acid (Gordon 1997; Asp, Claesson et al. 
2000) (Fig. 6). It has been shown that inhibition of ARF-1 slows down the maturation 
phase of VLDL assembly without affecting the formation of the apoB-containing precursor 
(Rustaeus, Lindberg et al. 1995). VLDL particles are mostly composed of TG (60%), 
phospholipids (15%), cholesterol (15%) and proteins (10%) (Gordon, Wetterau et al. 1995). 
Secretion of hepatic VLDL is an effective way for eliminating hepatic TG, thus preventing  
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Figure 6. Targets for the regulation of the TG-rich particle precursor of VLDL. Phosphatidic acid 
formed by the ARF-1-mediated activation of phospholipase D (PLD) contributes TG either to the TG-rich 
VLDL precursor particle or to the mature VLDL. Taken from Gibbons et al. (Gibbons, Wiggins et al. 2004). 
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potential liver TG accumulation. Accordingly, any alteration in the regulation of this 
mechanism could contribute to the development of NAHS. 
1.1.3.2 Molecular mediators of hepatic VLDL-TG production 
1.1.3.2.1 Microsomal triglyceride transfer protein (MTP)   
MTP is a heterodimer protein complex primarily present in the lumen of the 
endoplasmic reticulum in hepatocytes and enterocytes. It consists of a unique large (97-
kDa) subunit and a smaller multifunctional subunit (58-kDa) which is identical to protein 
disulfide-isomerase (PDI) (White, Bennett et al. 1998; Mohler, Zhu et al. 2007). The large 
subunit possesses lipid transfer activity on the complex (Jamil, Dickson et al. 1995; 
Mohler, Zhu et al. 2007) and PDI mediates the folding of the large apoB protein during 
translation (van Greevenbroek, van Meer et al. 1996). The complex is responsible for the 
transport of neutral lipid (TG and CE) between the phospholipid surfaces of the ER 
(Gordon, Jamil et al. 1994; Benoist, Nicodeme et al. 1996). It is essential for the assembly 
of VLDLs by liver and CMs by small intestine (Gordon and Jamil 2000; Hussain, Shi et al. 
2003). Synthesis of TG and CE is beneficial in avoiding toxicities associated with excess 
FFA and free cholesterol (Hussain and Bakillah 2008). MTP is expressed primarily in 
tissues that synthesize apoB containing lipoproteins such as liver and small intestine 
(Shoulders, Brett et al. 1993; Nakamuta, Chang et al. 1996). Its expression in other tissues 
including myocardium, ovary, testis, kidney, and retina as well as mouse brown and white 
adipose tissue has also been reported (Shoulders, Brett et al. 1993; Nielsen, Perko et al. 
2002; Li, Presley et al. 2005; Swift, Kakkad et al. 2005). Since some of these tissues do not 
express apoB, MTP might be implicated in other aspects of lipid trafficking or storage 
(Mohler, Zhu et al. 2007).  
MTP lipid transfer activity is involved in importing TGs into the lumen of the ER. 
In addition to its lipid transfer activity, MTP physically interacts with apoB (Hussain, Iqbal 
et al. 2003). The absolute requirement for the role of MTP in VLDL-TG assembly is shown 
by the clinical condition of abetalipoproteinaemia, a recessive genetic disease in humans 
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characterized by a mutation of the MTP gene (Gregg and Wetterau 1994), and from 
experimental studies in liver-specific MTP knockout mice (Raabe, Veniant et al. 1999). 
The absence of MTP in abetalipoproteinemia patients results in concentrations of plasma 
apoB undetectable in these patients (Wetterau, Aggerbeck et al. 1992; Shoulders, Brett et 
al. 1993). Similarly, the deletion of the MTP gene in mice liver resulted in impaired 
secretion of VLDL (Raabe, Flynn et al. 1998; Raabe, Veniant et al. 1999). Moreover, a 
polymorphism of this gene in human has been associated with the development of NAFLD 
(Gambino, Cassader et al. 2007). 
1.1.3.2.2 Apolipoprotein B (ApoB) 
Circulating plasma TG is a mixture of lipoprotein which is derived either from 
intestine (CMs) or the liver (VLDL). Lipoproteins are characterized by different densities 
and apoprotein compositions. A critical element of VLDL is a large protein of apoB which 
seems to preserve the structural integrity of the lipoprotein by associating both with the 
outer hydrophilic shell and with the hydrophobic core (Dixon and Ginsberg 1993; Gruffat, 
Durand et al. 1996). ApoB can be found in two types: apoB100 and apoB48. The name of 
apoB48 comes from the fact that its molecular weight is approximately 48% of apoB100. In 
human, apoB100 is associated with VLDL and is synthesized exclusively in the liver, while 
apoB48 is synthesized exclusively by enterocytes (intestinal absorptive cells) and is 
associated with CMs (Krishnaiah, Walker et al. 1980; Chen, Habib et al. 1987; Yao and 
McLeod 1994). ApoB is synthesized in the ER of hepatocytes where it is combined with 
lipids stored in liver (predominantly with TG) to form VLDL particles as it passes through 
the secretory pathway and is secreted into plasma as a lipid-rich lipoprotein particle (Mason 
1998). It appears that lipids contained in VLDL cannot be secreted in the absence of apoB 
(Cartwright and Higgins 1996). When the availability of TG is not sufficient for the 
formation of VLDL, apoB is degraded and VLDL particle formation is reduced (Mason 
1998). A genetic defect in apoB100 has been shown to be associated with impaired VLDL-
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TG production resulting in the excess deposition of TG in the liver (Badaloo, Reid et al. 
2005; Schonfeld, Yue et al. 2008). 
1.1.3.2.3 Diacylglycerol acyltransferase (DGAT)-1 and-2 
DGAT is an endoplasmic reticulum membrane-associated enzyme that catalyzes the 
final step of TG synthesis by facilitating the linkage of 1, 2 diacylglycerol (DAG) to a long 
chain fatty acyl-CoA. There are two isoforms of the enzyme: the overt (visible) type (on the 
cytosolic side of ER membrane; DGAT-1) that catalyzes the synthesis of TG destined to 
cytoplasmic droplets, and latent (invisible) type (on the lumen side of ER membrane; 
DGAT-2) that catalyzes the TG synthesis for VLDL formation (Owen, Corstorphine et al. 
1997). DGAT-2 is expressed primarily in the liver, intestine, and white adipose tissue, 
whereas DGAT-1 is expressed in all tissues (Cases, Smith et al. 1998; Cases, Stone et al. 
2001). It has been shown that greater activities of both DGATs are implicated in the 
increased rate of hepatic TG secretion and intracellular accumulation of TG in ob/ob, 
suggesting causal importance of both DGATs for the steatosis and hypertriglyceridemia 
observed in the ob/ob genotype (Waterman and Zammit 2002).  
However, the precise role of each enzyme in hepatic TG synthesis and VLDL 
secretion is unclear. Since it appears that cytosolic droplet TG cannot be incorporated 
directly into VLDL formation, the relative activities of these two functions of DGAT may 
have a significant impact on the level of triglyceridemia as well as on the development of 
hepatic steatosis (Yamazaki, Sasaki et al. 2005). DGAT-1 lacking mice have normal liver 
and plasma TG levels but are resistant to HF diet induced obesity through a mechanism 
involving increased energy expenditure as well as enhanced sensitivity to insulin and leptin 
(Smith, Cases et al. 2000). In contrast, DGAT-2 deficient mice which die shortly after birth 
because of lipopenia (an abnormally small amount or a deficiency of lipids in the body) and 
severe skin abnormality have large reductions in carcass, liver, and plasma TG as well as 
plasma FFA and glucose (Stone, Myers et al. 2004). Recently, Liu et al. showed that 
inhibition of DGAT-2 in wild type mouse liver resulted in decreased VLDL secretion in a 
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dose dependent manner and reduced plasma TG, total cholesterol, and apoB (Liu, Millar et 
al. 2008). In this last study, inhibition of DGAT-2 in DGAT-1 knockout mice produced the 
same effect. This indicates that DGAT-2 is the isoform responsible for synthesizing TG 
targeted for secretion and that presence and absence of DGAT-1 does not affect the 
process.  
1.1.3.3 Regulation of hepatic VLDL-TG production 
The regulation of hepatic VLDL-TG production depends mainly on lipid 
availability, activity of molecular mediators, mostly key MTP enzyme, and insulin (Julius 
2003). The importance of the VLDL-TG production’s molecular mediators including MTP 
has been reviewed earlier. In the next section the two other important regulators, lipid 
availability and insulin, are discussed. 
1.1.3.3.1 Liver lipid availability  
For lipoprotein synthesis, four sources of fatty acids are used: de novo lipogenesis, 
cytoplasmic TG stores, fatty acids derived from lipoproteins taken up directly by the liver, 
and plasma FFA (Julius 2003). It appears that de novo lipogenesis plays a minor role in 
regulating VLDL synthesis. However, it is clearly elevated under conditions of high 
carbohydrate intake. On the other hand, plasma FFAs which seem to play an important role 
in hepatic TG storage (Diraison and Beylot 1998) also stimulate hepatic VLDL production. 
It has been shown that an increased delivery of fatty acids increases the secretion of VLDL-
TG from the liver tissue (Lewis, Uffelman et al. 1995; Lewis 1997). Moreover, the 
importance of liver fat content for the assembly and secretion of VLDL has been 
demonstrated by in vivo turnover studies (Adiels, Taskinen et al. 2006). Secretion of VLDL 
increases with increasing concentrations of liver lipids and cytoplasmic TG stores appear to 
fundamentally contribute to VLDL-TG (Adiels, Olofsson et al. 2006; Fabbrini, Mohammed 
et al. 2008) (Fig. 7). In fact, the relationship between oxidation and esterification of fatty 
acids in hepatocytes appears to be important in regulating the VLDL synthesis: an 
enhanced esterification is accompanied by increased VLDL  
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Figure 7. Relationship between liver fat and basal hepatic VLDL-TG secretion. Basal VLDL-TG 
secretion rate increases linearly with increasing amount of intra-hepatic fat content within the normal range of 
liver fatness. Taken from Magkos (Magkos 2009). 
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secretion (Julius 2003). In addition, it has been suggested that hepatic TG concentration 
may positively regulate hepatic MTP activity and gene expression (Taguchi, Omachi et al. 
2002).  
1.1.3.3.2 Insulin and hepatic VLDL-TG production 
Studies that investigated the acute effect of insulin on VLDL kinetics indicate a 
decreased secretion of VLDL-TG (Lewis, Uffelman et al. 1993). Insulin seems to stimulate 
the suppression of some factors that are responsible for the normal transfer of the newly 
mobilized TG pool into the TG-rich VLDL precursor (Wiggins and Gibbons 1992; 
Gibbons, Wiggins et al. 2004) (Fig. 5 and 6). In general, insulin decreases VLDL formation 
by two mechanisms: (A) indirectly by regulating the amount of fatty acids in the 
circulation, and (B) by direct suppression of the production of VLDL in the liver, 
independently of the availability of fatty acids (Malmstrom, Packard et al. 1998). Since the 
VLDL production is regulated by the availability of intra-hepatic substrates, insulin may 
indirectly interfere with the production of hepatic VLDL by its anti-lipolytic effect on 
adipose tissue (Coppack, Jensen et al. 1994). Acute hyperinsulinemia in humans suppressed 
plasma FFA, inhibiting VLDL-TG production (Lewis, Uffelman et al. 1993). On the other 
hand, several mechanisms have been proposed for the molecular mechanisms involved in 
the direct suppression of VLDL by insulin. For instance, it has been shown that insulin can 
directly reduce the MTP gene expression via negatively regulating promoter region of MTP 
(Lin, Gordon et al. 1995), thus decreasing the rate of synthesis and secretion of VLDL. It 
seems that insulin down-regulates MTP expression through activation of the mitogen 
activated protein kinase (MAPK) pathway (Allister, Borradaile et al. 2005). Insulin also 
suppresses hepatic VLDL secretion by directly interfering with the maturation phase of 
VLDL assembly by the activation of phosphoinositide 3-kinase (PI3-K) in rat hepatocytes 
(Sparks and Sparks 1994; Sparks, Phung et al. 1996; Phung, Roncone et al. 1997). In 
agreement with these observations, results reported by Brown and Gibbons using labeled 
method in cultured rat hepatocytes suggest that insulin signaling via PI3-K inhibited the 
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maturation phase of VLDL assembly by preventing bulk lipid transfer to a VLDL 
precursor, thus enhancing the degradation of apoB (Brown and Gibbons 2001). Moreover, 
Lin et al. showed that the mRNA levels and secretion rate of apoB were decreased by 31% 
and 43% respectively, when cultured hepatocytes were incubated with insulin (Lin, Gordon 
et al. 1995).  
1.1.3.4 Exercise and hepatic VLDL-TG production 
Regular exercise has broad beneficial effects on the lipoprotein profile (Kraus, 
Houmard et al. 2002). It is well known that exercise training results in lowering plasma TG 
concentration in obese/overweight (Kelley, Kelley et al. 2005) and also in healthy subjects 
(Kelley, Kelley et al. 2004; Kelley and Kelley 2006). Since hepatic VLDL-TG production 
is a component of plasma TG concentration, it is reasonable to think that hepatic VLDL 
production is reduced following exercise training, thus resulting in improved plasma TG. In 
animals, it has been shown that exercise training is associated with reduced rate of hepatic 
VLDL-TG secretion (Simonelli and Eaton 1978; Lira, Tavares et al. 2008). In support of 
these results, the effects of interval aerobic training on in vivo hepatic VLDL production in 
human has been recently reported (Tsekouras, Magkos et al. 2008). After two months of 
exercise training, a 35% decrease in VLDL-TG secretion rate in the exercise group 
compared to the non-exercise control group was observed. The effects of exercise training 
on decreased intra-abdominal adipose tissue and liver fat along with increased insulin 
sensitivity are probably the primary mechanisms whereby exercise training could bring 
about a decrease in hepatic VLDL secretion. Decreased intra-abdominal fat is expected to 
limit the delivery of FFA to the liver through the portal vein (Nielsen, Guo et al. 2004) thus 
in turn leading to lower VLDL-TG secretion (Bjorntorp 1990; Chan, Barrett et al. 2004). 
However, the reduction in VLDL-TG secretion after exercise training occurs even in the 
absence of changes in body weight and body composition (Tsekouras, Magkos et al. 2008). 
Furthermore, high levels of physical activity are inversely associated with liver fat 
accumulation (Perseghin, Lattuada et al. 2007; Spassiani and Kuk 2008; Zelber-Sagi, 
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Nitzan-Kaluski et al. 2008) the latter being directly associated with basal VLDL-TG 
secretion rate (Fabbrini, Mohammed et al. 2008). In this regard, it has been suggested that 
stimulated lipid oxidation and reduced lipid synthesis in liver by exercise via possible 
mechanisms such as activation of AMP-activated kinase pathway, might play a role in 
VLDL-TG production (Lavoie and Gauthier 2006). Nevertheless, the effects of exercise 
training on liver TG and VLDL-TG production require further investigation especially in 
light of their important role in metabolic deregulation. 
To our knowledge, little is known on the effects of exercise training on the intra-
hepatic regulation of VLDL production and enzymes involved such as MTP. In two recent 
studies in animals, a 60% reduction in hepatic MTP gene expression (Lira, Tavares et al. 
2008) and a 25% reduction in hepatic MTP protein content with exercise training have been 
reported (Chapados, Seelaender et al. 2009). Moreover, reduced VLDL-apoB100 secretion 
rate and total apoB100 after a single, prolonged bout of moderate-intensity endurance 
exercise has been reported (Magkos, Wright et al. 2006). The exact mechanisms underlying 
these observations are not clear, however, it is speculated a possible role of insulin 
sensitivity following exercise training. Since whole-body as well as liver insulin sensitivity 
is increased after either a single bout or chronic exercise training (Devlin, Hirshman et al. 
1987; Mikines, Sonne et al. 1988; Perseghin, Price et al. 1996; Magkos, Tsekouras et al. 
2008), it is possible that insulin-sensitization after exercise reduces plasma FFA availability 
(Magkos, Mohammed et al. 2009) and brings temporal decrease in MTP protein content in 
the liver (Kamagate and Dong 2008). Therefore, this would be consistent with reduced 
hepatic VLDL-TG secretion (Tsekouras, Magkos et al. 2008) and VLDL-apoB100 (Alam, 
Stolinski et al. 2004) observed 2-3 days after exercise training in human. However, the 
counteracting effect of increased post-exercise FFA availability should be considered in the 
hepatic VLDL-TG secretion process (Magkos, Mohammed et al. 2009).   It seems that most 
of the suppressing action of insulin on hepatic VLDL-TG secretion is mediated by the 
diminution in plasma FFA availability (Lewis, Uffelman et al. 1995). In this regard, it has 
been shown that greater fatty acid availability after exercise does not stimulate VLDL-TG 
  
 
30
secretion; probably because of the increase in fatty acid oxidation and possibly also fatty 
acid use for restoration of tissue TG stores (Magkos, Wright et al. 2006). Considering the 
parameter of time after exercise, Magkos hypothesizes that exercise-induced 
hypotriacylglycerolemia could be mediated by a combination of increased VLDL-TG 
clearance early after exercise (< 24h) and reduced VLDL-TG secretion at later time points 
(2-3 days) (Magkos 2009).  
1.2 Implication of estrogen withdrawal in the development of 
hepatic steatosis 
1.2.1 Sources of estrogens 
Having major effects on the reproductive physiology, sex steroids such as estrogens, 
androgens, and progestogens are hormones produced primarily by the reproductive glands 
(Henderson 2009). Conventionally, estrogens (e.g. 17β-estradiol) and progestogens (e.g. 
progesterone) are classified as female sex hormones and androgens (e.g. testosterone) as 
male sex hormones. Estrogens play key roles in development, maturation and maintenance 
of female reproductive function (Ackerman and Carr 2002). Additionally, in both men and 
women they exert a wide range of biological actions in the cardiovascular, musculoskeletal, 
immune, and central nervous systems (Gustafsson 2003). Estrogens belong to a C18 steroid 
family primarily synthesized in ovary from cholesterol. The biosynthesis of estrogens is 
from C19 steroid precursors which is catalyzed by enzyme aromatase cytochrome P450 
(Simpson 2003). This enzyme is found in several human tissues and cells including ovarian 
cells, the placenta, adipose tissue, skin, bone, and the brain; and it locally catalyzes the 
conversion of C19 steroids to estrogens (Nelson and Bulun 2001). However, the type of 
estrogens produced at each tissue site is different: ovary produces 17β-estradiol (estradiol: 
E2), while adipose tissue and the placenta synthesize estrone (E1) and estriol (E3), 
respectively (Ackerman and Carr 2002). E2 is the predominant form in non-pregnant pre-
menopausal women, E1 is produced during menopause, and E3 is the primary estrogen of 
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pregnancy. It seems that the most potent estrogen produced in the body is E2 (Heldring, 
Pike et al. 2007). The ovaries are the principle source of estradiol in pre-menopausal 
women which functions as a circulating hormone to act on distal target tissues; while in 
post-menopausal women when the ovaries reduce the production of estrogen, estradiol is 
produced in a number of extra-gonadal sites such as the mesenchymal cells of adipose 
tissue including that of the breast, osteoblasts and chondrocytes of bone, the vascular 
endothelium and aortic smooth muscle cells, and numerous sites in the brain and acts 
locally at these sites as a paracrine or even intracrine factor (Simpson 2003). It appears that 
in post-menopausal women when the ovaries reduce the production of estrogen, the adrenal 
cortex is the principal source of C19 precursors which are aromatized to estrogens by 
adipose tissue (Grodin, Siiteri et al. 1973).  
1.2.2 Mechanisms of estrogen actions 
About half a century ago, Jensen and Jacobsen suggested that the biological effects of 
estrogens are mediated by a protein receptor (Jensen 1962). It is now accepted that the 
cellular signaling of estrogen is mediated through two estrogen receptors (ERs): the original 
ERα and the recently discovered ERβ (Hewitt and Korach 2002). The ERs are members of 
a steroid/thyroid hormone super-family of nuclear receptors which share a common 
structural and functional organization with distinct domains that are responsible for ligand 
binding, DNA binding, and transcriptional activation (Nilsson, Makela et al. 2001). They 
are composed of three independent but interacting functional domains: the A/B domain (the 
amino-terminal region or NH2-terminal), the C domain (the DNA-binding region), and the 
D/E/F domain (the ligand binding region) (Nilsson, Makela et al. 2001). The N-terminal 
domain of ERs encodes a ligand-independent activation function (AF-1) which is involved 
in protein-protein interactions and transcriptional activation of target-gene expression while 
AF-2 is hormone-dependent and located in the ligand binding domain (Tora, White et al. 
1989; Berry, Metzger et al. 1990; Onate, Boonyaratanakornkit et al. 1998). AF-1 domain is 
very active in ERα while it is yet unclear how AF-1 of ERβ contributes to the 
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transcriptional activity of the receptor and its activity in ERβ is negligible (Cowley and 
Parker 1999; Hall, Couse et al. 2001). Activation of ERs, such as binding a ligand to ER, 
triggers conformational alterations in the receptor leading (via different signaling pathways) 
to stimulation and/or suppression of the transcription of genes with important physiological 
functions (Ciocca and Roig 1995; Matthews and Gustafsson 2003). The multifaceted 
mechanisms of E2 and ER signaling are presented in Fig. 8 (Hall, Couse et al. 2001). The 
classical mechanism of estrogen’s genomic action involves estrogen binding specifically to 
its receptors that causes an allosteric change in the structure of receptor which converts the 
receptor to an active form. In this active conformation the receptors have the ability to bind 
to specific regulatory elements (EREs) of genes to activate or suppress their function 
(Ackerman and Carr 2002) (classical ligand-dependent signaling) (Fig. 8). However, ERs 
can regulate the expression of other estrogen-responsive genes without directly binding to 
DNA through ERE-independent pathway (Bjornstrom and Sjoberg 2005) (ERE-
independent signaling) (Fig. 8). One example of ERE-independent genomic action of 
estrogen is the inhibition of cytokine interleukin-6 (IL-6) expression through the interaction 
between ERα and nuclear factor-kappa B (NF-κB). This occurs through protein-protein 
interaction and prevents NF-κB from binding to and stimulating expression from the IL-6 
promoter (Galien and Garcia 1997). Moreover, both ERs can interact with the fos/jun 
transcription factor complex on the activator protein 1 (AP1) sites and stimulate gene 
expression (Webb, Nguyen et al. 1999). In addition to estrogen-mediated activation (ligand 
binding), other signaling pathways can modulate ER in the absence of estrogen through 
phosphorylation (ligand-independent activation of ERs) (Fig. 8). For instance, extra-cellular 
signals such as polypeptide growth factors like epidermal growth factor (EGF) and insulin-
like growth factor-1 (IGF-1) as well as the intracellular effector cAMP are able to activate 
ER and increase the expression of ER target genes (Smith 1998). Growth factor activation 
of ER requires the N-terminal AF-1 domain of the receptor; while, the effects of elevated 
intracellular cAMP are mediated through AF-2 (El-Tanani and Green 1997). Finally,  
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Figure 8. The multifaceted mechanisms of E2 and ER signaling. The biological effects of E2 are mediated 
through at least four ER pathways. 1,  Classical ligand-dependent, E2-ER complexes bind to EREs in target 
promoters leading to an up- or down-regulation of gene transcription and subsequent tissue responses. 2, 
Ligand-independent. Growth factors (GF) or cyclic adenosine monophosphate (cAMP) (not shown) activate 
intracellular kinase pathways, leading to phosphorylation (P) and activation of ER at ERE-containing 
promoters in a ligand-independent manner. 3, ERE-independent, E2-ER complexes alter transcription of 
genes containing alternative response elements such as AP-1 through association with other DNA-bound 
transcription factors (Fos/Jun), which tether the activated ER to DNA, resulting in an up-regulation of gene 
expression. 4, Cell-surface (nongenomic) signaling, E2 activates a putative membrane associated binding site, 
possibly a form of ER linked to intracellular signal transduction pathways that generate rapid tissue responses. 
Taken from Hall et al. (Hall, Couse et al. 2001). 
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evidence is accumulating that estrogen action in vivo is complex and often involves 
activation of cytoplasmic signaling cascades in addition to genomic actions mediated 
directly through ERα and β (Segars and Driggers 2002) (nongenomic signaling) (Fig. 8). 
E2 has been shown to exert rapid nongenomic biological effects through membrane bound 
subpopulations of ER (Kelly and Levin 2001; Evinger and Levin 2005; Revankar, Cimino 
et al. 2005). Nongenomic estrogen actions are frequently associated with the activation of 
various protein kinase cascades including ER and membrane-coupled tyrosine kinase 
pathways such as MAPK signaling pathway in a variety of cell types (Hall, Couse et al. 
2001). For example, there is increasing evidence that some of the vascular protective 
effects of E2 through ERα are mediated by a nongenomic mechanism involving a biphasic 
activation of endothelial nitric oxide synthase by estrogen through the MAPK (Chen, 
Yuhanna et al. 1999) and phosphatidylinositol 3-kinase/Akt pathways (Mendelsohn 2000; 
Simoncini, Hafezi-Moghadam et al. 2000). 
Although our understanding has changed largely during the past decade, it is 
anticipated that additional mechanisms of E2 and ER signaling and tissue response will be 
revealed providing a more clear understanding of the spectrum of estrogen action (Hall, 
Couse et al. 2001). Moreover, it is now well known that the effects of estrogens are not 
limited to the female reproductive system and almost all tissues are under estrogenic 
influence (Ciocca and Roig 1995; Matthews and Gustafsson 2003). The metabolically 
active tissues such as liver appear to be particularly sensible to the estrogenic effects 
concerning different functions including liver lipid metabolism. In this regard, the 
continued use of in vitro and animal models will certainly facilitate the development of 
novel potential interventions or pharmaceuticals for the treatment of estrogen-associated 
pathologies (Hall, Couse et al. 2001).  
1.2.3 Estrogen deficiency and hepatic steatosis 
Loss of ovarian function due to menopause results in decreased circulating estrogen 
levels consequently leading to deleterious metabolic disturbances. Ovariectomy and 
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menopause have been shown to increase body weight and adipose tissue in animals and 
humans (Pallier, Aubert et al. 1980; Tonkelaar, Seidell et al. 1989). More specifically, 
menopausal status in women concurs with a shift in body fat from the gluteal to the 
abdominal region (Carr 2003). Although whether age or menopause per se influences fat 
distribution remains controversial, results form a very recent 30-month longitudinal study 
indicated that menopause has an independent effect on an increase in fat mass and an 
increase in central obesity linking lack of estrogen to central obesity (Ho, Wu et al. 2010). 
This phenomenon can be explained by different mechanisms of estrogenic actions 
indicating a lower LPL activity, an increased lipolytic responsiveness, and a change in the 
sensitivity of femoral and abdominal adipocytes resulting in an increased abdominal fat 
deposits during transitional and post-menopausal stages (Lindberg, Crona et al. 1990; Price, 
O'Brien et al. 1998; Ferrara, Lynch et al. 2002; Misso, Jang et al. 2005). Considering the 
causes of metabolic disturbances after menopause, it has been known for a long time that 
estrogens act centrally to decrease food consumption and increase ambulatory activity 
(Wade, Gray et al. 1985). Estrogens have an indirect role in the regulation of appetite and 
body fat by acting through other tissues that regulate appetite, energy expenditure or 
metabolism (Mastorakos, Valsamakis et al. 2010). ERs are extensively distributed in 
hypothalamus, the primary site in brain which regulates energy balance, and the effects of 
estrogens on both energy intake and expenditure are well recognized (Cooke and Naaz 
2004). Therefore, withdrawal of estrogenic action can contribute to the development of 
obesity (particularly central obesity) by affecting two main components of energy balance 
(food intake and energy expenditure), thus playing an important role in the pathology of 
obesity and metabolic syndrome.   
In association with the above mentioned consequences, NAHS is twice as common 
in post-menopausal compared to pre-menopausal women (Hagymasi, Reismann et al. 
2009). Menopause as a natural state of estrogen deficiency has been shown to increase the 
risk of hepatic steatosis. In a Korean study, it was determined that the menopausal status 
contributes as a potential risk factor in the incidence of NAFLD in women (Park, Jeon et al. 
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2006). In a recent study that included 808 women aged 40–59 years, it was confirmed that 
the menopausal status is indeed associated with a state of hepatic steatosis (Volzke, 
Schwarz et al. 2007). This shows that endogenous estrogens might play a protective role 
against the development of hepatic steatosis. Therefore, one of the tissues particularly 
affected by fat accumulation in post-menopausal women (Clark 2006; Volzke, Schwarz et 
al. 2007) as well as in estrogen deficient animals (Deshaies, Dagnault et al. 1997; Picard, 
Deshaies et al. 2000; Paquette, Shinoda et al. 2007; Pighon, Paquette et al. 2009) is liver. It 
is clear that lack of central effects of estrogens are indirectly involved in liver fat 
accumulation via increased fatty acid flow into the liver (arising from higher intra-
abdominal fat depositions resulting most likely from increased food intake and decreased 
energy expenditure). However, there are different observations that indicate estrogen 
withdrawal induced liver fat accumulation is not solely associated with the reduced central 
actions of estrogens (Roy and Wade 1977; Wade and Gray 1979). For instance, it has been 
reported that despite similar food intake, estrogen-deficient-pair-fed animals gained 
markedly more weight than did Sham animals and nearly as much as estrogen-deficient-ad 
libitum animals (Fisher, Kohrt et al. 2000). Here, intra-hepatic pathways leading to liver 
lipid accumulation in estrogen deficient states will be shortly reviewed. 
Laboratory animal studies provide quite convincing evidence that estrogen 
deficiency can affect lipid metabolism in the liver. Mouse models of estrogen deficiency 
such as aromatase knockout (ArKO) mice which cannot synthesize endogenous E2 have 
been shown to present with age-progressive obesity and hepatic steatosis (Hewitt, Boon et 
al. 2003), the latter resulting from elevated hepatic TG that was reversed by E2 replacement 
(Hewitt, Pratis et al. 2004). In these studies, authors reported that the presence of hepatic 
steatosis was due in part to an increase in expression of enzymes involved in de novo 
lipogenesis (indicated by significant up-regulation of FAS, and ACC) and transporters 
involved in LCFA uptake (indicated by increased levels of adipocyte differentiated 
regulatory protein: ADRP, a fatty acid transporter) in the state of estrogen deficiency 
(Hewitt, Pratis et al. 2004). In another study on ArKO mouse model by Toda et al., the 
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presence of hepatic steatosis due to disruption in β-oxidation has also been reported (Toda, 
Takeda et al. 2001). E2 treatment reversed these disturbances in this mouse model of 
estrogen deficiency (Nemoto, Toda et al. 2000).  
Another model to study the decline in estrogen levels in post-menopausal women is 
the Ovx rat model which is considered as an experimental model of post-menopausal. Ovx 
model may also induce the characteristic features of the metabolic syndrome occurring in 
menopause. Mukherjea et al. in 1975 demonstrated that ovariectomy in rats increased the 
percentage of total lipids in the liver (Mukherjea and Biswas 1975). Although this 
observation was confirmed by more recent studies in an attempt to prevent obesity and 
abnormalities of lipid metabolism induced by ovariectomy in a rat model (Deshaies, 
Dagnault et al. 1997; Picard, Deshaies et al. 2000), until recently there was no study to 
investigate the mechanisms of the contribution of estrogen withdrawal in liver lipid 
infiltration. Recent data show that the ovarian hormonal status has important ectopic effects 
at the molecular level in the liver rather than only central effects of food consumption and 
energy expenditure (D'Eon, Souza et al. 2005). There has been some progress concerning 
estrogen deficiency and liver lipid metabolism that needs to be extended. It has been shown 
that estrogen withdrawal in animals is implicated in pathogenic pathways of hepatic 
steatosis such as stimulation of lipogenic pathway and inhibition of lipid oxidation process 
in the liver. Using pair-feeding model, D’Eon and colleagues studied the expression of 
genes involved in hepatic lipogenesis in the Ovx-control and OvxE2 replacement mice 
(D'Eon, Souza et al. 2005). They reported that E2 in Ovx mice inhibited fat storage in liver 
by demonstrating the observations that E2 supplementation decreased hepatic expression of 
the lipogenic gene SREBP-1c (80%), and its downstream target genes ACC-1 (40%) and 
FAS (60%) compared to Ovx-control rats. These results were confirmed by Paquette et al. 
who showed increased hepatic expression and protein levels of lipogenic factor, SREBP-1c 
in Ovx rats that was corrected with E2 replacement (Paquette, Wang et al. 2008). 
Moreover, a recent study has shown that pair-feeding Ovx mice presented Ovx-induced 
liver hepatic steatosis that was accompanied by increased hepatic PPAR-γ gene expression 
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(known to stimulate a program of lipogenesis) and downstream lipogenic gene expression 
(FAS and ACC) (Rogers, Perfield et al. 2009). Similar results have been reported in a study 
by Na et al. in HF fed Ovx rats (Na, Ezaki et al. 2008). However, it has to be mentioned 
that Rogers et al. (2009) recently concluded that Ovx-induced hepatic steatosis might be 
associated with decreased energy expenditure, without altering energy intake linking the 
causal central effects of estrogens withdrawal. Alternatively, findings of Toda et al. (2001) 
on ArKO mice indicated a pivotal role of estrogens in supporting constitutive hepatic 
expression of genes involved in fatty acid β-oxidation and in maintaining lipid homeostasis. 
In Ovx rats, Paquette et al. reported that the rate of fatty acid oxidation was diminished by 
34% in liver slices (Paquette, Chapados et al. 2009). Moreover, reduced hepatic gene 
expressions implicated in lipid oxidation including HSL and PPAR-α (key transcriptional 
regulator of fatty acid oxidation) were also reported in Ovx animals (Na, Ezaki et al. 2008; 
Paquette, Wang et al. 2008). In almost all of these studies, it has been shown that 17β-
estradiol replacement prevented the accumulation of lipids in the liver of Ovx animals and 
properly regulated the gene expression of the lipogenic and oxidative pathways in liver. 
These results have been confirmed in a recent study from our lab in which it was reported 
that disturbed liver gene expressions of important lipogenic and lipid oxidative molecules 
(increased SREBP-1c, ChREBP, SCD-1, ACC and decreased PPAR-α) were corrected with 
E2 supplementation in Ovx animals (Pighon, Gutkowska et al. 2010). These molecular 
results, therefore, suggest that estrogens do act on peripheral tissues such as liver 
contributing to disturbances in liver fat metabolism. If lipid oxidation and lipogenesis are 
contributing factors, the contribution of VLDL-TG production and secretion pathways as 
possible mechanisms involved in the development of hepatic steatosis in an estrogen 
deficient state is not well established. 
1.2.4 Estrogen withdrawal and hepatic VLDL-TG production 
Picard et al. reported that Ovx in female Sprague-Dawley rats resulted in a two-fold 
increase in liver TG and administration of E2 prevented this effect (Picard, Deshaies et al. 
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2000). On the other hand, treatment of Ovx rats with E2 increased plasma TG significantly 
over those of control animals (Picard, Deshaies et al. 2000). This elevation in plasma TG 
levels by estrogen supplementation could be due to a direct estrogenic action on the 
production and secretion of VLDL-TG by liver. Estrogens are known to elevate serum TG 
levels in both rats (Russell, Amy et al. 1993; DiPippo, Lindsay et al. 1995) and humans 
(Matthews, Meilahn et al. 1989; Love, Newcomb et al. 1990; Love, Wiebe et al. 1991; 
Walsh, Schiff et al. 1991; Barrett-Connor 1993) and this has been suggested to be due to 
increased hepatic VLDL production by estrogens (Krauss and Burkman 1992). For 
instance, Walsh et al. reported oral E2 replacement therapy in post-menopausal women 
increased the mean concentration of VLDL-apoB by 30% by increasing its production rate 
by 82% thus leading to conclusion that the increase in serum TG levels results from 
increased production of triglyceride-rich VLDL (Walsh, Schiff et al. 1991). In this latter 
study the metabolism of VLDL was measured by endogenously labeling its protein 
component, apoB. However, very few studies have evaluated the physiological effects of 
Ovx-induced hepatic steatosis on intra-hepatic regulators of VLDL-TG production 
mechanism. In a study by Lemieux et al. conducted on female Sprague-Dawley rats treated 
by acolbifene (ACOL: having estrogen-like actions on energy and lipid metabolism in 
rodents), it was found that VLDL-TG secretion was decreased and in turn was associated 
with MTP mRNA levels (Lemieux, Gelinas et al. 2005). Therefore, hepatic VLDL-TG 
production associated with estrogen removal is beginning to be elucidated. 
1.2.5 Exercise training and estrogen withdrawal-induced hepatic steatosis  
Interestingly, interventions that reduce hepatic fat content are often accompanied 
with important improvements in metabolic functions including insulin sensitivity (Petersen, 
Dufour et al. 2005). On the other hand, it is generally accepted that increasing physical 
activity improves features of the metabolic syndrome even in the absence of weight loss 
(Ross, Janssen et al. 2004; Nassis, Papantakou et al. 2005). Therefore, it is appropriate to 
investigate the preventive effects of exercise training in estrogen-deficient state which is 
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characterized with increased hepatic lipid accumulation. However, the precise information 
on the role of exercise training as a preventive and/or a treatment factor on estrogen 
withdrawal-induced liver lipid infiltration is scarce. The primary goal of our research group 
is the investigation of the effects of exercise training on hepatic steatosis in animal models. 
In 2003, our group has reported that exercise training if pursued at the same time of a HF 
diet, completely prevents the HF diet-induced hepatic steatosis (Gauthier, Couturier et al. 
2003). Moreover, working on an Ovx rat model, some works from our lab indicated that 
exercise training in the form of resistance program could be an asset in preventing 
ovariectomy-induced liver fat infiltration (Corriveau, Paquette et al. 2008; Pighon, Paquette 
et al. 2009; Pighon, Paquette et al. 2009). More recently, in an attempt to determine 
whether a training state protects against the metabolically deleterious effects of Ovx on 
liver and adipocyte fat accumulation in rats, we demonstrated that training conducted 
concurrently with estrogen withdrawal has protective effects, particularly on liver fat 
accumulation (Pighon, Barsalani et al. 2010). No protective effect of a previous exercise 
training state on Ovx-induced liver and adipocyte fat accumulation was observed in this 
study. Although all of these studies were not aimed at investigating underlying 
mechanisms, the authors speculated that mechanisms such as increased energy expenditure 
and activated metabolic pathways in liver by exercise training might be involved. 
Moreover, as previously mentioned it has been shown by our group and others that estrogen 
withdrawal in Ovx animals is involved in the stimulation of lipogenic pathway and 
inhibition of lipid oxidation process in the liver. In this regard, Pighon et al. very recently 
reported that endurance exercise training reduces fat accumulation in liver of Ovx rats 
possibly via regulation of key molecules involved in lipogenesis and lipid oxidation 
(Pighon , Gutkowska et al. 2010). They suggested that exercise training acts like estrogens 
and prevents lipid accumulation in the liver of Ovx rats possibly through proper regulation 
of key intra-hepatic molecules implicated in lipogenesis and lipid oxidation; and/or through 
its secondary effects on lowering adipocytes fat gain. It has been suggested that estrogen 
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receptor gene expression may mediate some of the adaptive effects of endurance training in 
liver of Ovx rats (Paquette, Wang et al. 2007). 
On the other hand, to our knowledge, there is no information on the effects of 
exercise training on intra-hepatic regulation of VLDL synthesis and/or secretion and 
molecules involved in Ovx animals. A recent experimental study showed that exercise 
training in HF fed rats resulted in a reduction in plasma TG concentrations and lower 
hepatic MTP protein content suggesting an effect of exercise training on decreasing TG 
synthesis and exportation from the liver in the form of VLDL  (Chapados, Seelaender et al. 
2009). 
1.3 Oxytocin-Atrial natriuretic peptide (OT-ANP) system 
1.3.1 Oxytocin 
Oxytocin (OT) is a neurohypophysial nonapeptide hormone mainly synthesized in 
the hypothalamus that belongs to the pituitary hormone family (Gimpl and Fahrenholz 
2001; Elabd, Basillais et al. 2008). OT is also synthesized in many other peripheral tissues 
such as uterus, placenta and testis. It is released from the posterior pituitary gland into the 
circulation in response to a variety of stimuli such as lactation, parturition, or certain kinds 
of stress and regulates the function of peripheral target organs (Gimpl and Fahrenholz 
2001). OT performs its actions by binding to the OT receptor (OTR), a G-protien coupled 
receptor (Barberis, Mouillac et al. 1998). Traditionally, OT had been known as a female 
reproductive hormone essential for reproduction through its action on uterine contraction at 
parturition and milk ejection (Gimpl and Fahrenholz 2001). However, new emerging data 
during the last two decades reveal the implication of OT in other important functions such 
as social behavior (e.g. sexual behavior, maternal behavior and relationship), food intake 
and cardiovascular functions (Gutkowska, Jankowski et al. 1997; Jankowski, Hajjar et al. 
1998; Gimpl and Fahrenholz 2001; Lim and Young 2006). Nishimori et al. have 
demonstrated that OT knockout (OT-/-) and OTR knockout (OTR-/-) mice have no obvious 
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deficits in fertility or reproduction including parturition (Nishimori, Young et al. 1996; 
Nishimori, Takayanagi et al. 2008). Moreover, it has been reported in a recent study that 
OT plays a role in regulation of energy homeostasis because OTR-/- male mice exhibited 
late-onset obesity with increases in abdominal fat pads and fasting plasma TG (Takayanagi, 
Kasahara et al. 2008). Although it was not confirmed in this study, OT has also been shown 
to be implicated in regulation of food intake (inhibitory effect) in rats (Arletti, Benelli et al. 
1989; Olson, Drutarosky et al. 1991). OT has also been identified as a major regulator of 
cardiovascular functions (McCann, Antunes-Rodrigues et al. 2002; Antunes-Rodrigues, de 
Castro et al. 2004). Recently it was shown that the heart and large vessels like aorta and 
vena cava are the sites of OT synthesis (Gutkowska, Jankowski et al. 2000; Jankowski, 
Wang et al. 2000; Gimpl and Fahrenholz 2001). In fact, it appears that OT plays a role in 
the embryonic development of cardiomyocytes in newborn rats (Jankowski, Danalache et 
al. 2004). Moreover, it has long been known that acute and chronic OT treatments induce 
natriuresis and causes a fall in mean arterial pressure (Gutkowska, Jankowski et al. 2000). 
Until the discovery of the natriuretic family, the mechanism of these functions was not 
clear. In heart and vascular beds, OTRs mediate the action of OT to release ANP, a potent 
natriuretic and vosorelaxant hormone, into plasma which slows the heart and reduces its 
force of contraction, decreases blood volume and regulates local vascular tone (Favaretto, 
Ballejo et al. 1997; Gutkowska, Jankowski et al. 1997; Gutkowska, Jankowski et al. 2000). 
There is accumulating evidence that physiological functions of OT are mediated by ANP 
(Gutkowska, Jankowski et al. 1997; Gutkowska and Jankowski 2008). 
1.3.2 ANP: synthesis and secretion 
In addition to being a very efficient pump, heart is also an important endocrine 
organ that produces and secretes a family of related peptide hormones called the natriuretic 
peptides (NPs) (Howarth, Al-Shamsi et al. 2006). There are three types of NPs: atrial, brain 
(B-type), and C-type NPs (ANP, BNP, and CNP; respectively). Their principal roles are 
mediating natriuretic, diuretic, vasorelaxant, and antimitogenic responses which results in 
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lowering blood pressure and maintaining fluid volume homeostasis thus regulating 
cardiovascular, renal, and endocrine homeostasis (de Bold, Borenstein et al. 1981; de Bold 
1985; Brenner, Ballermann et al. 1990; Kojima, Minamino et al. 1990). All three types of 
NPs have highly homologous structure although, they have distinct sites of synthesis, bind 
to specific cell surface receptors, and probably exert distinct biological functions (Brenner, 
Ballermann et al. 1990; Koller, de Sauvage et al. 1992; Venugopal 2001). The biological 
actions of NPs are mediated through the interaction with specific cell surface NP receptors 
(NPRs) in different target tissues (Fig. 9) (Pandey 2005). Three types of NPRs have been 
characterized, natriuretic peptide receptor-A, -B, and -C, (NPRA, NPRB, and NPRC). Both 
NPRA and NPRB contain guanylyl cyclase (GC) catalytic domain, therefore they also 
named as GC-A and GC-B, respectively (Garbers 1992; Koller, de Sauvage et al. 1992). 
ANP (with a high affinity) and BNP (with a lower affinity) preferentially bind to GC-A 
receptor (Tremblay, Desjardins et al. 2002; Kuhn 2003). GC-A is found not only in many 
known target organs for NPs such as kidney and blood vessels but also in metabolic organs 
including adipose tissue (Okamura, Kelly et al. 1988; Sarzani, Paci et al. 1993; Sarzani, 
Dessi-Fulgheri et al. 1996). GC-B is abundant in the brain and organs of the genito-urinary 
tract and is more specific for the physiological ligand of CNP (Dessi-Fulgheri, Sarzani et al. 
2003). NPRC that lacks the intracellular domain of GC has a role as a clearance/buffering 
receptor that binds and incorporates NPs into cytoplasm and inactivates them, regulating 
circulating plasma NP levels (Dessi-Fulgheri, Sarzani et al. 2003) (Fig. 9). 
It seems that these NPs are increased in response to hemodynamic overload such as 
congestive heart failure. However, ANP appears to be the predominant NP under normal 
hemodynamic conditions having some important metabolic effects such as lipolytic action 
in human fat cells (Moro, Galitzky et al. 2004; Pandey 2005).  ANP is the most studied and 
the first described member in NPs hormone family which was given a number of different 
names such as atrial natriuretic factor (ANF), cardionatrin, cardiodilatin, and atriopeptine 
(Potter, Abbey-Hosch et al. 2006). ANP is predominantly synthesized in the atrial  
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Figure 9. A schematic representation of the natriuretic peptides to specifically activate the natriuretic 
peptide receptors; NPRA, NPRB, and NPRC, is indicated. The solid lines connect the receptors with their 
preferred ligand. The extracellular ligand-binding domains, transmembrane regions, and intracellular regions 
containing protein kinase-like domains (KHDs) and guanylyl cyclase (GC) catalytic domains of NPRA and 
NPRB are indicated. The NPRA and NPRB are shown to generate the second messenger cGMP. Similarly, 
ligand-binding domain, transmembrane region, and short cytoplasmic tail of NPRC are indicated. NPRA, 
natriuretic peptide receptor-A; NPRB, natriuretic peptide receptor-B; and NPRC, natriuretic peptide receptor-
C. Taken from Pandey (Pandey 2005). 
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myocytes of the heart. However, the ventricle and a variety of extra-cardiac tissues also 
produce ANP but at a much less lower level than the atrium (Pandey 2005). The 
mechanism for control of ANP release by OT from the heart is not well understood. 
However, Gutkowska et al. have proposed a mechanism in which blood volume expansion 
by baroreceptor input to the brain stem, evokes the release of OT from the neurohypophysis 
in the blood that reaches to the heart and acts on OTRs to cause release of ANP (Fig. 10) 
(Gutkowska, Jankowski et al. 1997). It has been shown that intravenous injection of OT in 
rats induced a dose-related increase in plasma ANP levels (Haanwinckel, Elias et al. 1995). 
Conversely, administration of OT antagonist (OTA) inhibits ANP release (Favaretto, 
Ballejo et al. 1997; Gutkowska, Jankowski et al. 1997; Pournajafi-Nazarloo, Perry et al. 
2007; Gutkowska and Jankowski 2008) (Fig. 11). In addition, unpublished data from the 
Gutkowska’s lab (Jankowski et al. 2010) indicates that OTA administration decreased 
plasma ANP concentrations by about 60% in Ovx spontaneously hypertensive rats. Taken 
together, these results suggest the presence of an intra-cardiac oxytocinergic system that 
controls basal ANP release (Pournajafi-Nazarloo, Perry et al. 2007).  
1.3.3 GC-A/NPRA: signal transduction 
GC-A (NPRA) is the dominant form of the NPRs found in peripheral organs and mediates 
most of the known actions of ANP and BNP (Pandey 2005). GC-A is a 135 KDa trans-
membrane protein detected in high levels in rodent heart, lung, kidney, adrenal, testis, and 
liver tissues (Goy, Oliver et al. 2001; Muller, Mukhopadhyay et al. 2004; Gutkowska, 
Paquette et al. 2007). ANP exerts its biological effects by binding to GC-A and leads to the 
synthesis and accumulation of intracellular second messenger, cGMP (Drewett and Garbers 
1994; Lucas, Pitari et al. 2000; Chujo, Ueki et al. 2008). The production of cGMP results 
from ANP binding to the extracellular domain of GC-A which allosterically regulates 
increased specific activity of the GC-coupled receptors (Drewett and Garbers 1994; 
Garbers and Lowe 1994). In turn, the intracellular cGMP stimulates some cellular and  
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Figure 10. Schematic diagram of proposed mechanism of OT induced ANP release in the right atrium. 
Blood volume expansion by baroreceptor input to the brain stem evokes the release of OT from the 
neurohypophysis that circulates to the heart and acts on OTrs to cause release of ANP. OTr stimulation results 
in the elevation of intracellular [Ca++] which in turn stimulates cellular exocytosis and also stimulates ANP 
secretion by the heart. ANP then acts by its receptors in the right atrium to activate Gc. The released cGMP 
decreases the rate of cardiac contraction by an action on the sinoatrial node and, at the same time, decreases 
the force of contraction of the cardiac myocytes. As the ANP reaches the right ventricle, it may possibly 
reduce the force of ventricular contraction. Because there are OTr in the ventricle, these may cause local 
release of ANP which further decreases force of contraction. ANP has a vasodilatory action mediated by 
cGMP. In combination with the direct actions of ANP in the heart, a rapid reduction in circulating blood 
volume ensues, which may explain the fact that rapid volume expansion during 1 min in the rat is only 
accompanied by a transient release of ANP. The rapid reduction in the blood volume via ANP would remove 
the stimulus by the baroreceptors for stopping further secretion of OT and in turn ANP.   
Amyocyte, atrial myoctye; SANc, sinoatrial node cell; OT, oxytocin; OTr, oxytocin receptor; ANPg, ANP 
secretory granule; ANPr, ANP receptor; Gc, guanylyl cyclase; C, cardiac contraction; R, heart rate;   increase;   
     decrease. Taken from Gutkowska et al.  (Gutkowska, Jankowski et al. 1997). 
 
 
  
 
47
 
 
Figure 11. Changes over time from initial release of ANP from perfused heart with buffer alone or with 
oxytocin (10-6 mol/liter) in the presence or absence of OTA, compound V1 (10-7 and 10-6 mol/liter). Data 
are the mean ± SEM of five to nine experiments each. Insert represents values obtained from the mean ± SEM 
of total ANP released by each of the various treatments over 25 min perfusion period. *, P<0.001 versus 
control; **, P<0.002 versus OT (10-6 M). Taken from Gutkowska et al. (Gutkowska, Jankowski et al. 1997). 
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physiological responses by interacting with cGMP-dependent protein kinases (PKG), 
cGMP-gated ion channels (CGN), and cGMP-regulated cyclic nucleotide 
phosphodiesterases (PDEs) (Lincoln and Cornwell 1993). It seems that ATP is required for 
the stimulation of GC catalytic activity which increases the efficacy of the receptor function 
and enhances the generation of cGMP (Fig. 12) (Pandey 2005).  
1.3.4 Metabolic functions of ANP/GC-A in the liver 
Although, since the discovery of ANP in 1980 (de Bold, Borenstein et al. 1981), 
comprehensive roles of NPs in the regulation of blood pressure and cardiovascular 
homeostasis have been widely documented, a recent growing body of literature suggests 
that NPs should be the interest of new investigations in the field of energy and lipid 
metabolism. It has been shown that NPs were able to stimulate lipolysis (potency order of 
the lipolytic effect: ANP>BNP>CNP) (Dessi-Fulgheri, Sarzani et al. 2003). In fact, ANP is 
considered a lipolytic agent which has been reported to play a remarkable role in the 
control of lipid mobilization in humans (Moro, Crampes et al. 2004). ANP has been shown 
to promote human adipose tissue lipolysis through cGMP mediated HSL (the rate limiting 
enzyme of lipolytic cascade) activation (Sengenes, Bouloumie et al. 2003; Birkenfeld, 
Boschmann et al. 2006). Increased cGMP by ANP induces the phosphorylation of HSL 
through the activation of a PKG independent of the classical pathway of adipose tissue 
lipolysis (cAMP/PKA-regulated metabolic pathway under the control of catecholamines 
and insulin) (Sengenes, Moro et al. 2005). The lipolytic efficiency of ANP has been 
confirmed several times through intravenous administrations in pharmacological doses in 
humans that resulted an increase in plasma FFA and glycerol levels (Dessi-Fulgheri, 
Sarzani et al. 2003; Moro, Pillard et al. 2008). Furthermore, Birkenfeld et al. have shown 
that increased ANP-mediated lipolysis led to increase in postprandial lipid oxidation rate 
and energy expenditure in humans (Birkenfeld, Budziarek et al. 2008). In this study, the 
investigators infused human ANP in 12 healthy non-overweight men subjects before,  
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Figure 12. Schematic representation of ANP-dependent activation and post-binding events of GC-
A/NPRA. ANP binding activates GC-A/NPRA in ATP-dependent manner, which leads to enhanced 
production of second messenger cGMP. An increased accumulation of intra-cellular cGMP activates cGMP 
dependent protein kinase (PKG), which plays a critical role in ANP-dependent biological responsiveness. 
cGMP can also activate phosphodiesterases (PDEs) as well as cGMP-gated ion channels (CGN) to activate 
ANP-dependent cellular and physiological functions. Finally, ligand–receptor complexes of GC-A/NPRA are 
internalized into the intra-cellular compartments and a larger proportion of ligand-receptor complexes are 
degraded in the lysosomal compartments. However, a small population of receptor is dissociated from the 
ligand and recycles back to the plasma membrane. Adapted from Pandey (Pandey 2005). 
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during, and 2-h after ingestion of a standardized HF test meal. Beside a decrease in blood 
pressure in the postprandial phase, plasma ketone concentrations, used to reflect hepatic 
lipid oxidation, were increased sharply after ANP infusion compared with placebo. These 
data are interesting in a sense that they connect the effects of NPs in lipid metabolism 
possibly affecting the pathophysiology of obesity and obesity-related disorders such as 
hypertension (Dessi-Fulgheri, Sarzani et al. 2003). Although conflicting data exist, some 
findings raise the possibility that reduced NP activity is a manifestation of insulin resistance 
and the metabolic syndrome particularly in obese individuals (Wang, Larson et al. 2004; 
Wang, Larson et al. 2007). It seems that ANP exhibits its lipolytic action through the local 
balance of GC-A and NPRC expressions in target tissues (Sarzani, Strazzullo et al. 2004). 
In this regard, a very recent study by Nakatsuji et al. showed that insulin, an anti-lipolytic 
hormone, may effectively promote lipogenesis in part by reducing lipolytic action of ANP 
via decreasing GC-A mRNA level while increasing NPRC in adipocytes (Nakatsuji, Maeda 
et al. 2010). More importantly, new findings of Miyashita et al. indicate that NP-GC-A 
system has a significant role in mitochondrial biogenesis, fat oxidation and oxygen 
consumption demonstrating that the activation of this cascade would be therapeutically 
beneficial for the treatment of obesity, insulin resistance, fatty liver, and the metabolic 
syndrome (Miyashita, Itoh et al. 2009) (Fig. 13). Miyashita et al. used three types of 
genetically engineered mice: BNP transgenic mice that overexpress BNP in liver at super 
physiological levels of 100 times that of normal physiological conditions (BNP-Tg mice), 
PKG transgenic mice that overexpress cGMP-dependent protein kinase (cGK-Tg mice) and 
GC-A knockout mice (GC-A+/- mice). BNP-Tg mice fed HF diet resisted diet-induced 
obesity and insulin resistance and had lower total body, muscle, and liver fat in accordance 
with increased whole-body fat oxidation and increased mitochondrial biogenesis in skeletal 
muscle compared to wild type HF fed mice. cGK-Tg mice were leaner than controls even 
on SD diet and were protected against HF diet-induced obesity and liver fat accumulation 
and was associated with giant mitochondria in the skeletal muscle. GC-A+/- mice resulted in  
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Figure 13. Proposed role of ANP and BNP in energy metabolism under conditions of normal diet and 
activity levels vs. HF diet and inactivity. ANP and BNP induce cGMP signaling through GC-A, whereas 
NPR-C inactivates these peptides. The functional balance of GC-A to NPR-C therefore regulates their 
biological effect at the tissue level. cGMP/cGK signaling promotes lipolysis and adiponectin secretion in 
adipose tissue and mitochondrial biogenesis and fat oxidation in skeletal muscle (left panel). This dual action 
of NPs may confer resistance to obesity and type 2 diabetes. In contrast, reduced GC-A expression and 
increased NPR-C expression during HF feeding and/or inactivity depress cGMP signaling in adipose tissue 
and muscle leading to increased fat mass, ectopic fat deposition, insulin resistance, and increased 
susceptibility to type 2 diabetes (right panel). Taken from Moro and Smith. (Moro and Smith 2009).   
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promotion of obesity in mice. An interesting characteristic of this study was the observation 
that HF diet reduced the expression of GC-A suggesting that HF diet may diminish the 
response to NP stimulation and decrease mitochondrial biogenesis and fat oxidation (Fig. 
13), although the precise mechanisms need to be explored (Moro and Smith 2009). 
Therefore, although today our knowledge of the functions of ANP is broader, its role in 
lipid metabolism has yet to be elucidated particularly in the important metabolic tissue that 
constitutes the liver.  
Several studies reported organ-protective effects of ANP against serious tissue 
damages such as liver ischemia/reperfusion (I/R) injury (Bilzer, Witthaut et al. 1994; 
Gerbes, Vollmar et al. 1998; Kiemer, Vollmar et al. 2000; Kiemer, Gerbes et al. 2002; 
Carini, De Cesaris et al. 2003; Gerwig, Meissner et al. 2003; Kulhanek-Heinze, Gerbes et 
al. 2004). I/R is a major cause of acute tissue failure which prompts a release of reactive 
oxygen species (ROS) and pro-inflammatory mediators (Colletti, Remick et al. 1990; 
Jaeschke 1991). It seems that the hepato-protection role of ANP in I/R damage is associated 
with its anti-inflammatory potential due to its potency to inhibit the production of 
inflammatory mediators (Kiemer, Vollmar et al. 2000). This protective effect of ANP was 
shown to be mediated by its GC-A receptor signaling pathway reducing the activation of 
the redox-sensitive NF-κB and subsequently lowering the pro-inflammatory mediators such 
as tumor necrosis factor α (TNF-α) (Kiemer, Hartung et al. 2000; Kiemer, Vollmar et al. 
2000; Tsukagoshi, Shimizu et al. 2001). Therefore, ANP, its GC-A receptor, and signaling 
pathway has been suggested as new therapeutic targets to protect liver cells against 
preservation injury (Gerbes, Vollmar et al. 1998). However, besides I/R conditions, it is 
less known if ANP exerts protective effects and regulate inflammation in the liver in 
normal physiological conditions and if the action of ANP is mediated by OT. 
1.3.5 OT-ANP system: effects of estrogen and exercise training 
It has been known for many years that estrogen has marked effects on OT 
physiology stimulating OT release into the circulation (Yamaguchi, Akaishi et al. 1979; 
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Amico, Seif et al. 1981). The puberty, castration, and the oestrus cycle have been known to 
alter the expression of OT transcripts in hypothalamus suggesting that estrogen regulates 
the expression of OT (Van Tol, Bolwerk et al. 1988; Caldwell, Brooks et al. 1989; Miller, 
Ozimek et al. 1989). The relationship between estrogen and OT regulation seems to be 
complex. In rats, treatment with estrogen was sufficient to increase OT mRNA expression 
in the hypothalamus (Chung, McCabe et al. 1991). On the other hand, neonatal OT 
treatment in female rats increased heart OTR, ANP, and ERα mRNA expressions 
(Pournajafi-Nazarloo, Papademeteriou et al. 2007; Pournajafi-Nazarloo, Perry et al. 2007). 
However, it has been shown that estrogen through ER can directly influence OT gene 
promoter activity (Richard and Zingg 1990). In agreement with this, estrogen was reported 
to increase OT release and binding to OTR (Schumacher, Coirini et al. 1993). Furthermore, 
the stimulating effect of estrogen on ANP has been shown in many studies (Mukaddam-
Daher, Jankowski et al. 2002). Gutkowska et al. reported that plasma ANP concentrations 
were low in Ovx rats that was re-established by E2 supplementation; and also they have 
shown that gene expression of cardiac ANP and GC-A were decreased in Ovx rats while E2 
replacement increased OT and OTR mRNAs in aorta of Ovx rats (Wang, Gutkowska et al. 
2003; Gutkowska, Paquette et al. 2007). The control of hypothalamic OT and cardiac ANP 
synthesis and release by estrogen and ER-mediated mechanisms has been reported in 
animal models (Jankowski, Rachelska et al. 2001; van Eickels, Grohe et al. 2001; 
Jankowski, Wang et al. 2005). Although limited data are available on the effects of 
estrogen on NPs in humans (Karjalainen, Ruskoaho et al. 2004), observed higher 
circulating levels of ANP in women than in men and also during pregnancy suggests that 
female sex steroids have some influence on the OT-ANP system (Rutherford, Anderson et 
al. 1987; Clerico, Iervasi et al. 1998). Moreover, it has been shown that three months of 
hormone replacement therapy in post-menopausal women significantly increased 
circulating levels of ANP (Maffei, Del Ry et al. 2001). Several factors have been associated 
with exercise-induced beneficial effects on cardiovascular system such as decreased heart 
rate and blood pressure, circulating blood volume regulation along with various metabolic 
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processes. For instance, the improvement in cardiovascular control observed after 
endurance exercise training because of increased hypothalamic OT density in rats 
(increased OT content and gene expression) (Braga, Mori et al. 2000; Martins, Crescenzi et 
al. 2005). Moreover, it has been demonstrated that exercise training provokes the increased 
synthesis and release of ANP whose cardio-protective effects have been explained earlier 
(Tanaka, Shindo et al. 1986; Guezennec, Fournier et al. 1989; Barletta, Stefani et al. 1998; 
Ohba, Takada et al. 2001; Edwards 2002). The main stimulating factor of ANP release is 
atrial expansion or intra-atrial pressure. Greater maximal cardiac output along with 
augmented respiratory movement and limb muscular activity during exercise cause 
significant increase in venous return and results in atrial distension, which stimulate ANP 
release (Pan 2008). Circulating ANP levels, rise during short exercise bouts of increasing 
intensities (Moro, Crampes et al. 2004). In searching the precise mechanism, it has been 
recently reported that endurance exercise has direct influence on cardiac OT-ANP system 
(Gutkowska, Paquette et al. 2007). In that study, cardiac OT, OTR, ANP, and GC-A gene 
expressions were decreased in Ovx rats compared to control group. However, 8-week 
exercise training in these rats counteracted the effects of Ovx normalizing most of these 
genes in the heart.  
 
1.4 General objective of the thesis and presentation of the 
manuscripts 
NAHS results from lipid metabolism disorder which leads to lipid accumulation 
within hepatocytes in the absence of excessive alcohol consumption (Duvnjak, Lerotic et al. 
2007). NAHS is the hepatic manifestation of the metabolic syndrome, with insulin 
resistance as the main pathogenetic mechanism and considered as an independent predictor 
of cardiovascular disease (Vanni, Bugianesi et al. 2010). There is accumulating evidence 
that estrogen deficiency is associated with the development of hepatic steatosis in post-
  
 
55
menopausal women (Park, Jeon et al. 2006; Suzuki and Abdelmalek 2009) as well as in 
different animal models (Deshaies, Dagnault et al. 1997; Picard, Deshaies et al. 2000). The 
goal of the research program presented in this thesis is to further adresse the current 
understanding of the development of NAHS related to estrogen deficiency state. In 
previous section, the contributing mechanisms to the development of NAHS have been 
generally described including increased FFA influx into the liver, liver lipid uptake, de 
novo lipogenesis and decreased hepatic lipid oxidation. The contribution of VLDL-TG 
production mechanism in NAHS was presented in details. Then, the literature on the 
implication of estrogen deficiency in liver lipid infiltration and the effect of exercise 
training were discussed. Moreover, new interests on the investigation concerning the role of 
OT-ANP system in the field of energy and lipid metabolism have been presented.  
This thesis consists of three original research articles that have been conducted in 
ovariectomized rats, an animal model of post-menopausal women. These studies investigate 
the effects of estrogen withdrawal on liver fat metabolism and emphesize the effects of 
exercise training as a counteractive measure. In the first study, we designed an experiment 
to test the hypothesis that liver of Ovx rat is resistant to resorption of fat accumulation. 
Eight weeks after switching from a HF to a SD diet, Ovx rats accumulated as much fat in 
the liver as Ovx rats maintained on a HF diet. In contrast, Sham animals had lower levels of 
liver fat accumulation after the diet switch. Moreover, the results of this study led us to 
conduct our second study in which we used a physiological approach to determine if 
hepatic VLDL-TG production is altered following a 3-h infusion of lipids in Ovx rats. 
Results of this second study suggest that a decrease in VLDL production might be a 
contributing factor responsible for hepatic fat accumulation known to occur with estrogen 
withdrawal. In addition, in this study we showed that exercise training lowers VLDL-TG 
production, as well as gene expression of important regulatory molecules in VLDL 
assembly: MTP and DGAT-2, independently of the estrogen levels. Lastly, new emerging 
data on the metabolic effects of OT-ANP system triggered our interest in investigating if 
this axis may influence the lipid metabolism in the liver of Ovx animals. The findings of 
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our third study suggest that OT-ANP axis may contribute to the protection of hepatic tissue 
by reducing inflammatory markers through hepatic GC-A receptor.  
 
  
Chapter 2: Original research articles  
 
2.1 Article 1 
 
Title 
Liver of ovariectomized rats is resistant to resorption of lipids 
 
Authors  
Razieh Barsalani, Abdolnaser Pighon, Rémi Rabasa-Lhoret, Siham Yasari, Jean-Marc 
Lavoie 
 
Journal 
Physiol Behav. 2008 Sep 3; 95(1-2):216-21  
 
 
Reprinted with permission of Elsevier Limited 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
58
Liver of Ovariectomized Rats is Resistant to Resorption of Lipids 
 
 
Razieh Barsalani1, Abdolnaser Pighon1, Rémi Rabasa-Lhoret2, Siham Yasari1, 3, and Jean-
Marc Lavoie1 
 
 
1Department of kinesiology and 2Department of nutrition, University of Montreal, 
Montreal, Québec, Canada; 3School of Human Kinetics, Faculty of Health Sciences, 
University of Ottawa, Ottawa, Ontario, Canada 
 
 
Running title:  Liver lipid infiltration in ovariectomized rats  
 
Mailing Proofs:       Dr. Jean-Marc Lavoie 
                                Département de kinésiologie  
                                Université de Montréal  
                                CEPSUM  
                                2100, boul. Édouard-Montpetit  
                                Montréal (Quebec) Canada H3C 3J7 
                                Telephone : (514) 343-7044 
                                Fax : (514) 343-2181 
                                 
 
  
 
59
Abstract 
Ovarian hormones have been shown to regulate liver lipid accumulation in rats. The 
present study was designed to evaluate liver lipid resorption in ovariectomized (Ovx) rats. 
Ovx and sham-operated (Sham) rats were submitted to a high-fat (HF; 43 % kcal fat as 
energy) diet for 5 weeks and then either maintained on this diet or switched to a standard 
(SD; 12.5% kcal fat as energy) diet till weeks 8 and 13 (n = 8 rats/group). Body weight, 
energy intake, liver and intra-abdominal fat accumulation and plasma metabolic profile 
were determined. Body weight was significantly (P<0.01) higher in Ovx than in Sham 
groups at all times and switching diet did not alter the body weight pattern. The weight of 
the intra-abdominal fat depots and plasma leptin levels, along with liver triacylglycerol 
(TAG) concentrations, were significantly higher (P<0.01) in Ovx than in Sham rats. 
Switching diet reduced intra-abdominal fat depot weight and plasma leptin in all groups. 
Switching diet also resulted in a decrease in liver fat accumulation in Sham rats at all times. 
However, 8 weeks after the diet switch (week 13) liver fat accumulation was as high in Ovx 
rats as those maintained on the HF diet. When liver TAG values measured at week 13 were 
compared to initial pre-switching values (week 5), liver TAG levels in Ovx animals were 
maintained at the same level independently of the diet switch, while in Sham rats switching 
to a SD diet reduced liver TAG accumulation (P<0.05). The same comparisons with plasma 
TAG levels revealed an opposite relationship. These data suggest that liver lipid resorption 
in Ovx animals is more related to the ovarian hormone status than to the type of ingested 
diet.  
 
Keywords: Hepatic steatosis, Ovarian hormones, Intra-abdominal fat pads, Plasma 
triacylglycerols, Leptin 
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1. Introduction 
      Obesity is now recognized as a major public health problem that constitutes a risk factor 
for life-threatening diseases such as type 2 diabetes and cardiovascular disease, as well as 
some types of cancer [9]. These disorders represent major causes of morbidity and 
mortality in industrialized countries, and are increasing problems in developing countries as 
well [23]. In recent years, high dietary fat intake has been proposed as a main contributor to 
obesity [19]. It is well established that high-fat (HF) diets induce several obesity related 
metabolic deteriorations, including liver lipid infiltration, which has been recognized as an 
integral feature of the metabolic syndrome [6, 11]. 
There is accumulating evidence that estrogen deficiency is associated with the 
development of hepatic steatosis in different animal models [3, 13, 16] as well as in post-
menopausal women [1, 15, 25]. Hepatic steatosis is twice as common in postmenopausal 
women as in pre-menopausal women [1, 15]. Liver lipid infiltration in postmenopausal 
women is, therefore, a concern that needs to be characterized, especially in relation to the 
high dietary fat intake of western societies. In a recent study, our group [14] reported that 
ovariectomy (Ovx) in rats resulted in a progressive accumulation of fat in liver over a 13- 
week period, which was highly amplified by a high-fat diet. However, plasma FFA levels 
were not markedly increased in Ovx rats, indicating that liver lipid infiltration could hardly 
be attributed to increased hepatic lipid uptake. It was suggested that estrogens act intra-
hepatically as a protective tool against liver lipid infiltration. For this reason, reversal of 
lipid accumulation in liver may be complicated by estrogen deprivation. The present 
experiment was designed to test the hypothesis that livers of Ovx animals are resistant to 
reversal of liver lipid infiltration. Liver lipid infiltration was enhanced in Ovx and Sham 
rats by a HF diet containing 43% of its energy from lipids. Reversal was induced by 
switching from the ingestion of a HF to a standard (SD) diet containing 12.5% of its 
energy from lipids. In the Ovx group 8 weeks after switching from the HF to the SD diet 
there was no liver lipid resorption.  
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2. Materials and methods 
2.1. Animal care 
Female Sprague–Dawley strain rats (n = 80, Charles River, St-Constant, PQ, 
Canada), weighing 180–200 g (6 weeks of age) upon their arrival were housed individually 
and had ad libitum access to food and tap water. The diet, now referred to as the standard 
diet (SD; 12.5% lipid, 63.2% carbohydrate, and 24.3% protein; kcal) consisted of usual 
pellet rat chow (Agribrands Purina Canada, Woodstock, Ontario, Canada). Their 
environment was controlled in terms of light (12:12-h light–dark cycle starting at 06:00 
AM), humidity (53%) and room temperature (20–23 °C). All experiments described in this 
report were conducted according to the directives of the Canadian Council on Animal Care. 
2.2 Surgery 
Three days after their arrival, rats were randomly divided into ten groups (n=8 
rats/group). Rats in five of these groups underwent Ovx surgery and the other five groups 
were sham-operated (Sham). Ovx was conducted according to the technique described by 
Robertson et al. [18]. For surgery, rats were anesthetized using a mixture of ketamine-
xylazine (61.5-7.6 mg/kg, ip). Animals were injected with antibiotics (Tribrissen 24%; 
0.125 cm3/kg, sc) for 3 days, beginning on the day before surgery. 
2.3. Groups and Diet Protocol 
 Immediately after surgery, all Ovx and Sham animals were fed a HF diet for 5 
weeks. Following this 5-week period, one Sham-HF and one Ovx-HF group was killed at 5 
weeks and the remaining 4 Ovx and 4 Sham groups were divided in half with half 
continuing on the HF and half switched to the SD diet for 3 and 8 additional weeks. The HF 
diet consisted of 43% lipid, 38% carbohydrate, and 19% protein (kcal) and was provided in 
small pellets from Harlan, Teklad (WI, USA). The lipids included in the HF diet consisted 
of 35.2% saturated and 64.4% unsaturated (70.2% MUFA and 29.8% PUFA). Details of 
this diet have been presented elsewhere [5]. On the whole, 10 groups of rats were 
sacrificed. Two groups of animals were sacrificed at week 5 (Sham and Ovx), while 4 
groups were sacrificed at weeks 8 and 13, respectively (Sham and Ovx fed SD or HF diet, 
respectively). All rats were weighed daily and their food intake in g was monitored 3 
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Louis, Missouri, USA). Although small amount of free glycerol may be produced from 
hydrolysis of phospholipids, it is considered as negligible. Frayn and Maycock [4] have 
shown that omitting removal of phospholipids leads to only a ±2% error in the 
determination of muscle TAG. Plasma TAG concentrations were measured with an 
enzymatic colorimetric assay available from Sigma (St-Louis, Missouri, USA). Plasma 
glucose concentration was determined with the use of a glucose analyzer Yellow Springs 
Instruments 2300 (Yellow Springs, Ohio, USA). Plasma Insulin and leptin concentrations 
were determined with commercially available radioimmunoassay kits (Linco Research, St-
Charles, Missouri, USA). 
2.6. Statistical analysis 
Values are expressed as mean ±S.E. Statistical analyses were performed using a 
two-way ANOVA for non-repeated measures using diet (continuous HF or HF switched to 
SD) and surgery as the main effects at times 8 and 13 weeks, analyzed separately, and 
excluding time point 5 weeks (since no diet treatment was given at that time). In a second 
step, the effect of time was analyzed separately in Ovx and Sham rats using a one-way 
ANOVA for non-repeated measures. This second statistical analysis was performed to 
better characterize the effects of time including comparison with time 0.  Fisher LSD post-
hoc test was used in the event of a significant (P<0.05) F ratio. Relationship between liver 
triacylglycerol and plasma triacylglycerol concentrations was evaluated by linear regression 
analysis. 
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3. Results         
As expected, body weight was higher (P<0.01) in Ovx rats after the initial 5 weeks 
(Table 1). This was associated with an initial (5 weeks) higher (P<0.01) energy intake in 
Ovx animals. Although energy intake was not different anymore after the first 5 weeks 
between Ovx and Sham rats, Ovx rats maintained a higher body weight throughout the 
experiment. For an unknown reason, energy intake was somewhat higher (P<0.05) in some 
groups of rats during the first 5 weeks, although all rats were all fed the same HF diet. Body 
weight was increased significantly (P<0.05) in all groups throughout the experiment with 
the exception of the non-significant gain of body weight between weeks 5 and 8 in Sham 
and Ovx rats that switched diet. This may be attributed to the reduction in energy intake 
that resulted from the switch from the HF to the SD diet in both Sham (P<0.06) and Ovx 
(P<0.05) groups. A reduction in energy intake with time was also observed in Ovx-HF rats. 
Energy intake was also somewhat (P<0.05) higher in Sham and Ovx rats that switched diet 
compared to their respective groups in the last few weeks of the experiment. However, the 
effects of the diet switch on energy intake were the same in Sham and Ovx rats as they 
were observed in both groups at the same times. 
Ovx, as compared to Sham operation, resulted in higher (P<0.01) sum of muscles 
weights along with lower (P<0.01) uterus weight after the initial 5 weeks and throughout 
the following 8 weeks, whether rats switched to the SD diet or not (Table 2). Switching diet 
did not affect any of these variables when compared to rats maintained on the HF diet. 
Comparisons of values measured at 8 and 13 weeks to initial 5-week values revealed that 
the sum of muscle weight in Sham rats were higher (P<0.01) with time. In Ovx rats, 
however, there was no gain in the sum of muscle weights whether rats switched diet or not. 
Most of the effects of Ovx on the sum of muscle weight were already observed after 5 
weeks and were maintained in the following weeks. Femur weight was higher (P<0.01) 
with time in all groups. 
Liver TAG concentrations were higher (P<0. 05) in Ovx compared to Sham rats as 
soon as 5 weeks after the surgery (Fig. 1A). The higher liver TAG levels in Ovx compared 
to Sham rats were maintained throughout the following 8 weeks, independently of the diet. 
  
 
65
Switching from the HF to the SD diet resulted in lower (P<0.01) liver TAG levels in Ovx 
and Sham rats at the 8-week time point when compared to rats maintained on the HF diet. 
When the 8- and 13-week results were further analyzed by comparing them to the initial 5- 
week values, high liver TAG levels in Ovx rats were maintained whether the rats switched 
diet or not, while in Sham rats the switch of the diet reduced the HF-induced liver fat 
accumulation. These comparisons reveal that the 13-week measurements point the Ovx 
animals resistant to liver resorption. On the other hand, Ovx did not affect plasma TAG 
levels (Fig. 1B). Switching of HF to SD diet resulted in higher (P<0.05) plasma TAG levels 
in all groups when compared to rats maintained on the HF diet. As for the liver TAG data, 
we further analyzed plasma TAG values by comparing them to values measured at week 5. 
These analyzes revealed the opposite of the response found for liver TAG levels at week 
13. The switching of the diet resulted in higher (P<0.05) plasma TAG levels compared to 
week 5 in Sham rats, while in Ovx rats plasma TAG levels were maintained after the switch 
of the diet (Fig. 1B).  
When compared to the Sham groups the Ovx groups had a higher (P<0.05) 
accumulation of fat in the intra-abdominal and subcutaneous depots along with higher 
levels of plasma leptin at all times, independently of the switching of the diet (Fig. 2). The 
switching of the diet compared to continuous high-fat feeding resulted in lower (P<0.05) 
fat accumulation in all the fat depots after 8 weeks and lower (P<0.05) plasma leptin levels 
after 8 and 13 weeks in Sham as well as in Ovx groups. The switching of the diet did not 
affect fat depots weight after 13 weeks either in Sham and Ovx groups. Time comparisons 
using the 5-week initial values reveal similar changes of fat depots weight in Sham and 
Ovx rats. On the other hand, plasma leptin levels in Ovx rats at week 13 were higher (P< 
0.05) compared to initial 5-week values, which was not the case after the switch of the diet 
(Fig. 2C). This may be taken as an indication that plasma leptin was more sensible to the 
diet switch that adipose fat mass, at least in Ovx rats. 
Plasma glucose, insulin and FFA levels were not, on the whole, affected by the Ovx 
and the switch of diet (Table 3). The only significant comparisons found were lower  (P< 
0.05) plasma glucose concentrations with time in Ovx animals, lower  (P<0.05) insulin 
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levels in Ovx compared to Sham rats at week 13, and higher (P<0.05) plasma FFA 
concentrations with time (week 5 vs 13) in all groups with the exception of Ovx rats that 
switched diet.  
Fig. 3 shows the relationship between the levels of hepatic and plasma TAG using 
individual values for all rats throughout the experiment. This comparison reveals a modest, 
but significant negative relationship (R= - 0.235; P<0.04). 
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4. Discussion 
The present study was designed to test the hypothesis that once liver is infiltrated 
with lipids, reduction of fat accumulation is more difficult in Ovx than in rats with an intact 
estrogen production. To do that, we stimulated fat accretion in livers of Ovx and Sham rats 
by submitting them to a HF diet and evaluated reversal of liver TAG accumulation by 
switching feeding to a SD diet. Results of this approach show that, at week 13 (8 weeks 
after switching), liver of Ovx animals is as much infiltrated with lipids whether these 
animals switched to the SD diet or were maintained on the HF diet. When compared to the 
5-week initial values, liver TAG concentrations in Ovx rats did not show any significant 
reduction after the diet switch. In contrast, after switching to the SD diet, liver fat 
accumulation in the Sham rats was lower. These results may be taken as evidence that 
indeed liver fat resorption is hampered in absence of estrogens. In a recent study we 
observed that ovariectomy-induced liver lipid infiltration was completely prevented by 
estrogen replacement [14]. Taken together, our results support the interpretation that liver 
fat infiltration in Ovx rats is not solely related to an increased hepatic lipid uptake, but also 
facilitated by an intra-hepatic mechanism related to the absence of estrogens.   
The reduction in uterus weight, measured at the end of the experiment, along with 
the higher body weight, clearly indicate that the ovariectomies performed in this study were 
successful. As reported in previous studies, Ovx resulted in a significant gain in body 
weight accompanied by an increase in energy intake [12, 17]. The increase in body weight 
induced by Ovx was the result of both an increase in all fat depot weights and in the sum of 
muscle weights. Shifting from the HF to the SD diet resulted in a decrease in energy intake 
with time in both Sham and Ovx rats. This may explain the absence of significant gain in 
body weight between weeks 5 and 8 in both Sham and Ovx rats that switched diet. The 
decrease in energy intake may be attributed to the change from the HF to SD diet rich in 
carbohydrates, although a decrease in energy intake was also observed in the Ovx-HF rats 
that did not switch the diet. The decrease in energy intake in Ovx-HF rats was not as 
pronounced, however, since it did not affect the gain in body weight between weeks 5 and 
8. Most importantly, the changes in energy intake and body weight gain with the switch of 
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the diet were similar in Sham and Ovx animals as no interaction effects between diet and 
surgery were found throughout the 13 weeks. This means that the changes in energy intake 
with the switch of the diet cannot explain the absence of resorption of liver TG 
accumulation in Ovx rats at the 13-week time point. One may argue that the switch of the 
diet decreased energy intake somewhat more in Ovx than in Sham rats (~15 vs 10 
kcal/day). This, however, should have facilitated liver fat resorption in Ovx which is in 
contrast to what we observed. Finally, adipose tissue fat mass accumulation was reduced 
similarly in Sham as well as in Ovx rats after switching diet, indicating that the switch of 
the diet had similar effects on body composition in Ovx and Sham rats. This observation 
reinforces the concept that liver TG resorption in Ovx rats is hampered by mechanisms 
related to the absence of estrogens. 
One of the factors that support the contention that liver fat resorption is hampered in 
Ovx animals is its association with low plasma TAG levels. A lowering of plasma TAG 
levels has been previously observed in Ovx rats [10], while the existence of an inverse 
association between high liver TAG and low plasma TAG levels has been suggested in one 
of our recent study [14]. It is striking that the decrease in liver TAG following the diet 
switch in the present Sham rats at week 13 is associated with the highest plasma TAG 
concentrations, while the absence of changes in liver TAG in Ovx was associated with an 
absence of changes in plasma TAG. The mirror effect between the response of liver and 
plasma TAG levels was observed in the other groups as well. When all values in the present 
study for liver and plasma TAG for each rat were compared, a modest, but significant 
inverse relationship was found between these two variables (Fig. 3). Plasma TAG levels are 
mainly determined by the activity of the lipoprotein lipase and the hepatic production of 
very low density lipoproteins (VLDL). Low plasma TAG levels may, therefore, constitute 
an indication that VLDL production by the liver is reduced in Ovx animals. Estrogens have 
been shown to stimulate hepatic synthesis of apolipoprotein B-100 involved in VLDL 
synthesis [7, 20, 24]. Removal of estrogens in Ovx animals may, therefore, result in a 
reduction in VLDL production by the liver and in turn explain a decrease in liver fat 
resorption. Although this interpretation is obviously limited by the absence of direct 
  
 
69
measurements of hepatic VLDL production, it constitutes an interesting hypothesis to 
explain the intra-hepatic effect of estrogen removal on liver TAG metabolism. 
Besides a reduction in hepatic VLDL production, there are other factors that may 
explain the observation that fat accumulation was not reduced in liver of Ovx rats following 
the diet switch. One of the factor that is directly associated with the development and 
possibly the maintenance of liver lipid infiltration is hepatic fatty acid uptake that is directly 
proportional to plasma FFA concentrations [26]. However, in our previous works, we did 
not observe any effect of Ovx on plasma FFA levels [14, 22]. Plasma FFA levels in the 
present study were higher with time but to a similar extend in Ovx and Sham rats. Although 
statistically non-significant, plasma FFA levels appear to be lower following the shift of the 
diet in Ovx rats (week 13). This should have contributed to a reduction in liver TAG levels. 
Plasma FFA levels, therefore, can hardly be associated with the absence of effect of the diet 
shift on liver TAG levels in the Ovx group. In the same vein, it is interesting to observe that 
fat pad accumulation and plasma leptin levels were affected similarly by the diet switch in 
Ovx and Sham rats. This suggests that the effect of estrogen removal on the maintenance of 
liver fat accumulation is specific to the liver and reemphasizes the contention that in 
absence of a normal estrogenic status, liver fat resorption is dissociated from the diet and its 
associated effects on peripheral fat accumulation or diminution. Alternatively, lipid 
oxidation and de novo lipogenesis may be affected by the removal of estrogens. There is 
little information on the role of estrogens on both of these pathways. There is evidence that 
estrogens decreased the expression of lipogenic genes in liver and promote partitioning of 
FFA toward oxidation rather than storage [2]. Recent data from our group also indicate that 
oxidation is reduced in Ovx compared to Sham rats (unpublished observation).  
There is no indication that the present switch of the diet in Sham and Ovx rats 
resulted in a perturbation of glucose metabolism as judged from the present plasma glucose 
and insulin values. Liver fat accumulation has been reported to result in the development of 
insulin resistance [21]. There is at the present time no clear indication in the literature that 
Ovx in rat results in a perturbation of glucose metabolism. Studies using precise technique 
such as the hyperinsulinemic-euglycemic clamp will be needed to clarify this point. 
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In summary, results of the study indicate that 8 weeks after shifting from a HF to a 
SD diet, Ovx rats accumulate as much fat in liver as Ovx rats maintained on a HF diet. In 
contrast, Sham animals had lower levels of liver fat accumulation after the diet switch. 
These results indicate that Ovx rats are resistant to liver fat resorption induced by a change 
in the composition from HF to SD diet and suggest that hepatic fat accumulation and 
resorption are dependent on mechanisms associated with a normal estrogenic status. On a 
clinical point of view, the present data suggest that the removal of excess fat accumulation 
in liver may be complicated by the absence of estrogens in post-menopausal women.  
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Legends to figures 
Fig.1. Liver (mg/g of liver) and plasma triacylglycerol (TAG) concentrations in 
ovariectomized (Ovx) and sham-operated (Sham) rats fed a high-fat diet (HF) for 13 weeks 
and Ovx and Sham rats fed a HF diet for 5 weeks and then switched to a standard diet (SD) 
for the next 3 and 8 weeks. Values are means ± SE with n = 7-8 rats/group. + Significantly 
different from the corresponding Sham groups, P<0.05, ++ P<0.01. * Significantly different 
from corresponding group continuously fed the HF diet, P<0.05, ** P<0.01. & Significantly 
different from corresponding Sham and Ovx values measured at week 5, P<0.05, &&P< 
0.01. 
 
Fig.2. Sum of 3 intra-abdominal fat pad weights (mesenteric, retroperitoneal, and 
urogenital), subcutaneous fat pad weight, and plasma leptin concentrations in 
ovariectomized (Ovx) and sham-operated (Sham) rats fed a high-fat diet (HF) for 13 weeks 
and Ovx and Sham rats fed a HF diet for 5 weeks and then switched to a standard diet (SD) 
for the next 3 and 8 weeks. Values are means ± SE with n = 8 rats/group. + Significantly 
different from the corresponding Sham groups, P<0.05, ++ P<0.01. * Significantly different 
from corresponding group continuously fed the HF diet, P<0.05, ** P<0.01. & Significantly 
different from corresponding Sham or Ovx values measured at week 5, && P<0.01. 
 
Fig.3. Relationship between individual liver and plasma triacylglycerol (TAG) levels  
(n = 76, P<0.04) for all rats in all nutritional conditions.  
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Table 1. Body weight (BW) and energy intake (EI) in ovariectomized (Ovx) and sham-
operated (Sham) rats fed a high-fat diet (HF) for 13 weeks and Ovx and Sham rats fed a HF 
diet for 5 weeks and then switched to a standard diet (SD) for the next 8 wk.  
 
Values were measured throughout the experiment for the rats sacrificed at week 13. 
Values are means ± SE, n = 8 rats/group. + Significantly different from corresponding Sham 
groups, P<0.05, ++ P<0.01. * Significantly different from corresponding group continuously 
fed the HF diet, P<0.05. All values inside brackets ( [ ) are significantly different from the 
values of week 6. NS The only values that are not significantly increased compared to the 
preceding time value. 
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Table 2. Uterus weight, femur weight, and sum of 4 muscles weights in ovariectomized 
(Ovx) and sham-operated (Sham) rats fed a high-fat diet (HF) for 13 weeks and Ovx and 
Sham rats fed a HF diet for 5 weeks and then switched to a standard diet (SD) for the next 3 
and 8 weeks.   
 
Values are means ± SE, n = 8 rats/group. + Significantly different from corresponding Sham 
groups, P<0.05, ++ P<0.01. & Significantly different from corresponding Sham or Ovx 
values measured at week 5, P<0.05, && P<0.01.  
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Table 3. Plasma glucose, insulin, and free fatty acid (FFA) in ovariectomized (Ovx) and 
sham-operated (Sham) rats fed a high-fat diet (HF) for 13 weeks and Ovx and Sham rats 
fed a HF diet for 5 weeks and then switched to a standard diet (SD) for the next 3 and 8 
weeks.   
 
Values are means ± SE, n = 5-8 rats/group. + Significantly different from corresponding 
Sham group, P<0.05.  & Significantly different from corresponding Ovx values measured at 
week 5, P<0.05, && P<0.01.  
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Fig.1 
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Fig.2 
 
  
 
78
Fig.3 
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Abstract  
The present study was designed to investigate the effects of estrogen withdrawal and 
exercise training on hepatic very low density lipoprotein-triglyceride (VLDL-TG) 
production and on expression of genes involved in hepatic VLDL synthesis in response to 
lipid infusion. Female Sprague-Dawley rats underwent ovariectomy (Ovx), sham surgery 
(Sham), and Ovx with 17β-estradiol supplementation (OvxE2) before being subdivided into 
sedentary (Sed) and trained (Tr) groups for 8 weeks. Exercise training consisted of 
continuous running on a rodent treadmill 5 times/wk. At the end of the 8-week period, all 
rats in the fasted state were intravenously infused with a 20% solution of Intralipid for 3-h 
followed by an injection of Triton WR-1339 to block lipoprotein lipase activity. Plasma TG 
accumulation was subsequently measured during 90 min to estimate VLDL-TG production. 
An additional control group consisting of Sham-Sed rats was infused with saline (0.9% 
NaCl). Estrogen withdrawal resulted in higher (P<0.01) liver fat accumulation 
concomitantly with lower (P<0.01) VLDL-TG production and lower mRNA and protein 
content of hepatic microsomal triglyceride transfer protein (MTP). All of these effects in 
Ovx rats were corrected with estrogen supplementation. Training in Ovx rats reduced 
(P<0.01) liver fat accumulation and further reduced (P<0.01) hepatic VLDL-TG 
production along with gene expression of MTP and diacylglycerol acyltransferase-2 
(DGAT-2). It is concluded that VLDL-TG synthesis and/or secretion is decreased in Ovx 
rats probably via MTP regulation and that this decrease may constitute one of the factors 
involved in hepatic fat accumulation. The training effect on reducing VLDL production 
was independent of the estrogenic status. 
 
Keywords: hepatic steatosis, microsomal triglyceride transfer protein, diacylglycerol 
acyltransferase-1 and -2, lipid infusion 
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Introduction  
          Excessive storage of hepatocellular triglycerides (TG) has been recently identified as 
an independent risk factor of insulin resistance, metabolic syndrome, and cardiovascular 
disease [1]. One segment of the population that is particularly inclined to increased hepatic 
fat accumulation is postmenopausal women. Two third of postmenopausal women are 
considered overweight or obese and 43% present the metabolic syndrome [2]. Recent 
evidences indicate that menopause is indeed associated with the development of a state of 
hepatic steatosis [3, 4]. It seems, however, that liver fat accumulation observed with 
estrogen withdrawal is not strictly due to overall fat accumulation but also to deregulation 
of lipid metabolism in liver. 
          Increased lipid uptake by liver through estrogen withdrawal-induced hyperphagia 
could partially explain hepatic fat accumulation [5]. However, pair-feeding does not 
completely prevent fat accumulation in liver (unpublished data and [6]). Recent insight into 
molecular regulation of metabolic pathways possibly involved in reduced estrogen action in 
liver revealed an increase in gene expression of molecules involved in de novo lipogenesis 
and a reduction in gene expression of proteins involved in lipid oxidation [7]. Physiological 
evidence that fatty acid oxidation is reduced in liver of ovariectomized (Ovx) animals has 
also been recently reported [8]. On the other hand, there is no clear evidence as to whether 
estrogen withdrawal reduces lipid exportation from the liver through a reduction in very 
low density lipoprotein (VLDL) synthesis and/or secretion. Oral estradiol in 
postmenopausal women has been reported to increase the production rate of large VLDL-
apolipoprotein B [9]. Alternatively, Ovx with and without estradiol treatment has been 
reported to be without effect on TG production in Sprague-Dawley rats under anesthesia 
[10]. Therefore, whether estrogen removal is indeed associated with a change in VLDL 
production remains to be elucidated. The first purpose of the present study was to use a 
physiological approach to determine if VLDL-TG production is altered in Ovx rats.  
          VLDL assembly and secretion is a complex mechanism that involves several 
regulatory molecules including microsomal triglyceride transfer protein (MTP) and 
diacylglycerol acyltransferase-1 and -2 (DGAT-1 and -2) [11]. MTP is a protein complex 
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present in the lumen of the endoplasmic reticulum (ER) that has a capacity to transport 
significant quantities of lipids from the ER membrane to developing lipoprotein particles 
within the lumen of ER [12]. MTP activity is rate limiting for VLDL assembly and 
secretion [13]. DGATs are microsomal enzymes that catalyze the final steps in 
triacylglycerol synthesis [14]. It has been reported that the relative activities of the two 
types of DGAT may have a significant impact on the level of TG as well as on the 
development of steatosis [15]. To complement our investigation of estrogen withdrawal on 
VLDL-TG production, we measured the hepatic gene expression and the protein content of 
MTP along with the gene expression of DGAT 1 and 2. 
          Evidence of the impact of exercise training in the prevention and attenuation of 
hepatic steatosis is now well documented in humans and in animals [1, 16, 17]. Chronic 
exercise in obese Zucker rat has been shown to reduce TG production [18]. Hepatic VLDL-
TG secretion rate has also been recently reported to decrease following exercise training in 
humans [19], and in Sprague-Dawley rats fed a high-fat (HF) diet [20]. A decrease in 
hepatic protein content of MTP in HF fed rats and in the cachectic animals following 
exercise training has also been reported [20, 21]. However, it is not known if exercise 
training also reduces VLDL production in Ovx animals especially since we hypothesized 
that VLDL production is reduced in Ovx animals. The second purpose of the present study 
was to examine the effects of exercise training on hepatic VLDL-TG production and gene 
expression of related markers in Ovx rats and to compare these responses with 17β-
estradiol supplementation. 
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Materials and Methods 
Animal care 
          Female Sprague-Dawley strain rats, (Charles River, St-Constant, PQ, Canada) 230-
250 g  upon their arrival were housed individually and had free access to standard rat chow 
(12.5% fat, 63.2% carbohydrate, 24.3% protein; kcal, Agribrands Purina Canada, 
Woodstock, ON, Canada) and tap water. Their environment was maintained at 20-23 °C, 
under light-controlled 12:12-h light/dark cycle starting at 6:00 AM. The present study was 
conducted according to the Guidelines of the Canadian Council on Animal Care after 
institutional approval. 
Surgery 
          Four days after their arrival, animals underwent bilateral ovariectomy (Ovx) without 
and with 17β-estradiol supplementation (OvxE2) or were sham operated (Sham). Animals 
were injected with antibiotics (Tribrissen 24%; 0.125 mL/kg SC) for 3 days beginning with 
the day before surgery. Ovariectomy was performed according to the technique described 
by Robertson et al. [22] under isoflurane anesthesia. For OvxE2 rats, a small 17β-estradiol 
pellet (0.72 mg; 0.012 mg/d) with a biodegradable carrier binder efficient for 60 days 
(catalogue no. SE-121; Innovative Research of America, Sarasota, FL, USA) was 
implanted subcutaneously in the dorsal neck. El-Mas and Abdel-Rahman [23] previously 
showed that this estrogen regimen produces physiological levels of the hormone. A placebo 
60-day pellet containing the binding carrier only was used in all other rats (catalog no. SC-
111). 
Groups and exercise protocol 
          Three days after surgery, Sham, Ovx and OvxE2 rats were sub-divided into sedentary 
(Sed) and trained (Tr) groups. Each group was considered as complete when a minimum of 
8 rats/group was reached for all groups. Exercise training program consisted of continuous 
running on a motor-driven rodent treadmill (Quinton Instruments, Seattle, WA, USA) 5 
times/wk for the duration of the experiment. During the first 3 weeks, rats were 
progressively run from 15 min/day at 15 m/min, 0% slope up to 45 min/day at 26 m/min, 6 
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% slope. Thereafter, the training program was kept at 60 min at 26 m/min, 10% slope for 
the last 5 week. All trained animals were restrained from training 48 h before sacrifice.  
Surgical procedures 
          Rats were anesthetized with a mixture of ketamine - xylazine (61.5 - 7.6 mg/kg, ip).  
A vertical incision made in the front of the neck permitted the location and the insertion of 
a cannula into the right jugular.  In brief, a polyethylene tubing (catalogue no. 427411, 
0.58-mm inner diameter × 0.97-mm outer diameter, Becton Dickinson) filled with saline-
heparin (5U /ml) was inserted into the right jugular vein and the distal extremity was 
tunnelled subcutaneously and exteriorized at the nape of the neck.  The catheter was glued 
in place using Vet Bond (3M Animal Care Products) and all incisions were sutured closed.  
Once in place, the catheter was filled up with a 30% glycerol in heparin-saline (5U/ml) 
solution to keep it patent.  Rats were allowed a 3-day post-operative recovery before being 
submitted to the experimental procedures. 
Infusion study 
          Food was removed from cages at least 12 h before sacrifice. On the morning of the 
experiment, catheters were flushed with saline-heparin (5U/ml) and connected through 
polyethylene tubing to a KDS100 syringe infusion pump (KD Scientific Inc, New Hope 
PA, USA).  The infusion line was hanged above the cage and permitted the rat complete 
freedom of movement.  Rats received a 3-h intravenous infusion of 20% Intralipid (Baxter 
Corporation, Sherbrooke, Canada) at a rate of 0.4 ml/h. As used in several previous 
publications [20, 24], the lipid infusion allows measurement of the capacity of the liver to 
secrete VLDL in response to a large lipid load and eliminates potential confounders such as 
variations in endogenous lipid input. It has been speculated that Intralipid TG-FFA 
delivered to the liver during the infusion reached the liver as albumin-bound FFA after 
lipolysis in the circulation by either lipoprotein or hepatic lipase [24]. Blood was 
withdrawn from the right jugular vein at different time points during the experiment by the 
same infusion line after being completely rinsed with saline-heparin (5U/ml).  In addition to 
the experimental groups, a group of Sham-Sed rats, now referred to as control, was 
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submitted to all testing procedures with the exception that they were infused with saline 
(0.9% NaCl) instead of Intralipid. 
Determination of in vivo TG secretion 
          After the 3-h lipid or saline (control group) infusion, rats received an intravenous 
injection of Triton WR-1339 (500mg/kg) (25301-02-4, Sigma-Aldrich) diluted in saline. 
Triton WR-1339 is a non ionic detergent that effectively blocks lipoprotein lipase activity 
in vivo and therefore inhibits VLDL hydrolysis. Under these circumstances, accumulation 
of plasma TG is considered a good estimate of liver VLDL secretion [24].  Blood samples 
were collected in precooled tubes containing ethylenediaminetetraacetic acid (EDTA) 
(15%) as an anticoagulant at the end of the lipid infusion (preinjection) and at 30, 60 and 90 
min after the Triton WR-1339 injection. Plasma was immediately centrifuged and used for 
plasma TG determination. VLDL-TG production was determined as the total area 
calculated for the 90 min period. 
Blood and tissue samplings 
          At the end of the experiment and after complete anaesthesia with a mixture of 
ketamine xylazine (61.5 - 7.6 mg/kg, ip), the abdominal cavity was rapidly opened 
following the median line of the abdomen. Blood was rapidly (< 45 s) drawn from the 
abdominal vena cava (∼4 ml) into syringes pretreated with EDTA (15%). Blood was 
centrifuged (3000 RPM for 10 min, 4 °C; Beckman GPR Centrifuge) and the plasma kept 
for free fatty acid (FFA), glucose, insulin and leptin determinations. The liver was excised, 
the median lobe immediately clamp-frozen was used for triacylglycerol determination, 
mRNA and protein extraction and quantification. The mesenteric, retroperitoneal, 
urogenital and subcutaneous fat depots were, thereafter, rapidly excised and weighed. The 
plasma samples were stored at –78 °C until analyses. 
Analytical procedures 
          Plasma TG levels were determined with an enzymatic colorimetric assay available 
from SIGMA (Saint-Louis, MO, USA). Liver TG concentrations were estimated from 
glycerol released after ethanolic KOH hydrolysis by using commercial kit from SIGMA 
(Saint-Louis, MO, USA). Plasma glucose concentrations were determined with the use of a 
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glucose analyzer (Yellow Springs Instruments 2300, Yellow Springs, OH, USA).  Plasma 
FFA levels were measured with commercially available kits from Roche Diagnostics 
(Mannheim, Germany). Plasma insulin and leptin concentrations were determined with 
radioimmunoassay kits distributed by LINCO Research (St. Charles, MO, USA). 
RNA isolation and quantitative real-time (RT) polymerase chain reaction (PCR)      
          RNA extraction and cDNA preparation. Quick-frozen tissue samples of the liver were 
powdered with cold mortar and pestle, and approximately 100 mg was used for the 
isolation of RNA. Total RNA was extracted by the guanidine thiocyanate method and 
mRNA purified using PureLink RNA Mini Kit (Invitrogen) according to the 
manufacturer’s instruction. Total RNA was reverse transcribed in a final volume of 100 μL 
using the High Capacity cDNA Reverse Transcription Kit with random primers (Applied 
Biosystems, Foster City, CA, USA) as described by the manufacturer. Reverse transcribed 
samples were stored at -20°C. A reference RNA (Human reference total RNA, Stratagene, 
Ca, USA) was also transcribed in cDNA. 
qPCR Reactions- Taqman® Gene Expression Assays – Endogenous controls. Gene 
expression level for endogenous controls was determined using prevalidated Taqman Gene 
Expression Assays (Applied Biosystems). PCR reactions for 384 well plate formats were 
performed using 2 µl of cDNA samples (25-50 ng), 5µl of the Fast Universal qPCR 
MasterMix (Applied Biosystems), 0.5 µl of the TaqMan Gene Expression Assay (20X) and 
2.5 µl of water in a total volume of 10 µl. The following assay was used as endogenous 
control: GAPDH (glyceraldehyde-3-phosphate dehydrogenase). 
qPCR Reactions- Universal Probe Library (UPL) Assays. Gene expression level 
was determined using assays designed with the Universal Probe Library from Roche 
(www.universalprobelibrary.com). This technology utilizes short hydrolysis probes of 8 or 
9 bases. The high melting temperature characteristic of longer probes is retained by using 
Locked Nucleic Acid (LNA) nucleotide chemistry in these shorter probes. Because probes 
are only 8 or 9 bases long, each probe can hybridize to over 7000 transcripts; thus, a set of 
100 probes can enable the quantification of virtually any transcript in a transcriptome. PCR 
reactions for 384 well plate formats were performed using 2 µl of cDNA samples (25 ng), 5 
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µl of the Fast Universal qPCR MasterMix (Applied Biosystems), 2 µM of each primer and 
1 µM of a UPL probe in a total volume of 10 µl.The primer sets served to generate 
amplicons are presented in Table 1.  
Detection and analysis. The ABI PRISM® 7900HT Sequence Detection System 
(Applied Biosystems) was used to detect the amplification level and was programmed with 
an initial step of 3 minutes at 95˚C, followed by 45 cycles of: 5 seconds at 95˚C and 30 
seconds at 60˚C. All reactions were run in triplicata and the average values of Cts were 
used for quantification. GAPDH was used as endogenous controls. The relative 
quantification of target genes was determined using the UUCT method. Briefly, the Ct 
(threshold cycle) values of target genes were normalized to an endogenous control gene 
(GAPDH) (UCT = Ct target – Ct GAPDH) and compared with a calibrator: UUCT = UCt 
Sample - UCt Calibrator. Relative expression (RQ) was calculated using the sequence detection 
system (SDS) 2.2.2 software (Applied Biosystems) and the formula is RQ = 2-UUCT. 
Microsomal triglyceride transfer protein western blotting 
          Briefly, 100mg of liver was hemogenized in TPER containing protease inhibitor 
(10µl/ml pepstatin, and 1mM phenylmethanesulfonyl fluoride (PMSF) and 100U Trasylol) 
using a polytron and centrifuged at 12000g, 4ºC for 10 min. The infranatant was collected 
with a blunt-tipped Pasteur pipette and stored at -80 ºC until MTP determination. MTP 
content in the liver was determined by Western blotting. All samples (10µg of proteins) 
were separated on a 7.5% SDS-polyacrylamide gel and electro transferred onto Hybond-C 
extra nitrocellulose membrane (Amersham). Membranes were blocked overnight in Tris-
Buffered saline containing 0.05% Tween 20 (TBS-T 0.05%) and 5% nonfat dry milk at 
4ºC. The blot was then incubated with an anti-rabbit MTP antibody (kindly provided by Dr. 
David Gordon, Bristol-Myers-Squibb) for 60 min at room temperature. After two washes in 
TBS-T (0.05%) and two washes in TBS-T (0.05%) contacting 0.5% nonfat dry milk, the 
membrane was incubated for 30 min with an anti-rabbit, anti-mouse IgG-POD (BM 
Chemiluminescence Western Blotting Kit, catalogue  no.11520709001, Roche Diagnostics) 
at room temperature. Then the membrane was washed four times for 20 min each time in 
TBS-T (0.05%) before a chemiluminescence substrate (catalogue no. 11520709001, Roche 
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diagnostics) was applied to the membrane. The resulting signal was detected on scientific 
imaging films (Amersham). The bands were quantified with Image J software and 
expressed as arbitrary units. Equal protein loading was determined using Monoclonal anti-
β-Actin antibody, produced in mouse (product No. A 5441; SIGMA, Saint- Louis, MO, 
USA). 
Statistical analysis 
          Values are expressed as mean ± S.E. Statistical analysis were performed using a two-
way ANOVA for nonrepeated measures using surgery and training as the main effects at 
common time points, excluding control group (since no exercise treatment were given at 
that time). Fisher’s PLSD posthoc test was used in the event of a significant (P <0.05) F 
ratio. 
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Results 
          Body weight was higher (P < 0.01) in Ovx compared to Sham and OvxE2 rats in 
both Sed and Tr groups (Table 2). Intra-abdominal fat pad weights and plasma leptin 
concentrations were also higher in Ovx than in Sham (P < 0.05) and OvxE2 rats (P < 0.01). 
Training decreased (P < 0.05) values of both of these variables in Sham and Ovx groups. 
Surgery did not affect plasma insulin and glucose concentrations with the exception of 
lower (P < 0.01) glucose levels in OvxE2 rats (Table 2). Training lowered (P < 0.01) both 
plasma insulin and glucose values in all groups. 
          Plasma FFA levels were largely lower in all lipid-infused groups 90 min after the 
Triton injection most likely as a result of their conversion into TG by the liver (Fig.1A). A 
significant (P < 0.05) effect of Tr was found for plasma FFA in all groups.  Liver TG levels 
measured at the end of the experiment were higher (170 %) higher in Ovx than in Sham (54 
± 4.4 vs 20.4 ± 1.7 mg/g; P<0.01; Fig. 1B). The Ovx-induced hepatic TG accumulation was 
strongly prevented by 17β-estradiol supplementation. Exercise training resulted in a large 
reduction (P < 0.01) in hepatic fat accumulation in Ovx and to a lesser extent (P < 0.05) in 
Sham rats. 
          To estimate the effect of training and/or estrogen deficiency and replacement on 
hepatic VLDL-TG synthesis and secretion at the end of the lipid infusion period, the 
lipoprotein lipase was momentarily blocked with Triton WR-1339 injection. The resulting 
accumulation of TG in plasma reflected the hepatic VLDL-TG synthesis and secretion. 
Statistical analyses were conducted only for values of total area calculated for the 90 min 
period. VLDL-TG accumulation was significantly (P < 0.01) lower in Ovx than in Sham 
rats (Fig. 2B). Estrogens supplementation reincreased VLDL-TG accumulation to the level 
of Sham animals. Plasma TG accumulation was lower (P < 0.01) in Tr compared to Sed 
rats in all surgery groups. 
          As for plasma VLDL-TG accumulation, MTP mRNA levels and protein content were 
significantly lower (P < 0.01) in liver of Ovx animals compared to Sham rats (Fig. 3).The 
Ovx-induced lower MTP gene expression was completely prevented by 17β-estradiol 
replacement. Similarly to plasma VLDL-TG accumulation, MTP mRNA levels and protein 
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content were lower (P < 0.01) following exercise training in all groups (Fig. 3).  To go one 
step further, we measured gene expression of DGAT-1 and-2, two enzymes involved in 
VLDL synthesis. There was no effect of estrogen levels or Tr on gene expression of 
DGAT-1 (Fig. 4A). On the other hand, DGAT-2 mRNA levels were slightly lower in Ovx 
than in Sham and OvxE2 rats, but the difference did not reach the statistical significance (P 
< 0.1). DGAT-2 mRNA levels were, however, lower (P < 0.05) in Tr animals in all groups 
(Fig. 4B). 
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Discussion  
          The emergence of estrogens as an important regulator of hepatic lipid homeostasis is 
becoming increasingly clear. In the present study, we addressed the question if VLDL-TG 
production is reduced in Ovx rats. Since hepatic VLDL production is primarily substrate-
driven [25-27], VLDL-TG production in the present study was measured in response to 
lipid infusion. Using this physiological approach, the present results indicate that VLDL-
TG production is reduced in Ovx rats. In addition, we report data showing that the liver 
protein content and mRNA levels of MTP, a key factor in VLDL synthesis, is reduced in 
Ovx rats. Finally, we found that VLDL-TG production, as well as mRNA levels of MTP 
and DGAT-2, are decreased following exercise training independently of the estrogenic 
level. 
Effect of estrogen removal and supplementation on hepatic VLDL-TG production 
          The present data on liver fat accumulation are consistent with previous findings of 
the development of a state of hepatic steatosis in Ovx animals and its prevention by 17β-
estradiol supplementation [7, 28]. These observations suggest that estrogens act as a 
protective tool to keep normal lipid accumulation in the liver. In link with this observation, 
the present study, using a physiological approach, clearly indicates that plasma VLDL-TG 
levels are decreased in Ovx rats, thus suggesting a reduction in VLDL synthesis and/or 
secretion with estrogen withdrawal. Supporting this interpretation, the decrease in plasma 
VLDL-TG accumulation in Ovx-Sed rats was completely prevented by estrogen 
supplementation in accordance with the reduction in liver fat accumulation. These data, 
therefore, may be taken as an indication that a reduction in VLDL production by the liver 
may be a contributing factor responsible for the large hepatic fat accumulation observed in 
Ovx rats. 
          To support the physiological finding that indeed VLDL production is decreased in 
Ovx rats, we measured gene expression of MTP, a molecule that exerts a central regulatory 
role in VLDL assembly and secretion [13].  Our study provides the first molecular evidence 
that hepatic MTP mRNA is decreased (-31%) by estrogen withdrawal. This observation 
was confirmed at the protein level (-28%). Such a decrease in MTP mRNA, as well as in 
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VLDL-TG secretion rate, has previously been found in Sprague-Dawley rats treated with 
the selective estrogen receptor modulator (SERM) acolbifene (ACOL) [29]. Reduced MTP 
mRNA and protein content in liver of Ovx rats was reestablished by estrogen replacement 
to levels measured in Sham animals. This strongly suggests that indeed estrogens regulate 
MTP gene expression. In addition, we measured gene expression of DGAT-1 and -2. The 
lack of response of DGAT-1 to estrogen withdrawal may be related to the fact that this 
enzyme is involved in TG synthesis that accumulates in hepatocytes and not the TG 
incorporated into VLDL. DGAT-2 is more relevant to estrogen action on VLDL synthesis 
since it catalyzes the final step of the synthesis of TGs that are going to be incorporated into 
VLDL [11]. Accordingly, knockdown of DGAT-2 with antisense oligonucleotide reduces 
VLDL-TG and ApoB secretion in mice [30]. Taking into account the limitation that 
DGAT-2 mRNA levels measured in the present Ovx rats only show a tendency (~ 30%) to 
be decreased and reincreased with E2 supplementation, these results may be taken as a 
further indication that VLDL-TG synthesis is indeed reduced with estrogen withdrawal.  
          Molecular mechanisms by which estrogens regulate transcription of target genes in 
VLDL-TG production pathway are not well known. The biological effects of estrogen are 
mediated by genomic and nongenomic mechanisms [31]. The classical genomic mechanism 
of estrogen action involves activation of its nuclear receptors (ERs) α and β, receptors 
dimerization, and subsequently binding to estrogen response elements (EREs) located in the 
promoters of target genes [5, 32]. Besides the classical model, estrogen has also been 
shown to have rapid non-genomic actions mediated through a subpopulation of ER α and 
ER β that is located at the plasma membrane [33, 34]. This model may indirectly influence 
gene expression, through the activation of signal transduction pathways that eventually act 
on target transcription factors. Nongenomic actions of estrogen are frequently associated 
with the activation of various protein kinase cascades [35] like mitogen-activated protein 
kinase (MAPK) and phosphoinosital (PI) 3-kinase (PI 3-kinase) signaling pathways [31]. It 
is thus possible that estrogens affect gene expressions of target genes involved in liver lipid 
exportation through protein-protein interaction in the nucleus and/or activation of signal 
transduction pathways at the plasma membrane. It seems that estrogens are involved in the 
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regulation of all pathways (i.e. de novo lipogenesis, lipid oxidation [7, 8] and exportation) 
of liver lipid accumulation. However, the contribution of each pathway under estrogen 
deficiency status is unclear and needs to be revealed by further investigations. It must also 
be acknowledged that hyperphagia, well known to occur in Ovx rats [36], may also be a 
contributing factor to the present effects of estrogen withdrawal in liver.  
Effect of exercise training on hepatic VLDL-TG production 
          As previously reported, we observed that endurance exercise training prevented the 
accumulation of lipids in the liver of Ovx rats [36]. Interestingly, the present results also 
show that plasma VLDL-TG levels were also reduced by exercise training in all groups, 
including the Ovx rats for which VLDL-TG levels were already reduced by the absence of 
estrogens. VLDL-TG production has been recently reported to be reduced following 
training in HF fed rats and in humans [19, 20]. In addition, the direct effect of exercise 
training on the reduction of gene expression of key molecules involved in VLDL-TG 
synthesis has been recently reported [20, 21].  In the present study, hepatic MTP mRNA 
and protein content as well as DGAT-2 mRNA levels were suppressed by exercise training 
in all groups including the Ovx animals. This suggests that the effects of exercise training 
and estrogen withdrawal on VLDL-TG synthesis and/or secretion are additive. 
Furthermore, the additive effects suggest that these two actions may take place through 
different pathways. On the other hand, the reduction in VLDL-TG synthesis with exercise 
training was accompanied by a reduction in liver TG levels. This is opposite to what we 
observed with estrogen withdrawal. This may be explained by the fact that exercise training 
increases the use of lipids, therefore, reducing body fat accumulation and substrate delivery 
to the liver. Accordingly, intra-abdominal fat pad weights were lower in the present Ovx 
rats submitted to the training program.  
 It has been suggested that the mechanisms underlying decreased hepatic VLDL-TG 
secretion following exercise training are regulated by insulin [19]. It is well documented 
that hepatic VLDL production is suppressed in response to insulin action, resulting in a 
decreased release of VLDL into the circulation [37]. Insulin exerts an inhibitory effect on 
hepatic MTP gene expression [38, 39]. On the other hand, it is well known that exercise 
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training improves insulin sensitivity [40]. Insulin sensitivity was not measured in the 
present study, but our results of lower plasma insulin levels observed following training in 
all groups may be taken as an indication of improved insulin sensitivity. It is, therefore, 
reasonable to assume that Tr in Ovx rats might reduce VLDL-TG secretion, not only as a 
result of a reduction in substrate availability, but also by reducing, as in Sham and OvxE2 
rats, the action of key molecules (i.e. MTP) involved in synthesis and/or secretion. 
          In summary, results of the present study indicate that VLDL-TG accumulation 
following lipoproteinlipase blockade, as well as gene expression of liver MTP, a molecule 
that exerts a central regulatory role in VLDL assembly, are reduced in Ovx rats. These 
results suggest that a decrease in VLDL production might be a contributing factor 
responsible for hepatic fat accumulation known to occur with estrogen withdrawal. In 
addition, exercise training lowered VLDL-TG production, as well as gene expression of 
MTP and DGAT-2, independently of the estrogen levels. This suggests that exercise 
training regulates VLDL production through a different pathway than the estrogenic 
pathway. 
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Legends 
Fig.1. A) Plasma free fatty acid (FFA) concentrations and B) liver triacylglycerol (TG) in 
sham-operated (Sham), ovariectomized (Ovx) and ovariectomized with 17β-estradiol 
supplementation (OvxE2) rats measured in sedentary (Sed) and trained (Tr) states, before 
(0 min) and 90 min after injection of Triton WR-1339 for FFA and at the end of the 
experiment for liver TG. Values at time 0 are taken after 3-h infusion of Intralipid in all six 
experimental groups while the control group (Sham-Sed) was infused with saline. Values 
are means ± S.E., n = 7-10 for FFA rats/group and n = 7-12 for liver TG. ** Significantly 
different from Sham, P < 0.01. && Significantly different from OvxE2, P < 0.01. + 
Significantly different from Sed, P < 0.05, ++ P < 0.01.  
 
Fig.2. A) Accumulation of plasma triglyceride (TG) concentrations and B) total area under 
the plasma triglyceride concentrations curves in sham-operated (Sham), ovariectomized 
(Ovx) and ovariectomized with 17β-estradiol supplementation (OvxE2) rats measured in 
sedentary (Sed) and trained (Tr) states, before (0 min) and 30, 60, and 90 min after 
injection of Triton WR-1339. Values at time 0 are taken after 3-h infusion of Intralipid in 
all six experimental groups while the control group (Sham-Sed) was infused with saline. 
Values are means ± S.E., n = 6-11 rats/group. Statistical analyses were conducted only for 
values of total area under the curves for 90 min.   
 ** Significantly different from Sham, P < 0.01. && Significantly different from OvxE2, P < 
0.01. ++ Significantly different from Sed, P < 0.01.  
 
Fig.3. A) mRNA abundance and B) protein content of microsomal triglyceride transfer 
protein (MTP) in liver of sham-operated (Sham), ovariectomized (Ovx) and ovariectomized 
with 17β-estradiol supplementation (OvxE2) measured in sedentary (Sed) and trained (Tr) 
states at the end of the experiment. The six experimental groups received a 3-h infusion of 
Intralipid while the control group (Sham-Sed) was infused with saline. MTP protein content 
was measured by Western blotting and expressed in arbitrary units (AU). Values are means 
± S.E., n = 6-11 rats/group for mRNA and n = 6-8 for protein content rats/group. ** 
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Significantly different from Sham, P < 0.01. && Significantly different from OvxE2, P < 
0.01. ++ Significantly different from Sed, ++ P < 0.01.  
 
Fig.4. A) Hepatic diacylglycerol acyltransferase-1 (DGAT-1) and B) DGAT-2 mRNA 
levels in sham-operated (Sham), ovariectomized (Ovx) and ovariectomized with 17β-
estradiol supplementation (OvxE2) measured in sedentary (Sed) and trained (Tr) states. The 
six experimental groups received a 3-h infusion of Intralipid while the control group 
(Sham-Sed) was infused with saline. Values are means ± S.E., n = 6-10 for DGAT-1 and n 
= 8-12 for DGAT-2 rats/group.  + Significantly different from Sed, P < 0.05.  
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Table 1. Oligonucleotide primers used for quantitative real-time polymerase chain reaction. 
Genes Accession no Sense primer (5′-3′) Antisense primer (5′-3′) 
MTP NM_001107727.1 
 
GCGAGTCTAAAACCCGAGTG 
 
CACTGTGATGTCGCTGGTTATT 
 
DGAT-1 NM_053437.1 AAGGGTCAAGGCCAAAGC TTGTCCGGATAGCTTACAGTGTT 
DGAT-2 NM_001012345.1 AGGATCTGCCCTGTCACG GTCTTGGAGGGCCGAGAG 
GAPDH NM_017008 CCCTCTGGAAAGCTGTGG AGTGGATGCAGGGATGATG 
 
 
MTP: microsomal triglyceride transfer protein; DGAT-1: diacylglycerol acyltransferase-1; 
DGAT-2: diacyglycerol acyltransferase-2; GAPDH: glyceraldehyde-3-phosphate 
dehyrogenase  
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Table 2. Body composition and plasma leptin, glucose, and insulin concentrations in sham 
operated (Sham), ovariectomized (Ovx), and Ovx rats with 17 β-estradiol supplementation 
(OvxE2) in sedentary (Sed) and trained (Tr) states. 
  
Control  
        Sham 
 
        Ovx 
 
        OvxE2 
 
 
Sed Tr Sed Tr Sed Tr 
 
Body weight (g) 
 
 
329±7 
 
314±8 
 
326±8 
 
390±7** 
 
369±8** 
 
312±11&& 
 
298±8&& 
 
Intra-abdominal 
fat   
weight (g) 
 
 
28 ±2.6 
 
26±2.6 
 
20±2.4++ 
 
39±3* 
 
23±2.9*++ 
 
22±2.3&& 
 
15±2.2&& 
 
Leptin (ng/ml) 
 
 
3.9±0.8 
 
5.1±1.1 
 
1.8±0.5+ 
 
12.9±2.0**
 
3.0±0.8**++ 
 
4.4±1.3&& 
 
1.9±0.5&& 
 
Glucose (mM) 
 
 
7.42±0.3 
 
8.45±0.4 
 
7.22±0.2++
 
8.75±0.8 
 
7.69±0.2++ 
 
7.56±0.5&&
 
5.88±0.2&&++
 
Insulin (pM) 
 
 
100±17 
 
111±15 
 
72±18++ 
 
145±23 
 
68±12++ 
 
89±12 
 
59±7++ 
        
 
The six experimental groups received a 3-h infusion of Intralipid while the control group 
(Sham-Sed) was infused with saline. Values are mean ± S.E., n = 6-12 rats/group 
* Significantly different from Sham, P < 0.05, ** P < 0.01. && Significantly different from 
OvxE2, P < 0.01. + Significantly different from Sed P < 0.05, ++ P < 0.01.  
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Fig. 2. 
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Fig. 4. 
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Abstract 
The objective of present study was to investigate effects of blocking oxytocin-atrial 
natriuretic peptide (OT-ANP) system by OT antagonist (OTA), on hepatic guanylyl 
cyclase-A (GC-A) mRNA, in ovariectomized (Ovx) rats. In the second step, we tested the 
adaptation of this system to exercise training. Since both OT and ANP possess anti-
inflammatory potential, we measured gene expression of some inflammatory markers in the 
liver of OTA-treated rats. Ovx and sham-operated (Sham) female Sprague-Dawley rats 
were kept in a sedentary (Sed) or trained (Tr) state for 8 wk. Ten days before sacrifice, Ovx 
and Sham rats were sub-divided into OTA and vehicle-treated groups (0.1 μg/g BW, daily 
IP injections). Hepatic GC-A mRNAs were decreased (P < 0.05) in Ovx and Sham OTA-
treated rats in Sed state. Exercise training had no effect on hepatic GC-A mRNA in these 
groups. Conversely, training increased (P < 0.01) GC-A mRNA in vehicle-treated Ovx rats 
while an opposite effect was found in Sham rats. Hepatic C-reactive protein (CRP) mRNA 
increased in Ovx and Sham OTA-treated rats in Sed state (P < 0.05). Training had no 
effects on hepatic CRP mRNA in any groups. Hepatic nuclear factor-kappa B (NF-κB) 
protein content was not affected by OTA and training but was higher (P < 0.05) in all Ovx 
rats. Although Ovx caused an increase in liver fat, intra-abdominal, and subcutaneous fat 
pad weights along with plasma leptin concentrations (P < 0.01), OTA administration did 
not influence the response of these variables with the exception of a significant (P < 0.01) 
OTA effect in Ovx Sed rats resulting in higher subcutaneous fat pad weight. The present 
data indicate that a blockade of the OT-ANP axis results in down-regulation of hepatic GC-
A mRNA that is associated with an increased hepatic CRP mRNA. These effects were not 
influenced by ovariectomy or exercise training. 
 
 
Keywords: Oxytocin antagonist (OTA), hepatic C-reactive protein (CRP), endurance 
training, liver fat 
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Introduction 
  Oxytocin (OT) is a nonapeptide hormone that is largely produced in hypothalamus 
[1] and released into blood stream from the posterior lobe of pituitary gland. This hormone 
has long been recognized as a factor for fluid and electrolyte homeostasis, maintenance of 
blood volume and importantly for its role during parturition and lactation [2]. New study 
demonstrates that OT plays essential roles in the regulation of energy homeostasis because 
oxytocin receptor (OTR)-deficient male mice exhibited late-onset obesity with increases in 
abdominal fat pads and fasting plasma triacylglycerol (TAG) [3]. The mechanism of this 
deficiency is unknown and may involve the liver function. OT also sub serves other 
important physiological fuctions such as the ones involving cardiac natriuretic peptide 
system [4]. Circulating OT binds to OTR in the right atrium and activates its receptor. 
Activated OTR stimulates atrial natriuretic peptide (ANP) release into plasma from atrial 
myocytes [5, 6]. This polypeptide hormone is primarily expressed and stored in the atria, 
although it is present at lower concentrations in other tissues such as the ventricles and 
kidney [7].  
  ANP acts through its signaling receptor guanylyl cyclase type A receptor (GC-A) 
[8] which has been highly expressed in the rodent heart [9], lung, kidney, adrenal, testis, 
and liver tissues [10, 11]. It has been shown that intravenous injection of OT induced a 
dose-related increase in plasma ANP levels [12]. Conversely, administration of oxytocin 
antagonist (OTA) inhibits ANP release by blocking OTR [4, 6, 13].  
  Since ANP discovery, most of the studies have focused on its renal and 
cardiovascular effects [14, 15]. However, there is increasing evidence for other biological 
effects of ANP [16]. For instance, ANP has been reported to increase lipid mobilization in 
subcutaneous adipose tissue during exercise in overweight men [17]. In a recent study, 
Miyashita et al., using a series of mouse transgenic models, convincingly demonstrated that 
natriuretic peptides/cGMP cascades exert significant roles in mitochondrial biogenesis, fat 
oxidation, and oxygen consumption [18]. This led to the interpretation that natriuretic 
peptides are new players in energy metabolism [19]. In liver, ANP was reported to have a 
protective action against ischemia-reperfusion (I/R) injury through its effect on macrophage 
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activation and reduction in reactive oxygen species (ROS) production [20]. Moreover, the 
marked augmentation of nuclear factor-kappa B (NF-κB) binding activity during 
reperfusion was prevented in ANP-pretreated livers. These effects of ANP on the liver are 
mediated by membrane bound GC-A receptor [21]. However, besides I/R conditions, it is 
not known if ANP exerts a physiological action on liver in normal physiological conditions 
and if the action of ANP is mediated by OT.  
  The aim of present study was to investigate whether OTR blockage targets liver. 
The OTR expression in the liver is low because the methylation of the CpG island in the 
OTR gene promoter suppresses its transcription [22]. Therefore, we hypothesized that the 
treatment with OTA will predominantly target ANP in the heart and, indirectly, the gene 
expression of ANP receptor in the liver. Since we recently reported that gene expressions of 
cardiac ANP and GC-A were under estrogenic control [9] the present experiment was 
conducted in ovariectomized (Ovx) and Sham rats. To evaluate one possible effect of OT-
ANP system in liver, we measured hepatic gene expression of some inflammatory markers 
and hypothesized that these markers should increase following blockade of OT-ANP axis. 
Finally, exercise training was demonstrated to positively influence cardiac OT-ANP 
system, this positive effect of exercise training being shown in estrogen deficient condition 
[9]. Therefore, a second objective of the study was to test the hypothesis that exercise 
training stimulates the hepatic GC-A gene expression in OTA administrated rats leading to 
positive outcomes of exercise training, especially in estrogen deficient state.  
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Materials and Methods 
Animal care: Female Sprague-Dawley strain rats (n = 56) weighing 180-200 g (6 
wk old), obtained from Charles River (St-Constant, PQ, Canada), were housed individually 
and maintained at 20-23 °C, under light-controlled 12:12-h light/dark cycle starting at 6:00 
AM. 
Animals had free access to standard rat chow (12.5% fat, 63.2% carbohydrate, 24.3% 
protein; Kcal, Agribrands Purina Canada, Woodstock, ON) and tap water. The 
experimental protocols were conducted according to the Guidelines of the Canadian 
Council on Animal Care after institutional approval. 
Surgical procedures: Two days after their arrival in our laboratory, the rats were 
randomly assigned to eight experimental groups (n = 7 rats/group). Four groups underwent 
ovariectomy surgery (Ovx), and four groups were sham-operated (Sham). Ovx was 
performed according to the technique described by Robertson et al [23]. For surgery, 
animals were anesthetized with isoflurane inhalation. Animals were treated with antibiotics 
(Tribrissen 24%; 0.125 ml/kg, sc) for 3 days, beginning on the day before surgery. Body 
weight (BW) and food intake in g were monitored every other day. 
Training protocol: Both Ovx and Sham rats were divided into sedentary (Sed) and 
trained (Tr) groups. Ovx and Sham Sed groups remained sedentary and Ovx and Sham Tr 
groups underwent endurance training consisting of continuous running on a motor-driven 
rodent treadmill (Quinton Instruments, Seattle, WA), 5 times/wk for 8 wk. Exercise 
intensity was progressively increased from 15 min/day at 15 m/min, 0% slope, up to 
60 min/day at 26 m/min, 8% slope, for the last 5 weeks of the program. At the end of this 8 
weeks training period, rats were killed 48 h after the last training session.  
Injection procedure: Sham and Ovx rats from the training and sedentary groups 
were divided into two subgroups: OTA and vehicle-treated groups. Rats received a dose 
(200 µl) of drug or vehicle, respectively, which was intra-peritoneally administrated once a 
day for 10 consecutive days until the day before sacrifice. The drug solutions were prepared 
freshly before the experiments. All injection experiments took place at 9:00 AM, and the 
whole injection procedure for one rat lasted about 60 s. The dosage for OTA [d(CH2)51, 
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Tyr(Me)2, Orn8]-vasotocin, (Peninsula Laboratories, a Division of Bachem, Belmont, CA, 
USA) was estimated at approximately 0.1 μg/g BW. This dose of OTA was used because 
there is extensive literature indicating that it can affect a variety of physiological and 
behavioral responses in rats and voles [24-26].  
Blood and tissue sampling: All rats were killed between 9:00 and 12:00 AM. Food 
was removed from their cage 2 h before sacrifice. Immediately after complete anesthesia 
(pentobarbital sodium; 50 mg/kg, IP), the abdominal cavity was opened along the median 
line of the abdomen, and approximately 5 ml of blood were collected from the abdominal 
vena cava (<45 s) into syringes pretreated with EDTA (15%). Then, blood was centrifuged 
at 3,000 rpm, 4 °C, for 10 min (Beckman GPR Centrifuge), and plasma was kept at -78 °C 
for further analysis. The liver, uterus, femur, intra-abdominal (mesenteric, urogenital, 
retroperitoneal) fat depots and subcutaneous fat pad along with the skeletal muscles of the 
right limb (soleus, plantaris, and gastrocnemius) were removed. The liver median lobe was 
rapidly excised and quickly freeze-clamped in liquid nitrogen then processed for TAG, 
mRNA, and protein extraction and quantification. All tissue samples were weighted 
(Mettler AE 100) and then frozen immediately in liquid nitrogen and stored along with 
plasma samples at -78 °C until analysis were performed. Uterus were excised and weight to 
confirm the Ovx and sham operation. The right femur weight was obtained following a 
short boiling period in a KOH (10%) solution in order to remove the surrounding tissue. 
 Biochemical analyses: Liver TAG concentrations (mg/g of liver) were estimated 
from glycerol released after ethanolic potassium hydroxide hydrolysis, using commercial 
kits from Sigma (St. Louis, Missouri, USA). Plasma insulin and leptin concentrations were 
determined with radioimmunoassay kits distributed by Linco Research (St. Charles, 
Missouri, USA). Plasma glucose concentrations were determined with the use of a glucose 
analyzer (Model 2300; Yellow Springs Instruments, Yellow Springs, OH). Plasma TAG 
concentrations were measured by enzymatic colorimetric assay with kits available from 
Sigma (St. Louis, Missouri, USA). 
 Isolation of RNA and quantitative real-time (RT) polymerase chain reaction 
(PCR): Total RNA was extracted from freeze-clamped livers with Trizol reagent 
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(Invitrogen Life Technologies, Inc., Burlington, ON) according to the manufacturer’s 
protocol. To remove genomic DNA, RNA samples were incubated with 2 U of 
deoxyribonuclease I (DNase I; Invitrogen Life Technologies, Inc.) per microgram of RNA 
for 30 min at 37°C. PCR was carried out in the iCycler IQ Real Time PCR detection system 
(Bio-Rad Laboratories, Inc., Hercules, CA), using SYBR green chemistry. The samples 
were analyzed in duplicate. For amplification, 2 µL of diluted cDNA were added to a 20 μL 
reaction mixture containing 1X iQ SYBR Green Supermix (Bio-Rad laboratories, Inc.) and 
200 nM forward and reverse primers. The thermal cycling program was 95°C for 2 min, 
followed by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 s. The 
primers were purchased from Invitrogen Life Technologies, Inc. Primers sets served to 
generate amplicons (Table 1). Optical data were recorded during the annealing step of each 
cycle. After PCR, the reaction products were melted for 1 min at 95°C, the temperature was 
lowered to 55°C, and then gradually increased to 95°C in 1.0°C increments, 10 s per 
increment. Optical data were collected over the duration of the temperature increments, 
with a dramatic decrease in fluorescence occurring. This was done to ensure that only one 
PCR product was amplified per reaction. The relative expression of the RT-PCR products 
was determined by the ΔΔCt method. This method calculates relative expression using the 
equation: fold induction = 2-[UUCt] where Ct = the threshold cycle, ie, the cycle number at 
which the sample’s relative fluorescence increases to more than the background 
fluorescence, and ΔΔCt = [Ct gene of interest (unknown sample) – Ct glyceraldehyde-3-
phosphate dehydrogenase (unknown sample)] – [Ct gene of interest (calibrator sample) – Ct 
glyceraldehyde-3-phosphate dehydrogenase (calibrator sample)]. One of the control 
samples was chosen as the calibrator sample and tested in each PCR. Each sample was run 
in duplicate, and the mean Ct was taken in the ΔΔCt equation. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was chosen for normalization because this gene showed 
consistent expression relative to other housekeeping genes among the treatment groups in 
our array experiments. 
 Western blot analyses: Liver samples (~ 100 mg) were prepared by 
homogenization in modified RIPA buffer [1x phosphate-buffered saline, 1% Igepal CA-
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630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 10 mg/ml 
phenylmethylsulfonyl fluoride, aprotinin, 100 mM sodium orthovanadate, and 4%  protease 
inhibitor] and then centrifuged at 10,000g for 20 min at 4°C. The supernatants were 
collected, and protein concentration was determined by modified Bradford assay. Thirty 
micrograms of total protein were applied to each well of 10% polyacrylamide gel and 
electrophoresed for 2 h at 130 V along with a set of molecular weight markers (RPN800, 
Amersham Biosciences). The resolved protein bands were then transferred onto 
polyvinylidene difluoride membranes (Hybond-C; Amersham-Pharmacia) at 30 V for 120 
min, at room temperature, using a transfer buffer (25 mmol/l Tris base, 192 mmol/l glycine, 
and 20% methanol). The blots were blocked overnight at 4°C with blocking buffer (5% 
nonfat milk in 10 mmol/l Tris, pH 7.5, 100 mmol/l NaCl, 0.1% Tween 20). The membrane 
were then probed with specific primary antibody: NF-κB (1:2,000) obtained from Cell 
Signaling) overnight at 4°C. As an internal control, blots were probed with a GAPDH 
antibody (1:15,000; Sigma). They were then washed in triethanolamine-buffered saline 
washing buffer (10 mmol/l Tris, pH 7.5, 100 mmol/l NaCl, 0.1% Tween 20) and incubated 
with horseradish peroxidase conjugated immunoglobulin G (anti-rabbit; Santa Cruz 
Biotechnology). The blots were detected by a chemiluminescence detection system 
(RPN2132, Amersham-Pharmacia) and visualized by exposure to Kodak X-Omat film. 
Densitometric measurement of the bands was performed using Image J software. 
 Statistical analysis: Values are expressed as mean ± SE. Statistical analyses were 
performed using a three-way ANOVA for non-repeated measures using surgery, OTA and 
training as the main effects. Fisher’s post hoc test was used in the event of a significant (P 
< 0.05) F ratio. 
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Results  
Body weight (P < 0.01) and energy intake were higher (P < 0.05) and uterus weight 
was lower (P < 0.01) in Ovx compared to Sham rats (Table 2). All of these variables were 
not affected either by training or the OTA administration. Femur weight was higher (P < 
0.01) with training in all groups. A small but significant (P < 0.05) decrease in femur 
weight with OTA administration was found in all groups. The sum of leg muscle weights 
was higher (P < 0.01) in Ovx than in Sham rats while unchanged by OTA and significantly 
(P < 0.01) increased following training in Ovx animals (Table 2).  
Gene expression levels of hepatic GC-A measured in the Sed state were 
significantly (P < 0.05) decreased in Sham and Ovx rats injected with OTA compared to 
respective groups receiving only the vehicle (Fig. 1a). Hepatic GC-A mRNA was not 
affected by training in OTA injected rats. In non-injected OTA rats, however, hepatic GC-
A gene expression was decreased (P < 0.05) in Sham rats and increased (P < 0.01) in Ovx 
rats by training. There was no isolated effect of Ovx on GC-A mRNA. 
 To evaluate the potential effect of a reduction in the OT-ANP axis in liver, we 
measured some inflammatory markers. Ovx resulted in lower (P < 0.01) hepatic C-reactive 
protein (CRP) mRNA in all Sed rats with and without OTA administration (Fig. 1b). 
Opposite to the GC-A gene response, OTA administration resulted in a significant (P < 
0.05) increase in hepatic CRP mRNA in Sham and Ovx rats measured in the Sed state. On 
the other hand, training had no significant effect on hepatic CRP gene expression. Protein 
content of NF-κB on the whole was increased (P < 0.05) in Ovx animals independently of 
the training state or the OTA injection (Fig. 2). 
Liver TAG levels were higher (P < 0.01) in Ovx than in Sham rats independently of 
OTA administration (Fig. 3a). Training resulted in lower (P < 0.05) hepatic fat 
accumulation in Ovx rats. Plasma TAG levels were lower (P < 0.01) in Ovx than in Sham 
rats independently of the training state and the OTA administration (Fig. 3b). Intra-
abdominal and subcutaneous fat pat weights as well as plasma leptin levels were higher (P 
< 0.01) in Ovx than in Sham rats in the Sed state in both OTA and vehicle-injected 
conditions (Fig. 4). These differences disappeared in Tr rats. There was no effect of OTA in 
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any of these variables with the exception of a significant (P < 0.01) OTA effect resulting in 
higher subcutaneous fat pad weight found in Ovx Sed rats (Fig. 4b).  
Higher (P < 0.05) plasma glucose concentrations was found in Ovx rats 
independently of the Tr state and OTA administration (Fig. 5a). Training was associated 
with a significant (P < 0.05) decrease in plasma insulin levels in Ovx and Sham rats 
independently of OTA administration (Fig. 5b).  
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Discussion 
The main finding of the present study is that OTA administration over 10 days 
down-regulated hepatic GC-A gene expression in Sham as well as in Ovx rats. This 
strongly suggests an indirect action of the OT system on liver independently of the 
estrogenic status of the animal. OTA administration also resulted in an increase in CRP 
mRNA levels, an important pro-inflammatory marker synthesized in the liver. This is in 
line with previous suggestions that a reduction in ANP action in the liver during 
reperfusion may result in an increase in pro-inflammatory response [27]. A small but 
significant decrease in femur weight with OTA administration is consistent with the recent 
observations that OT is involved in osteogenesis and protection against osteoporosis [28]. 
Finally, it seems that exercise training does not play an essential role in these actions. 
1. GC-A in OTA-injected groups 
The down-regulation of the ANP receptor gene expression in liver of OTA-injected 
rats may be taken as an indication that the inhibition of OT-ANP system targets the liver. In 
this context, it is reasonable to speculate that ANP release from the heart was inhibited by 
cardiac OTR blockade in OTA-injected rats thus leading to a decrease in hepatic GC-A 
gene expression. Plasma ANP levels were not measured in the present study. However, in a 
previous study from our group (Jankowski et al. 2010, unpublished data), it was found that 
the same OTA administered at the same dose for 10 days decreased plasma ANP 
concentrations by about 60% in Ovx spontaneously hypertensive rats. Recent findings 
demonstrated that even a single injection of OTA to neonatal rats decreases cardiac ANP 
mRNA expression [13]. The reduction in hepatic GC-A mRNA in OTA animals was 
observed in Sham as well as in Ovx rats. This indicates that the reduction of GC-A gene 
expression by rat treatment with OTA was not further aggravated by the absence of 
estrogens. It is possible that the effect of OTA administration completely overcomes the 
estrogen withdrawal in regulating ANP receptors in liver.  On the other hand, GC-A gene 
expression was not reduced in Ovx animals injected with the vehicle but the OTA treatment 
blocked response of liver GC-A mRNA to training exercise. Interestingly, the training 
response in Sham rats injected with the vehicle was manifested by down-regulation and in 
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the Ovx rats injected with the vehicle by up-regulation of GCA mRNA. Although exercise 
training has been reported to have several corrective effects of metabolic disturbances, the 
exercise training could not compensate the negative effect of OTA treatment at least as far 
as ANP receptor expression is concerned.  
One of the known effects of ANP action in liver is a protective effect against I/R 
injury [21, 29]. This effect takes place through, among others, a reduction in inflammatory 
markers. Based on these observations, we postulated that a blockade of the OT-ANP 
system would result in reduction of the ANP protective action in the liver under the present 
physiological conditions, thus causing an increase in gene expression of inflammatory 
markers. Supporting this hypothesis, we found that CRP gene expression was indeed 
increased in liver of OTA-injected rats and as for GC-A mRNA reduction, in Sham as well 
as in Ovx animals. CRP is an important pro-inflammatory marker synthesized and secreted 
by the liver. CRP levels increase very fast in response to trauma, inflammation, and 
infection and decrease just as rapidly with the resolution of the condition. Thus, the 
measurement of CRP is commonly used to monitor various inflammatory states [30].  
The present increase in CRP mRNA reinforces the concept that a reduction in ANP 
receptors could contribute to increase in inflammatory markers in the liver. On the other 
hand, NF-κB protein content was, on the whole, higher in Ovx than in Sham rats indicating 
that the absence of estrogens is a factor that triggers an increase in pro-inflammatory 
markers in the liver. This finding is in agreement with previous reports [31]. However, 
opposite to CRP, the protein content of NF-κB was not affected by OTA administration. 
Hepatic protein content of NF-κB was not changed either by exercise training in Ovx rats 
although training resulted in a decrease in liver fat accumulation. It is possible that ANP 
action in the liver may not take place through the NF-κB pathway. Surprisingly, 
ovariectomy resulted in lower CRP mRNA in spite of the large increase in liver fat. It has 
been suggested that estrogen withdrawal-mediated decrease in CRP may not represent 
down-regulation of the inflammatory response [32]. 
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1.1 Metabolic parameters 
  As previously reported liver and adipose tissue fat accumulation was higher in Ovx 
rats and reduced in Ovx-Tr animals [33, 34]. Liver and intra-abdominal fat accumulation in 
Ovx rats was not affected by OTA administration. This argues against a role for OT in fat 
accumulation in these tissues. However, fat accumulation in subcutaneous tissue was higher 
in OTA- than in vehicle-injected Ovx animals. It is interesting to recall that exercise-
induced lipid mobilization in subcutaneous tissue has been reported to be mainly related to 
natriuretic peptides in overweight men [17]. It is thus possible that the absence of ANP in 
OTA-Ovx rats might have contributed to the higher increase in fat accumulation in the 
subcutaneous tissue of these rats. However, subcutaneous fat accumulation was reduced 
similarly in exercise trained rats whether they were injected with OTA or the vehicle. Since 
the action of ANP in the study of Morro et al. [17] was during exercise, it is uncertain if 
ANP might play a role important enough to influence fat accumulation on a long term 
basis.  
2. GC-A in non-receiving OTA groups  
  Even though exercise training was without effect on the reduced GC-A gene 
expression in OTA-injected rats, the response in Sham rats was quite different. 
Interestingly, GC-A mRNA response was opposite according to the presence or the absence 
of estrogen. GC-A gene expression was reduced in Sham and increased in Ovx rats 
following training. Interestingly, the same type of response has been previously observed in 
the right atrial tissue [9]. The response of GC-A mRNA to exercise training in the present 
Sham rats suggests that exercise training had compensatory action only in estrogen 
deprived state. Although it remains speculative, it is possible that under normal estrogenic 
conditions, exercise training reduced ANP receptors expression in liver because ANP 
action in liver is a protective mechanism that does not need to be maintained under the 
training state. Under estrogen withdrawal conditions, however, liver fat is increased and the 
protective role of ANP in liver must be accentuated.  
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2.1 Metabolic parameters 
   In our study, ovariectomy showed a tendency to decrease in hepatic GC-A mRNA, 
while Gutkowska et al. reported cardiac GC-A gene expression significantly decreased by 
ovariectomy. Interestingly hepatic CRP mRNA level was significantly lower in Ovx than in 
Sham rats in sedentary state. Our observation is similar to previous reports indicating that 
ovariectomy significantly reduced plasma CRP in rats [35] and 17β-estradiol replacement 
increase plasma CRP levels in rats [32, 36, 37]. The mechanism by which estrogen- 
mediated elevations in CRP levels remains unknown. The present data of liver TAG 
content in vehicle receiving rats was consistent with previous findings on the development 
of hepatic steatosis after ovariectomy, showing higher liver TAG content in Ovx than in 
Sham rats. According to a previous study from our group, reduction in lipid oxidation and 
an increase in lipogenic gene expressions are defective mechanisms leading to lipid 
accumulation in the liver of Ovx rats [38].  
  In addition to liver fat accumulation, we found increased adiposity fat mass by 
ovariectomy, as previously observed, [9] corroborating the important role played by 
estrogens in adipose tissue fat regulation. We observed that treatment with OTA stimulated 
subcutaneous fat mass in Ovx rats. This is an interesting observation considering that recent 
data in GC-A knockout mice suggest that high fat diet induce obesity at least partially 
through down-regulation of GC-A receptor [18]. Both adipose tissue fat mass accumulation 
and liver TAG content were reduced by training in Ovx animals. The level of reduction in 
adipose tissue with training appears to be higher than the level of reduction in the liver, 
suggesting that removal of excess fat accumulation by ovariectomy in the liver may be 
more complicated than in the adipose tissue in the absence of estrogen. The decrease of 
plasma TAG following ovariectomy is quite common, and is reverse of liver TAG content. 
The existence of such an inverse association between high liver TAG and low plasma TAG 
levels has also been observed in a recent study [39].  
In summary, findings of the present study suggest that OT-ANP axis may contribute 
to the protection of hepatic tissue under physiological conditions. ANP may exert its role 
through GC-A expression to reduce inflammatory markers within the hepatocytes. The 
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mechanism by which ANP triggers hepatic protection against inflammation via GC-A, and 
transduction pathway(s) has yet to be defined. 
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Table 1. RT-PCR primer sequences
Gene Sense Primer (5'-3') Antisense Primer (5'-3') Accession No.
    
GC-A ATCACAGTGAATCACCAGGAGTTC AGATGTAGATAACTCTGCCCTTTCG NM012613 
 
CRP CTTCTCTCAGGCTTTTGGTCA GCTTCCAGTGGCTTCTTTGA NM017096 
    
GAPDH TTCAATGGCACAGTCAAGGC TCACCCCATTTGATGTTAGCG NM017008 
 
 
GC-A: guanylyl cyclase type A receptor, CRP: C-reactive protein, GAPDH: 
glyceraldehyde-3-phosphate dehydrogenase 
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Table 2. Body weight, energy intake, uterus, femur and the sum of leg muscle weights in 
sham-operated (Sham) and ovariectomized (Ovx) rats either kept sedentary (Sed) or trained 
(Tr) for 8 wk and either injected with oxytocin antagonist (OTA) or vehicle. 
 Sham-vehicle Sham-OTA Ovx-vehicle Ovx-OTA 
Body weight, g 
Sed 
Tr 
 
303 ± 7 
305 ± 7 
 
290 ± 7 
298 ± 8 
 
  346 ± 10++ 
343 ± 8++ 
 
347 ± 9++ 
  341 ± 14++ 
Energy intake, kcal/day 
Sed 
Tr 
 
74 ± 3 
74 ± 3 
 
69 ± 2 
71 ± 2 
 
76 ± 2+ 
75± 1+ 
 
80 ± 2+ 
73 ± 3+ 
Uterus, g 
Sed 
Tr 
 
0.62 ± 0.08 
0.67 ± 0.06 
 
0.54 ± 0.04 
0.63 ± 0.07 
 
0.1 ± 0.007+ 
0.1 ± 0.004++ 
 
    0.09 ± 0.007+ 
0.1 ± 0.01++ 
Femur weight, g 
Sed 
Tr 
 
0.67 ± 0.02 
     0.72 ± 0.03&&
 
0.65 ± 0.02* 
     0.68 ± 0.02*&&
 
0.64 ± 0.02 
     0.72 ± 0.03&& 
 
0.6 ± 0.03* 
        0.68 ± 0.02*&& 
Sum of muscle weights, g 
Sed 
Tr 
 
2.1 ± 0.04 
2.2 ± 0.07 
 
2.0 ± 0.07 
2.0 ± 0.06 
 
2.2 ± 0.07++ 
     2.5 ± 0.05&&++ 
 
 
2.1 ± 0.06++ 
     2.5 ± 0.13&&++ 
 
 
 
Values are means ± SE, n = 6 rats/group. * Significantly different from respective vehicle 
group P < 0.05. + Significantly different from respective Sham group P < 0.05, ++P < 0.01. 
&& Significantly different from respective sedentary group P < 0.01. 
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Figure legends 
 Fig. 1 a) Hepatic guanylyl cyclase type A receptor (GC-A) mRNA levels and b) Hepatic 
C-reactive protrotein (CRP) mRNA levels in sham-operated (Sham) and ovariectomized 
(Ovx) rats either kept sedentary (Sed) or trained (Tr) for 8 wk and either injected with 
oxytocin antagonist (OTA) or vehicle. Values are means ± SE, n = 6 rats/group. * 
Significantly different from respective vehicle group P < 0.05, ** P < 0.01. ++ Significantly 
different from respective Sham group P < 0.01. & Significantly different from respective 
sedentary group P < 0.05, &&P < 0.01. 
 
 Fig. 2 Hepatic nuclear factor-kappa B (NF-κB) protein content in sham-operated (Sham) 
and ovariectomized (Ovx) rats either kept sedentary (Sed) or trained (Tr) for 8 wk and 
either injected with oxytocin antagonist (OTA) or vehicle. Values are means ± SE, n = 6 
rats/group. + Significantly different from respective Sham group P < 0.05. 
 
 Fig. 3 a) Liver triacylglycerol (TAG) concentrations and b) plasma levels of TAG in sham-
operated (Sham) and ovariectomized (Ovx) rats either kept sedentary (Sed) or trained (Tr) 
for 8 wk and either injected with oxytocin antagonist (OTA) or vehicle. Values are means ± 
SE, n = 6 rats/group. + Significantly different from respective Sham group P < 0.05, ++ P < 
0.01. & Significantly different from respective sedentary group P < 0.05. 
 
Fig. 4 a) Intra-abdominal (mesenteric, retroperitoneal, and urogenital), b) subcutaneous fat 
pad weight, and c) plasma leptin concentrations in sham-operated (Sham) and 
ovariectomized (Ovx) rats either kept sedentary (Sed) or trained (Tr) for 8 wk and either 
injected with oxytocin antagonist (OTA) or vehicle. Values are means ± SE, n = 6 
rats/group. ** Significantly different from respective vehicle group P < 0.01. ++ 
Significantly different from respective Sham group P < 0.01. & Significantly different from 
respective sedentary group P < 0.05, && P < 0.01. 
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Fig. 5 a) Plasma concentrations of glucose and b) insulin in sham-operated (Sham) and 
ovariectomized (Ovx) rats either kept sedentary (Sed) or trained (Tr) for 8 wk and either 
injected with oxytocin antagonist (OTA) or vehicle. Values are means ± SE, n = 6 
rats/group. + Significantly different from respective Sham group P < 0.05. & Significantly 
different from respective sedentary group P < 0.05. 
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Fig 3. 
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Fig 4. 
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Fig 5.  
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Chapter 3: General discussion and conclusion 
3.1 General discussion 
The general goal of the three studies presented in this thesis was to determine 
contributing factors related to the development of NAHS in an estrogen deficient state. 
Menopausal transition in women represents an experimental environment to study the role 
of estrogen on fat and body weight along with related deleterious metabolic complications 
(Shi and Clegg 2009). On the other hand, since estrogen secretion does not cease rapidly 
following the last menses in women, making menopause a relatively long and gradual 
process, collection and interpretation of data regarding the estrogen deficiency and 
aforementioned parameters seems to be complicated (Demerath, Towne et al. 1999; 
Longcope 2001). Ovariectomy in rodents that consists of bilateral removal of the ovaries, 
results in reductions in circulating estrogens and leads to increased food intake and body 
weight, thus resulting in increased adipose tissue and liver fat accretion (Pighon, Paquette 
et al. 2009). Therefore, although not perfect, the Ovx animal model provides an appropriate 
research tool to mimic the post-menopausal hormonal status to study the phenomenon of 
hepatic steatosis as well as to better understand certain adaptations of estrogen withdrawal 
in response to endurance exercise training. 
At first, it should be noted that the conclusions in all of three studies are limited to 
the used of the experimental model. In fact, the interpretation of results obtained from Ovx 
rats must be made with caution when it comes to transpose them to humans. We have to 
take into account that while menopause in women implies a continuum reduction of 
estrogen, Ovx in rats is an aggressive method of estrogen withdrawal which may result in 
metabolic alterations that may differ from those associated with menopause in human. 
Moreover, it would have been preferable to impose in our Ovx rats an energy restriction 
equivalent to the food intake of Sham rats to prevent the confounding effect of Ovx-
induced hyperphagia. In addition, the model of NAHS induction by a diet rich in fat is 
perhaps not representative of all cases associated with obesity. Nevertheless, we believe 
that the results obtained from the present Ovx animal model provide valuable information 
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on estrogen withdrawal induced hepatic steatosis. In the three studies, all ovariectomized 
animals depicted an increase in body mass and adiposity with a significant reduction in 
uterus weight. These morphologic changes, typically associated with Ovx in many studies, 
confirm the quality of our ovariectomy surgeries (Wade, Gray et al. 1985; Deshaies, 
Dagnault et al. 1997; Picard, Deshaies et al. 2000; Lemieux, Picard et al. 2003; Paquette, 
Shinoda et al. 2007).  
The three studies conducted confirmed the results of previous studies on the relation 
between the estrogen withdrawal and the development of hepatic steatosis in rats (Paquette, 
Shinoda et al. 2007; Paquette, Wang et al. 2008). In all cases, ovariectomy induced an 
important accumulation of lipids in the form of TG in the liver. In the first study we found 
that the fat accumulation in the liver was not reduced following an 8-week diet switch from 
HF to SD. This experiment was designed to test the hypothesis that once liver is infiltrated 
with lipids, reduction of fat accumulation is more difficult in Ovx than in rats with a normal 
estrogen production. To verify this hypothesis, we stimulated fat accretion in livers of Ovx 
and Sham rats by submitting them to a HF diet and evaluated reversal of liver TG 
accumulation by switching feeding to a SD diet. Results of this approach showed that, at 
week 13 (8 weeks after switching), liver of Ovx animals was as much infiltrated with lipids 
whether these animals switched to the SD diet or were maintained on the HF diet. Our data 
on energy intake with the switch of the diet could not explain the absence of resorption of 
liver TG accumulation in Ovx rats. Moreover, the switch of the diet had similar effects on 
body composition in both Ovx and Sham rats. Taken together, these observations point to 
the interpretation that liver fat resorption is hampered in the absence of estrogens and 
support the contention that liver fat infiltration in Ovx rats is not exclusively related to an 
increased hepatic lipid uptake, but also facilitated by an intra-hepatic mechanisms related to 
the absence of estrogens. In this regard, some evidence has recently been gathered 
indicating that estrogen deprivation might affect intra-hepatic pathways leading to 
excessive lipid accumulation. Augmented lipogenesis (shown by increased expression of 
important lipogenic genes such as SREBP-1c, SCD-1, PPAR-γ, FAS, and ACC) along with 
reduced lipid oxidation (shown by decreased fatty acid oxidation rate and expressions of 
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HSL and PPAR-α) has been reported in liver of Ovx rodents thus supporting the 
interpretation that indeed estrogens act locally in liver increasing the risk of metabolic 
disturbances (D'Eon, Souza et al. 2005; Na, Ezaki et al. 2008; Paquette, Wang et al. 2008; 
Paquette, Chapados et al. 2009; Rogers, Perfield et al. 2009; Pighon, Gutkowska et al. 
2010).  
An interesting abservation in our first study was the observation of an inverse 
association between high liver TG and low plasma TG levels in all experimental groups. 
Since plasma TG concentrations are mainly determined by the activity of the LPL and the 
hepatic VLDL-TG production, we hypothesized that VLDL-TG production in liver of Ovx 
rats is decreased thus resulting in lower plasma TG levels in these animal.  Estrogens are 
known to elevate serum TG levels in both rat (Russell, Amy et al. 1993; DiPippo, Lindsay 
et al. 1995) and human (Matthews, Meilahn et al. 1989; Love, Newcomb et al. 1990; Love, 
Wiebe et al. 1991; Walsh, Schiff et al. 1991; Barrett-Connor 1993) and this has been 
suggested to be due to increased hepatic VLDL production by estrogens (Krauss and 
Burkman 1992).  
Based on the postulate that estrogens are linked to the VLDL pathway, we 
conducted a second study targeting the elimination mechanism of liver lipids in Ovx rats, 
that is, hepatic VLDL-TG production along with the expression of MTP, a molecule that 
exerts a central regulatory role in VLDL assembly and secretion. The data reported in this 
study were consistent with previous findings of the development of a state of hepatic 
steatosis in Ovx animals and its prevention by E2 supplementation (Paquette, Wang et al. 
2008). Results of our physiological approach indicated that VLDL-TG production was 
decreased in Ovx rats, suggesting a reduction in VLDL synthesis and secretion with 
estrogen withdrawal. Moreover, our study provided the first molecular evidence that 
hepatic MTP gene expression decreased (~ -30%) by estrogen withdrawal. Both of these 
responses were re-established by E2 replacement. These observations suggest that 
estrogens act as a protective tool to keep normal lipid accumulation in the liver and indicate 
that a reduction in VLDL production by the liver may be a contributing factor responsible 
  
 
146
for the large hepatic fat accumulation observed in Ovx rats. Molecular mechanisms by 
which estrogens regulate liver lipid metabolism and related target genes are not well 
known. It is possible that estrogens affect gene expressions of target genes involved in liver 
lipid exportation through protein-protein interaction in the nucleus and/or activation of 
signal transduction pathways at the plasma membrane. As mentioned earlier, it seems that 
estrogens are involved in the regulation of other pathways of liver lipid accumulation. 
However, the contribution of each pathway under estrogen deficiency status is unclear and 
needs to be revealed by future investigations considering the limitations of our present 
studies. The assessment of hepatic VLDL-TG production rate in this project was carried out 
by measuring plasma concentrations of TG over a period of 90 min following the 3-h lipid 
infusion and injection of Triton WR-1339 to block LPL activity while the rats were alive 
under otherwise normal physiological conditions. The analysis of TG levels in plasma is 
regarded as an estimate of the synthesis and secretion of hepatic VLDL (Lewis, Uffelman 
et al. 1995; Zhang, Hernandez-Ono et al. 2004). It would have been more appropriate to 
proceed to the quantification of plasma apoB to obtain a more precise rate of the synthesis 
and secretion of hepatic VLDL. Infusion of stable isotopes may also have offered a more 
reliable approach for measuring in vivo VLDL-TG kinetics (Adiels, Olofsson et al. 2008). 
However, the information obtained with the use of the present approach has proven to be 
effective in evaluating the production of hepatic VLDL (Chapados, Seelaender et al. 2009). 
Since recent results indicated that exercise training has a significant reducing effect 
on Ovx-induced fat accumulation in liver (Corriveau, Paquette et al. 2008; Pighon, Paquette 
et al. 2009; Pighon, Paquette et al. 2009; Pighon, Barsalani et al. 2010), we also examined 
the effects of exercise training on hepatic VLDL-TG production and gene expression of 
related makers in Ovx rats. Surperisingly, our results show that plasma VLDL-TG levels 
were also reduced by exercise training in all groups, including the Ovx rats for which 
VLDL-TG levels were already reduced by the absence of estrogens. Liver MTP and 
DGAT-2 mRNA levels were also suppressed by exercise training. The direct effect of 
exercise training on the diminished gene expression of key molecules involved in VLDL-
TG synthesis resulting in reduced VLDL-TG production has been recently reported (Lira, 
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Tavares et al. 2008; Tsekouras, Magkos et al. 2008; Chapados, Seelaender et al. 2009). 
Given that intra-abdominal fat pad weights were lower in our Ovx animals submitted to the 
training program, this may primarily be explained by the fact that exercise training 
increases the use of lipids, therefore reducing body fat accumulation and the availability of 
lipids taken up by the liver. However, a very recent research work from our lab reported 
that exercise training, similarly to estrogens reduces fat accumulation inside the liver of 
Ovx rats through regulation of key molecules involved in lipogenesis and lipid oxidation 
(Pighon, Gutkowska et al. 2010). Moreover, since insulin has an inhibitory impact on 
hepatic VLDL-TG production, improved insulin sensitivity (observed as lower plasma 
insulin levels) following exercise training might be a contributing factor in exercise-
reduced VLDL synthesis and/or secretion. Taken together, these data indicate that 
endurance exercise training is an effective intervention for the improvement of lipid profile 
in Ovx animals not only by reducing the FFA release from adipose tissue and liver, but also 
by positively affecting intra-hepatic pathways of lipid accumulation. Nevertheless, these 
interpretations should be confirmed by further studies employing more precise models 
(such as pair-feeding) and measuring insulin sensitivity using more sophisticated 
techniques. 
Finally, in an attempt to broaden our knowledge of the metabolic functions of OT-
ANP system we conducted our third study to investigating the possibility that OTR 
blockage targets liver lipid metabolism. We hypothesized that the treatment with OTA (for 
ten consecutive days before sacrifice day) will reduce ANP synthesis in the heart and, in 
turn, the gene expression of ANP receptor in the liver. Since it has been recently reported 
that gene expressions of cardiac ANP and GC-A were under estrogenic control 
(Gutkowska, Paquette et al. 2007) this experiment was conducted in Ovx and Sham rats. 
The key finding of the study was that OTA administration over 10 days down-regulated 
hepatic GC-A gene expression in both Sham and Ovx rats; suggesting an indirect action of 
the OT system on the liver independently of the estrogenic status of the animal. It seems 
that the effect of OTA administration overcomes the estrogen withdrawal in regulating 
ANP receptors in liver. This finding also may be an indication that inhibition of OT-ANP 
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system targets the liver demonstrating that OTA treatment targets directly cardiac ANP and 
indirectly hepatic ANP receptor. The main limitation of this study was that because of some 
technical problems we were not able to measure plasma ANP levels in a reasonable time 
frame. However, in a previous study from our group (Jankowski et al. 2010, unpublished 
data) the same interventions of OTA administration decreased plasma ANP concentrations 
by about 60% in Ovx rats. In addition, based on the observations that ANP plays a 
protective role against I/R injury through a reduction in inflammatory markers, we 
postulated that a blockade of the OT-ANP system would result in decreased protective 
effect of the ANP in the liver under the normal physiological conditions. Supporting this, 
OTA administration resulted in an increase in CRP mRNA levels, an important pro-
inflammatory marker synthesized in the liver. However, the protein content of NF-κB was 
not affected by OTA administration. This may indicate that ANP action in the liver does 
not take place via NF-κB pathway. However, the mechanism by which ANP triggers 
hepatic protection against inflammation via GC-A, and transduction pathway(s) has yet to 
be defined. In this regard, employment of older animal models is suggested for the 
investigation of the relevant effects of post-menopausal hormonal state and/or OT-ANP 
system on the inflammatory markers. As for the results of this study, a blockade of the OT-
ANP axis results in down-regulation of hepatic GC-A gene expression that is associated 
with an increased hepatic CRP gene expression which occurs independently of the 
estrogenic status. Moreover, although exercise training has been reported to have several 
corrective effects of metabolic disturbances, the exercise training could not compensate the 
negative effects of OTA treatment. We also observed that treatment with OTA stimulated 
subcutaneous fat mass in Ovx rats without effects on TG content in plasma and liver. Both 
adipose tissue fat mass accumulation and liver TG content were reduced by training in Ovx 
animals but the level of reduction in adipose tissue was higher than the level of reduction in 
the liver, suggesting that removal of excess fat accumulation by ovariectomy in the liver 
may be more complicated than in the adipose tissue in the absence of estrogen. Again, this 
implies the intra-hepatic effects of estrogen withdrawal on liver lipid infiltration.  
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It has been demonstrated that the accumulation of liver TG observed in HF feeding 
is mostly the result of an increase in FFA uptake (Gauthier, Favier et al. 2006). We did not 
observe such augmentation in plasma FFA levels in Ovx rats, which may be consistent with 
the loss of the lipolytic action of estrogens in visceral adipose tissue (D'Eon, Souza et al. 
2005). However, increased lipid uptake by liver as the consequence of the central effects of 
estrogen withdrawal (such as increased food intake which results in higher total and intra-
abdominal fat) may primarily explain the development of Ovx-induced NAHS. 
Nevertheless, Fisher et al. demonstrated that despite a similar food intake, Ovx-pair fed 
animals gained markedly more weight than did Sham animals and nearly as much as Ovx-
ad libitum animals (Fisher, Kohrt et al. 2000). D’Eon et al. also reported that estrogen 
decreased adiposity in Ovx rodents not confounded by differences in food intake (D'Eon, 
Souza et al. 2005). Unpublished data from our lab also showed that despite a certain 
resorption of hepatic steatosis, pair-feeding in Ovx rats did not completely prevent liver fat 
accretion in estrogen deficiency state and the degree of liver lipid infiltration was 
significantly higher in Ovx rats than in Sham animals (Fig. 14A). Supporting this, the 
results of our second study on food intake demonstrate that the large increase in liver fat in 
Ovx group can hardly be explained by the higher energy intake in these estrogen deprived 
animals (Fig. 14B). Only E2 replacement prevented the development of Ovx-induced 
NAHS as shown in Fig. 14B as previously reported (Paquette, Shinoda et al. 2007; 
Paquette, Wang et al. 2008; Pighon, Barsalani et al. 2010; Pighon, Gutkowska et al. 2010). 
Therefore, we can conclude that estrogen withdrawal favors the development of NAHS 
even in the absence of excessive energy intake suggesting that alterations of intra-hepatic 
mechanisms including reduced VLDL-TG production are most likely contributing factors 
in the pathology Ovx-induced NAHS.   
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A) 
 
Figure 14A. Effect of energy restriction in Ovx rats equivalent to food intake of intact rats on the 
hepatic TG accumulation. n = 8/group. sham-operated (Sham), ovariectomize (Ovx), and Ovx group with 
energy restriction (OvxPF). * Significantly different from Sham,  P < 0.05. + Significantly different from Ovx,  
P < 0.05. Taken from (Paquette A. 2008). 
B)
Figure 14B. a) Energy intake and b) Liver TG content in sham-operated (Sham), ovariectomize (Ovx), and 
Ovx rats with 17β-estradiol supplementation (OvxE2) in sedentary (Sed) and trained (Tr) states. n = 8-10 
rats/group for energy intake and  n = 7-12 for liver TG.  ** Significantly different from Sham, P < 0.01; && 
Significantly different from OvxE2, P < 0.01;   + Significantly different from Sed, P < 0.05,   ++ P < 0.01. 
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Taken together, observations from the three studies indicate the important role of 
estrogen in the regulation of lipid metabolism in the liver. These data also indicate that liver 
fat infiltration in Ovx rats is not solely related to an increased hepatic lipid uptake, but also 
facilitated by an intra-hepatic mechanisms related to the absence of estrogens. Among these 
mechanisms a reduction in hepatic VLDL-TG production seems to be of importance. In 
addition, the demonstration of the reduction in gene expression of ANP receptors in OT 
blocked animals may be of importance in further work on the action of OT-ANP system in 
liver. Experimental approaches employed in the studies of this thesis may be useful for 
developing future design projects on the identification of the intra-cellular mechanisms 
which have yet to be elucidated in estrogen deficient-induced hepatic steatosis. 
3.2 Conclusion 
The overall results of the studies that comprise this thesis indicate the emergence of 
estrogens as an important regulator of hepatic lipid homeostasis. Results from this thesis 
reinforce the concept that estrogens act as a protective tool to keep normal lipid 
accumulation in the liver. These data also support the interpretation that liver fat infiltration 
in Ovx rats is not exclusively related to an increased hepatic lipid uptake, but also 
facilitated by an intra-hepatic mechanisms related to the absence of estrogens. We provide 
evidences that hepatic fat accumulation and resorption are dependent on mechanisms 
associated with a normal estrogenic status, more specifically; a decrease in VLDL-TG 
production might be a contributing factor responsible for hepatic fat accumulation induced 
by estrogen deficiency. In addition, we showed that endurance exercise training lowers 
liver fat accretion and VLDL-TG production independently of the estrogen levels. Lastly, 
results from the third study suggest that the OT-ANP axis may contribute to the protection 
of hepatic tissue under normal physiological conditions.  ANP may exert its role through 
GC-A expression to reduce inflammatory markers within hepatocytes. However, the 
present results do not provide any evidence that the action of OT-ANP axis on liver is 
influenced by ovariectomy or exercise training. The OT-ANP axis action on metabolic 
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activity in liver is unknown and may reveal to be very important in the near future as it was 
the case for its action in the heart. 
On a clinical point of view, the results of this PhD thesis suggest that the reduction 
of excess fat accumulation in the liver may be complicated by the absence of estrogens in 
post-menopausal women and emphasizes the importance of preventive strategies. 
Furthermore, the data from this thesis indicates that exercise training in post-menopausal 
women could prevent menopausal associated hepatic steatosis and consequently lead to an 
improvement in lipid profile and prevent the development of cardiovascular diseases.  
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